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RÉSUMÉ
L’athérosclérose est la principale cause de décès et la complication
majeure du diabète de type 2. Le récepteur-1 “lectin-like oxidized low-density
lipoprotein” (LOX-1) est un récepteur vasculaire nouvellement identifié pour les
[DL oxydées (LDL0x) et les produits de glycation (AGEs). LOX-1 est surexprimé
dans les lésions athérosclérotiques humaines et dans l’aorte de rats diabétiques,
ce qui suggère un rôle de ce récepteur dans la pathogenèse de l’athérosclérose
associée au diabète. Dans la présente étude, nous avons étudié la régulation
vasculaire de LOX-1 par le glucose et la CRP et le rôle de LOX-1 dans l’adhésion
des monocytes à l’endothélium et la formation de cellules spumeuses. Nos
résultats démontrent que: 1) l’incubation de cellules endothéliales aortiques
humaines (HAECs) et de macrophages dérivés de monocytes humains (hMDM)
avec des concentrations de glucose élevées augmente l’expression génique et
protéique de LOX-1 de manière dose- et temps-dépendant; 2) l’augmentation de
l’expression protéique de LOX-1, induite par des concentrations élevées de
glucose, est abolie par des agents antioxydants et des inhibiteurs de la protéine
kinase C (PKC), des protéines kinases activées par les mitogènes (MAPK), du
facteur nucléaire-kappaB (NF-icB) et de la protéine activée-1 (AP-1). Des MDM
humains incubés en présence de concentrations élevées de glucose démontrent
une augmentation de l’expression de PKC32 et une phosphorylation des
protéines kinases régulées par des signaux extracellulaires (ERK) 1/2.
L’activation de ces kinases est inhibée par les antioxydants et par l’inhibiteur
spécifique de PKCj32, le LY379196. Des concentrations élevées de glucose
augmentent également la liaison des protéines nucléaires extraites de MDM
in
humains aux séquences régulatrices NE-KB et AP-1 présentes dans le promoteur
du gène de LOX-1; 3) l’incubation de HAECs et de MDM avec des
concentrations élevées de glucose augmente l’adhésion des monocytes à
l’endothélium et la formation de cellules spumeuses, respectivement, par
l’entremise de mécanismes de signalisation LOX-1 -dépendant; 4) l’incubation de
HAECs avec la CRP augmente l’expression génique et protéique de LOX-1 de
façon dose- et temps-dépendant. Cet effet est attenué pat une préincubation
des cellules avec des anticorps anti-CD32 et anti-CD64. Enfin, le traitement des
HAECs par la CRP induit une augmentation de l’adhésion des monocytes à
l’endothelium. Cette augmentation est dépendante de LOX-1. Globalement, ces
résultats démontrent que des concentrations élevées de glucose augmentent in
vitro l’expression endothéliale et macrophagique de LOX-1 et que ces effets sont
associés à une adhésion accrue des monocytes à l’endothélium et à la formation
de cellules spumeuses. Nous avons également demontré que la CRP augmente,
in vitro, l’expression endothéliale de LOX-1 et que cet effet est associé à une
augmentation de l’adhésion des monocytes à I’endothélium. En résumé, ces
données suggèrent un rôle clé de divers facteurs métaboliques et inflammatoires
dans la régulation vasculaire de LOX-1 et suggèrent un rôle de LOX-1 comme
médiateur de l’athérogenèse associée au diabète humain. Une meilleure
compréhension du rôle des facteurs métaboliques et inflammatoires dans la
régulation vasculaire de LOX-1 dans le diabète pourrait permettre le
développement de nouvelles stratégies dans le traitement de l’athérosclérose
associée au diabète.
Mots clés: Diabète, LOX-1, glucose, macrophages, cellules endothéliales, CRP.
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SUMMARY
Atherosclerosis is the leading cause of death and the major complication
cf type 2 diabetes. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)
is a newly identified vascular receptor for oxidized LDL (0xLDL) and advanced
glycation end products (AGEs). LOX-1 is highly exptessed in human
atherosclerotic lesions and is upregulated in the aorta cf diabetic rats. In the
present study, we sought to determine the regulation of vascular LOX-1 in
diabetes. Our resuits demonstrated that: 1) incubation of human aortic
endothelial cells (HAECs) and human monocyte-derived macrophages (hMDM)
with elevated glucose concentration enhanced, in a dose- and time-dependent
manner, LOX-1 gene and protein expression; 2) high glucose-induced
macrophage LOX-1 protein expression was abo!ished by antioxidants, protein
kinase C (PKC), mitogen-activated protein kinase (MAPK), nuclear factor-kappaB
(NE-KB) and activated protein-1 (AP-1) inhibitors. n human MDM cultured with
high glucose, increased expression of PKCE32 and enhanced phosphorylation of
extracellular signal-regulated protein kinase (ERK) 1/2 were also observed.
Activation cf these kinases was inhibited by the antioxidant and by the PKCf32
inhibitor, LY379196. High glucose also enhanced the binding of nuclear proteins
extracted from human MDM te the NE-KB and AP-1 regulatory elements cf the
LOX-1 gene promoter. High glucose-induced endothelial LOX-1 protein
expression was abolished by antioxidants, PKC, MAPK, and NE-KB inhibitors.
High glucose enhanced the binding cf nuclear protein extracted from HAECs to
O
the NF-icB regulatory element cf the LOX-1 gene promoter; 3) incubation cf
HAECs and macrophages with high glucose increased monocyte adhesion te
V
endothelium and foam cell formation, respectively, through LOX-1-dependent
signaling mechanism; 4) incubation of HAECs with CRP enhanced, in a dose
and time-dependent manner, LOX-1 mRNA and protein levels. This effect was
reduced by anti-CD32 and -CD64 antibodies, whereas it was unaffected by
hyperglycemia, tumor necrosis factor Œ (TNFŒ) and interleukin-6 (IL-6). In CRP
treated HAECs, a LOX-1-dependent induction of monocyte adhesion to
endothelium was observed. Overall, these resuits demonstrate that high glucose
enhances human endothelial and macrophage LOX-1 expression in vitro and that
this effect is associated with enhanced monocyte adhesion to endothelium and
foam cell formation. We also found that CRP increases human endothelial LOX-1
expression in vitro and that this effect is associated with increased monocyte
adhesion to endothelium. Taken collectively, these data indicate a key role for
metabolic and inflammatory factors in the regulation of vascular LOX-1 in
diabetes. They identify LOX-1 as one potential important mediator in the
pathogenesis of atherosclerosis in human diabetes. Better understanding of the
role of metabolic and inflammatory factors in the regulation of vascular LOX-1 in
diabetes might provide new strategies in the treatment cf diabetic
atherosclerosis.
Keywords: Diabetes, LOX-1, glucose, macrophages, endothelial cells, CRP.
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QI. INTRODUCTION
Q
I. Introduction
LI. Atherosclerosis
1.1.1. General
Atherosclerosis is a chronic, multifactorial and progressive disease
characterized by the accumulation of lipids and fibrous elements in the large and
medium arteries. Epidemiological studies over the past 50 years have identified
numerous risk factors for atherosclerosis. These can be grouped into factors with
an important genetic component and those that are largely environmental.
Among the primary events in atherosclerosis are the accumulation of low-density
lipoproteins (LDL) in the subendothelial space [Guyton et al. 1996, Van De Graif
et al. 19921 and the adhesion of inflammatory cells, such as monocytes and T
lymphocytes, to the endothelium. The notion that atherosclerosis is an immune
mediated inflammatory disease is now widely accepted and provides the basis
for the development of new strategies in the diagnosis and management of this
disease.
1.1.2. Development and progression of the atherosclerotic lesion
1.1.2.1. Endothelial dysfunction in atherosclerosis
1.1.2.1.1. Endothelial function
The vascular endothelium is considered to be a monolayer acting as a
selectively permeable barrier between blood and tissues. It is a dynamic and
heterogeneous organ. It has also become evident that the vascular endothelium
1
is an active paracrine, endocrine, and autocrine organ that is indispensable for
the regulation cf vascular tone and maintenance cf vascular homeostasis as
shown in Table I [Bonetti et al. 2003].
Table J. Favorable and Atheroprotective Effects of the Healthy Endothelium.
Promotion of vasodilation
Antioxidant effects
Antiinflammatory effects
Inhibition cf leukocyte adhesion and migration
Inhibition cf smooth muscle celI proliferation and migration
Inhibition cf platelet aggregaticn and adhesicn
Anticoagulant effects
Profibrinolytic effects
Endothelium can generate effector molecules, such as nitric oxide (NO),
prostacyclin, platelet-derived growth factor (PDGF), angiotensin Il, and
endothelin [Ross 1999]. These molecules control and regulate thrombosis,
inflammation, vascular tone, and vascular remodeling. Furthermore, the
endothelium has important anti-coagulant and fibrinolytic functions.
LL2.1 .2. Endothelial dysfunction
Endothelial dysfuncticn is characterized by an imbalance between the
production cf relaxing and contracting factors, anticoagulant and procoagulant
mediators, or growth-inhibiting and promoting factors. Endothelial dysfunction is
closely linked to the occurrence cf vascular diseases such as hypertension,
s
2
diabetes, inflammation, and aging and preceeds the development of
atherosclerosis. It is characterized by a reduction of the bioavailability of
vasodilators such as NO and an increased production of endothelium-derived
contracting factors [Bonetti et al. 2003]. This imba lance leads to an impairment 0f
endothelium-dependent vasodilation, which represents the functional
characteristic of endothelial dysfunction. Aside from denoting the impaired
endothelium-dependent vasodilation, endothelial dysfunction also comprises a
specific state of endothelial activation, which is characterized by a
proinflammatory, proliferative, and procoagulatory milieu that favors ail stages of
atherogenesis [Anderson. 19991. This results in increased permeability of
endothelium to macromolecules such as LDL and enhanced migration of
inflammatory cells to the subintimal space through the effect of oxidized LDL
(0xLDL), monocyte chemotactic protein 1 (MCP-1), interleukin-8 (IL-8), PDGF,
macrophage-colony stimulating factor (M-CSF), and osteopontin, leading to the
formation of early atherosclerotic lesions or fatty streaks [Kita et al. 2001].
1.1.2.2. Fafty-streak lesion
As mentioned above, early atherosclerotic lesions, or fatty streaks are
characterized by the accumulation of LDL and the migration of monocytes and
lymphocytes into the subendotheliai space of the arterial wall. Fatty streaks
initiaily consist of lipid-laden monocyte-derived macrophages (foam cells) mixed
together with variable numbers of T lymphocytes [Ross 1999]. The formation of
foam cells is mediated mainly by M-CSF, tumor necrosis factor a (TNF-a), and
C
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interleukin-1 (IL-1) [Rosenfeid et al. 1990, Hamilton et al. 1999]. Later, these ceNs
are joined by various numbers of smooth muscle cells (SMCs). SMC migration is
stimuiated by PDGF, flbroblast growth factor-2 (FGF-2) and transforming growth
factor 3 (TGF-J3) [Boring et al. 1997, Boisvert et al. 1998]. Platelet adherence and
aggregation are aiso observed and are stimulated by integrins, P-selectin, fibrin,
thromboxane A2, and tissue factor (TF) [Ross 19991.
1.1.2.3. Advanced lesion of atherosclerosis
As fatty streaks progress to intermediate and advanced lesions, they tend to
form a fibrous cap that walls off the lesion from the lumen. This represents a type
of healing or fibrous response to the injury [Ross 1999]. Advanced
atherosclerotic lesions result from a variety of pathogenetic processes, including
macrophage foam cell formation and death, accumulation of extracellular lipid,
reduction of structural intercellular matrix and SMCs, generation of minerai
deposits, chronic inflammation, and neovascularization [Stary 2000]. Coronary
artery calcification is rather a marker for atherosclerotic lesion. Ectopic vascular
calcification occurs commonly in atherosclerosis. Its presence and location in
cotonary arteries have been documented by ultrafast computed tomography
scanning [Fallavallita et al. 1994, Janowitz 2001]. Electron beam computed
tomography (EBT) can also rapidiy and noninvasively detect and quantify
caicified atherosclerotic plaque in the coronary arteries [O’Rourke et al. 2000]. A
higher quantity of cotonary artery calcium is associated with Iikelihood of
obstructive lesions [O’Rourke et al. 2000], and with an increased risk of future
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cardiovascular disease (CVD) [Arad et al. 2000]. The recent finding that TNF-Œ
promotes, through the cycc adenosine monophosphate (cAMP) pathway,
osteoblastic differentiation of vascular celis [Tintut et al. 2000] suggests a role of
pro-inflammatory cytokines in the vascular calcification process.
1.1.2.4. Unstable fibrous plaques in atherosclerosis
1.1.2.4.1. Local factors
The influx of inflammatory celis, macrophages, and T lymphocytes in
atherosclerotic plaques increases with plaque progression and these cells
preferentially accumulate at sites of plaque rupture [Ross 1999, Hosono et al.
2003]. Inflammatory mediators and proteases released by these cells and
expressed in human atherosclerotic lesions contribute to plaque rupture. For
example, it is well known that macrophages release metalloproteinases and
other proteolytic enzymes at sites of thinning of the fibrous cap. These enzymes
cause degradation of the matrix, which leads to hemorrhage from the vasa
vasorum or from the arterial lumen, resulting in thrombus formation and arterial
occlusion [Ross 1999]. Apoptosis of vascular ceils such as SMCs and
macrophages are associated with plaque instability as well [Von det Thusen et
al. 2002, Kockx et al. 2000, Geng et al. 1995, Libby et al. 1996]. Local
modulators of plaque rupture also include factors involved in the coagulation
cascade [Khrenov et al. 2002]. For example, both TE and TF pathway inhibitor
(TFPI) are expressed in advanced human atherosclerotic lesions and are
abundant at sites of plaque rupture [Kaikita et al. 1999]. Studies also
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Ç demonstrate that plasminogen activator inhibitor (PAl) and prothrombin are
increased in advanced human plaques [Falkenberg et al. 1996, Smith et al.
1981]. Recent studies on gene profiling have identified a differential expression
of various genes between stable and ruptured human atherosclerotic plaques
including perilipin and cathepsin K. In addition to suggest an important role for
these genes in plaque stability, this study also supports a role for many other
unknown genes such as vasculin [Faber et al. 2001 Bijnens et al. 2003, Lutgens
et al. 20031.
1.1.2.4.2. Systemïc factors
It has been stated that plaque rupture does not occur as an isolated
phenomenon but rather as a systemic disease [Lutgens et al. 2003]. Rupture of
the fibrous cap leads to the exposure of the thrombogenic parts of the
atherosclerotic plaque with subsequent activation of the coagulation cascade and
platelet aggregation. This leads to thrombosis and acute ischemia resulting from
abrupt luminal compromise. Histomorphological features of vulnerable plaques
include a) positive remodeling producing less luminal stenosis; b) large lipid cote
( 40% plaque volume); C) large number of inflammatory cells; d) a thin cap
depleted of SMCs and collagen and finally increased neovascularity. Recently,
the term ‘cardiovascular vulnerable patient” has been ptoposed to define
subjects susceptible to an acute cotonary syndrome or sudden cardiac death
based on plaque, blood, or myocardial vulnerability [Naghavi et al. 2003].
Vulnerable patients often present with multiple ruptured plaques. Systemic
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(J factors that are correlated with plaque rupture are altered blood rheology,
increased coagulability, increased systemic inflammation, and recurrent
infections. These unfavorable systemic changes often interact synergistically with
risk factors of atherosclerosis, such as hyperlipidemia, smoking, and diabetes
[Fuster et al. 1999, Corti et al. 2003, Sambola et al. 2003].
1.1.3. Risk factors
113.1. Traditional risk factors
1.1.3.1.1. Hypercholesterolemia and dyslipoproteinemia
High plasma levels of cholesterol and cf pro-atherogenic lipoproteins
represent major risk factors for cardiovascular diseases. In particular, increased
levels cf circulating LDL is considered as a major risk factor of coronary heart
disease and one of the earliest events in athetogenesis is the accumulation cf
LDL in the vessel wall. Retention and modification cf LDL are key factors in
atherosclerotic lesion formation. LDL can be modified by several mechanisms,
including oxidation, glycation, aggregation, association with proteog lycans, or
incorporation into immune complexes [Steinberg et al. 1997, Khoo et al. 1998,
Khoo et al. 1992, Navab et al. 1996]. Progressive oxidation of LDL takes place
during the process cf LDL particle trapping in arteries. OxLDL is internalized by
macrophages through surface scavenger receptors [Steinberg et al. 1997, Khoo
et al. 1992, Navab et al. 1996, Griendling et al. 1997, Han et al. 1997]. The
uptake of oxLDL by macrophages results in intracellular cholesterol ester
accumulation and foam cell formation. Macrophage-derived foam cells are
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present in ail stages cf atherogenesis and play a key role in the development and
progression cf atherosclerosis. Lipoprotein fa) (Lp(a)) closely resembles LDL in
its content cf cholesterci and apolipoprotein B-100 but differs by the presence cf
an attached glycoprotein, known as apoprotein fa). The involvement cf Lp(a) in
the pathogenesis cf atherosclerosis is strongly suggested by the presence of
Lp(a) in the human atherosclerotic lesions [Rath et al. 1989, Jutgen et aI. 1993].
Numerous cross-sectional and prospective studies have also revealed
associations between high plasma levels cf Lp(a) and atherosclerotic vascular
diseases, such as ccrcnary heart disease and stroke [Utermann 1995, Djurovic
et al. 1997]. The effect cf high plasma levels cf Lp(a) in the develcpment cf
athercsclercsis has aise been well-studied in transgenic animal mcdels [Lawn et
aI. 1992, Fan et ai. 2001]. Although the importance cf high LDL chclestercl as a
risk factcr for ccrcnary artery disease is well estabiished, the rcle cf
hypertriglyceridemia as an independent risk factcr for the develcpment cf
vascular diseases is stiii ccntrcversial. Varicus factors asscciated with
hypertriglyceridemia, including dyslipcprcteinemia, aiteraticns cf hemcstatic
processes, cbesity and hypertension may acccunt for the deletericus effect cf
high triglyceride ieveis on the atherosclerotic prccess [Malaguarnera et ai. 2000].
Althcugh, the meta-analysis cf Austin and Hckanscn, 1998 has recentiy
suggested that hypertriglyceridemia is an independent risk factor for
cardiovascular diseases, many investigatcrs stiil believe that triglyceride-rich
iipcproteins cannct migrate thrcugh the vascular endcthelium [Faegerman,
1998]. Recently it has been suggested that postprandial hypertriglyceridemia
$
( may cause endothelial dysfunction via enhanced oxidative stress [Bae et aL
20011. In addition, a lcw level of HDL-choiesterol as an important risk factor foc
cardiovascular disease has been weII established thtough epidemiological and
clinical studies [Gordon et al. 1989]. A growing body cf evidence suggests that
HDL exerts part cf its antiatherogenic effect by counteracting LDL oxidation
[Assmann et al. 2004].
1.1.3.1.2. Hypertension
1.1.3.1.2.1. Renin-angiotensin system (RAS)
The RAS plays an important role in the pathogenesis cf cardiovascular
disease. Angiotensin II, the principal product of the RAS, increases blood
pressure through increasing vascular resistance, stimulating aldosterone
synthesis and release, increasing renal tubular sodium reabsorption, augmenting
the release cf antidiuretic hormone, and enhancing sympathetic outflow from the
brain. Nctably, angiotensin II induces cardiac and vascular cell hypertrophy and
hyperplasia directly by activating the angiotensin II type 1 (AT1) receptor and
indirectly by stimulating the release cf several growth factors and cytokines
[McConnaughey et al. 1999]. The mechanisms thrcugh which angiotensin II
increases blood pressure include binding cf angiotensin te specific receptors on
SMC, eliciting the activation cf phospholipase C (PLC) and leading to increased
intracellular calcium concentrations and 5MO hypertrophy [Gibbons et al. 1992].
Angiotensin II also decreases NO production, increases cxidative stress
[Yanagitani et al. 1999] and induces the activation cf nuclear factor-icB (NF-KB)
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[Kranzhôfer et al. 1999], protein kinase C (PKC) [Henrion et al. 1996] and
mitogen activated protein kinases (MAPK) [Haendeler and Berk, 2000].
1.1.3.1.2.2. Endothelin
Endothelin is a potent vasoactive peptide, produced by endothelial oeIls.
Endothelin is secreted in an abluminal direction by endothelial ceils and acts in a
paracrine fashion on underlying SMCs to cause vasoconstriction and elevate
blood pressure [Oparil et aI. 2003]. Circulating endothelin levels are increased in
some hypertensive patients, particularly African Americans and persons with
transplant hypertension, endothelial tumors, and vasculitis [Ergul et al. 1996]. Da
Silva et al. [2004] recently reported that endothelin-1 (ET-1) contributes to
increased arterial pressure in a model of visceral obesity produced by feeding
Sprague-Dawley rats with a high-fat (HE) diet.
LL3.1.3. Diabetes
Patients with diabetes are at high risk of cardiovascular diseases [Resnick
et al. 2002]. Several risk factors associated with diabetes including dyslipidemia,
obesity, hypertension, hyperglycemia and hyperinsulinemia contribute to the
accelerated atherosclerosis in human diabetes. (See section 1.11. for details)
1.1.3.1.4. Family history, age and gender
It is clear that positive family history, advanced age and male gender
increase the risk of developing coronary artery disease [Saniko et aI. 1990].
‘o
Numerous studies have shown that individuals with a family history cf coronary
heart disease (CHD) are at higher risk 0f atherosclerosis. For example, Pankow
et al. [1997] and Li et aI. [2000] investigated family CHD risk scores and found
higher traditional CHD risk factors in individuals with a family history of heart
disease.
Because of protection by female hormones, the onset of CHD tends to be
delayed in women by about 10 years with some catch-up after menopause
[Matthews et al. 1989].
1.1.3.1.5. Obesity and smoking habit
Obesity, especially visceral obesity, is associated with a cluster of
metabolic complications increasing the risk of type 2 diabetes and CHD. For
example, obese patients with visceral obesity show increased glycemic and
insulinemic responses to an oral glucose load compared to normal weight
individuals or compared to obese individuals with low visceral adiposity [Kothari
et al. 1998]. Viscerally obese patients are also characterized by an unfavorable
plasma lipid profile which includes elevated triglyceride and apolipoprotein B
concentrations, reduced high density lipoproteins (HDL)-cholesterol levels as well
as increased proportion of small, dense LDL particles [Despres et al. 2000].
Despite the epidemiological evidence linking cigarette smoking with
cardiovascular disease, the precise components of cigarette smoke responsible
for this relationship and the mechanisms by which they exert their deleterious
effects have not yet been fully elucidated. Cigarette smoke is a complex mixture
11
and only a few components have been extensively studied. Nicotine and ca
rbon
monoxide are much less damaging than is whole smoke. There is conside
rable
evidence that cigarette smoking can result in both morphological and bioche
mical
endothelial disturbances both in vivo and in vitro [Michael Pittilo 2000].
1.1.3.2. New risk factors
In recent years, a number of new candidate risk factors or markers ha
ve
been proposed as significant predictors of atherosclerosis and its com
plications.
These risk factors and markers are summarized in Table 2 [Hackam et al. 2003].
Among these factors, four of them will be discussed emphatically
due to their
unique advantages. 1). There is substantial evidence on their predictive abilities.
2). A genetic basis for premature disease involves these factors. 3). Modifying
treatments of these factors are available. 4). These factors are the subject cf
ongoing or completed clinical trials. Ihese factors are C-reactive pro
tein (CRP),
Lp (a), fibrinogen, homocysteine, and infection.
1.1.3.2.1. CRP
CRP is a circulating acute-phase reactant that is increased man
y-fold
during the inflammatory response to tissue injury or infection [Du Clos. 2000].
This protein has received substantial attention in recent years as
a promising
biological predictor of atherosclerotic disease [Pearson et al. 2003]. Studies have
provided evidence that CRP is flot only a risk marker for atherosclero
sis but also
promotes atherosclerosis. (See section I.VL for details).
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1.1.3.2.2. Lpfa)
Lp(a) is an LDL-Iike particle in which an apolipoprotein fa) moiety is Iinked
via a disulfide bond to apoB-100 of LDL [Milionis et al. 20001. Concentrations of
Lp fa) are Iargely under genetic control and vary substantially between
individuals depending on the size of the apo fa) isoform present. On the other
hand, Lpfa) levels change littie with diet or exercise, unlike other lipoproteins
such as LDL and HDL [Kraft et al. 1996]. Cross-sectional and many prospective
studies have revealed the association between high plasma levels of Lp(a) and
atherosclerotic vascular diseases [Djurovic et al. 1997, Danesh et al. 2000].
These epidemiological evidence largely support the hypothesis that Lp fa) is a
highly atherothrombotic lipoprotein. Lpfa) is an acute-phase reactant [Min et al.
1997], more than doubling in concentration in response to the proinflammatory
cytokine interleukin 6 (IL-6) [Craig et al. 1992]. The mechanisms through which
Lpfa) triggers atherosclerosis have been identified. Lp(a) binds avidly to
endothelial cells, macrophages, fibroblasts, and platelets, as well as to the
subendothelial matrix [Pillarisetti et al. 1997, Poon et al. 1997]. After binding, it
promotes proliferation of vascular SMCs and chemotaxis of human monocytes
[Pillarisetti et al. 1997, Grainger et al. 1994, Poon et al. 1997]. However, its most
important putative role in atherothrombosis is to inhibit dot fibrinolysis at sites of
tissue injury. As Lp(a) has unique structural homology to plasminogen, it is
thought to compete with plasminogen for binding to plasminogen receptors,
fibrinogen, and fibrin [Loscalzo 1990]. Lpfa) may also induce the production of
PAl-1 and may inhibit the secretion of tissue-plasminogen activator by
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endotheliaf celis [Li et al. 1997, Levin et al. 1994]. Thus, Lp(a) is considered as
an emerging cardiovascular risk factor due to its properties as an atherogen
ic
and prothrombotic molecule [Lippi et aI [2003].
Table 2. Novel risk factors for atherosclerotic vascular disease.
lnflammatory Mackers
CRP
Interleukins (e.g. IL-6)
Serum amyloid A
Vascular and cellular adhesion molecules
Soluble CD4O ligand
Leukocyte count
Homeostasis/Thrombosis Markers
Fibrinogen
Von Willebrand factor antigen
PAl-1
Tissue-plasminogen activator
Factors V, VII
D-dimer
Fibrinopeptide A
Prothrombin fragment 1+2
Platelet-Related Factors
Platelet aggregation
Platelet activity
Platelet size and volume
Lipid-Related Factors
SmaIl dense LDL
Lp fa)
Remnant lipoproteins
Apolipoprotien Al and B
HDL subtypes
OxLDL
Other Factors
Homocysteine
Lipoprotein-associated phospholipase A (2)
Microalbuminuria
Insulin resistance
PAl-1 genotype
Angiotensin-converting enzyme genotype
ApoE genotype
I nfectious agents: Cytomegalovirus, Chlamydia pneumonia, Helicobacter
Pylori, Herpes simplex virus
Psychosocial factors
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1.1.3.2.3. Fibrinogen
Fibrinogen is a circulating gtycoprotein, which acts at the final step in the
coagulation pathway [Herrick et al.1999J. Epidemiological data support an
independent association between elevated levels of fibrinogen and cardio
vascular morbidity [Danesh et al. 1998, Matesca et al. 1999, Orem et al. 2003]. A
recent study reports the effect of genetic variant of platelet fibrinogen receptor on
the risk of cardiovascular event associated with elevated fibrinogen plasma levels
[Boekholdt et al. 2004]. Ihe potential pathophysiological mechanisms by which
elevated fibrinogen levels mediate cardiovascular risk include the following
aspects [Koenig et al. 2003]. 1). It forms the substrate for thrombin and
represents the final step in the coagulation cascade. 2). It is essential for platelet
aggregation and modulates endothelial function. 3). It promotes SMC
proliferation and migration. 4). It interacts with the binding of plasmin with its
receptor. 5). It represents a major acute phase protein.
1.1.3.2.4. Homocysteine
Homocysteine is a non-protein-forming sulfhydryl amino acid derived from
the methionine metabolism [Mangoni et al. 2002]. Cells remetabolize
homocysteine by a number of possible pathways involving several different
enzymes. These enzymes variously use B vitamins as substrates or cofactors,
namely folate, cobalamin, and pyridoxine [De Bree et al. 2002].
Hyperhomocysteinemia is considered to be a novel risk factor for coronary,
cerebral, and peripheral atherosclerotic disease. A common gene mutation
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encoding one cf the enzymes that metabolizes homocysteine, namely 5, 10-
methylenetetrahydrofolate teductase [MTHFRJ leads to moderate increase in
homocysteine levels, particularly in the presence of 10w folate intake [Frosst et al.
1995]. Hyperhomocysteinemia seen in general adult populations may be
associated with cystathionine synthase (CS) and MTHFR deficiencies [McCully
1996, Nehler et al. 1997, Nyard et al. 1997, Malinow 1995]. Mild homocysteine
increase is observed in 20-30% cf patients with atherosclerotic disease.
Treatment with folic acid returns plasma homocysteine concentrations to normal
[Yarnell 1991J. There is also considerable epidemiological evidence that the
homocysteine concentration is a risk factot for venous thrombosis [den Heijer et
al. 1998, Ray 1998].
Several mechanisms have been proposed to explain the atherogenic
properties ot homocysteine. They include endothelial dysfunction, oxidative
damage, SMC proliferation, activation of the PKC/c-fos signaling pathway,
platelet aggregation, and activation of the coagulation pathway [Dalton et al.
1997, Welch et al. 1997, Durand et al. 1997, Mangoni et al. 2002, De Bree et al.
2002, Werstuck et al. 2001].
1.1.3.2.5. Infection
There is increasing evidence that infectious pathogens, such as
Helicobacter pylori, cytomegalovirus, and Chlamydia pneumoniae, can promote
the atherosclerotic cascade. Proposed mechanisms include macrophage
transformation, endothelial injury, chronic inflammation, and thrombosis.
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Herpes viruses and Chlamydia pneumoniae are two main types cf
infecticus micrccrganisms that have been shcwn te correlate with the incidence
cf atherosclerosis [Leinonen et al. 2002]. Bcth organisms have been found in
coronary atheromatous lesions [Hendrix et al. 1990, Jackson et al. 19971. A
possible role cf hepatitis A in the pathogenesis cf atherosclerosis has also been
proposed [Zhu et al. 2000]. The role cf infectious agents in the pathcgenesis cf
athercsclerosis will further be discussed in section 1.1.4.4..
1.1.4. Pathogenesis of atherosclerosis
Athercsclercsis has been reccgnized for over a century, and the
understanding cf its pathcgenesis has undergone many changes. We discuss
some cf the hypothesis asscciated with the develcpment cf athercscleorsis as
fol lows.
1.1.4.1. Endothelial dysfunction hypothesis
The endothelium retains a reduced vascmctor tone, prevents leukccyte
and platelet adhesicn, and inhibits the prcliferaticn cf vascular SMCs under
physiclcgical ccnditions. Conversely, endcthelial dysfuncticn refers te several
pathological conditions, including altered anticoagulant and anti-inflammatory
prcperties cf the endothelium, impaired modulation cf vascular grcwth, and
dysregulaticn cf vascular remodeling. Endothelial dysfunction plays a pathcgenic
rcle in the initial development cf atherosclerosis [Ross 1999, Poredos 2002].
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Abundant evidence has proven that endothelial dysfunction also preceeds the
development of atherosclerotic lesions [Celermajer 1997, Poredos 2001].
I.I.4.tl. Risk factors for endothelial dysfunction
Endothelial dysfunction has been demonstrated in subjects with different
risk factors of atherosclerosis, including hypercholesterolemia, diabetes,
hypertension, smoking, obesity, and others [Celermajer et al. 1992, Libby et al.
2002]. Treatment of these risk factors results in improvement of endothelial
dysfunction. Over the past few years, it has been documented that chronic
inflammation is a key pathogenic factor in endothelial dysfunction [Verma et al.
2003]. Inflammatory activity and endothelial dysfunction are thought to be
strongly interrelated [Ross 1999]. Inflammatory cytokines such as TNFa and IL-6
can cause endothelial dysfunction either directly or indirectly [Ross 1999,
Stehouwer et al. 1997, Yudkin et al. 1999]. CRP is induced by cytokines such as
IL-6 [Xing et al. 1998] under inflammatory conditions and has been shown to
induce endothelial dysfunction [Verma et al. 2003]. For example, CRP potently
downregulates eNOS transcription in endothelial cells and destabilized eNOS
mRNA, with resultant decrease in both basal and stimulated NO release [Verma
et al. 2002]. Induction of adhesion molecule expression has also been
documented in CRP-treated endothelial cells in vitro. Importantly, investigators
have shown a direct correlation between endothelial dysfunction and plasma
levels of CRP has been demonstrated [Fichtlscherer et al. 2000a, Fichtlscherer
et al. 2000b].
1$
LL4.1.2. Mechanisms of endothelial dysfunction in atherosclerosis
Endothelial dysfunction implies diminished production or availability of NO.
NO is generated by the conversion of the amino acid L-arginine to NO and L
citrulline by the enzyme NO synthase (NOS). it is the key endothelium-derived
relaxing factor and plays a pivotai role in the regulation of vascular tone and
vasomotor function [Albrecht et aI. 2003]. Diminished NO production leads to
decreased endothelium-dependent vasodilation, increased platelet aggregation
and adhesion of monocytes to the endothelium, and enhanced vascular SMC
proliferation. Reduction of NO production/bioactivity mediates oxLDL-induced
endothelial dysfunction/activation [Cominacini et al. 2001]. NO released from the
endothelium is decreased in patients with coronary atherosclerosis [Ludmer et al.
1986, Vita et al. 1990J. Endothelial dysfunction is elicited from imbalance
between the release of endothelium-derived relaxing and contracting factors,
such as ET-1 and angiotensin [Verma et al. 2002]. High plasma ET-1
concentrations have been reported in myocardial infarction, cardiogenic shock,
unstable angina pectoris, coronary artery disease in general, cardiac failure, and
essential hypertension [Poch et al. 1995, Agapitov et aI. 2002]. Endothelium
dysfunction/activation is associated with increased expression of endothetial cell
adhesion molecules including selectins, vascular ceil adhesion molecule (VCAM
1), and intercellular adhesion molecule-1 (ICAM-1), which promote adherence of
monocytes to endothelium. This process can be triggered by proinflammatory
cytokines, CRP, 0xLDL, and CD4O/CD4O ligand (CD4OL and CD154) interaction
C [Collins et al. 2001, Chen et al. 2002, Verma et al. 2002, Kaplanski et aI. 1998,
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Schonbeck et al. 2001]. Endothelial dysfunction is associated with major risk
factors cf atherosclerosis including hyperlipidemia, hypertension, smoking,
diabetes, and aging.
114.2. Lipid infiltration hypothesis
In the early l9th century, von Rokitansky [1852] found that the main
characteristic feature of atherosclerosis is cholesterol accumulation in the intima.
Much later, the lipid infiltration hypothesis was supported by the studies of Deng
et al. [1993] demonstrating the presence of atherosclerotic lesions in rabbits fed
a cholesterol-enriched diet. The lipid infiltration hypothesis postulates that high
plasma LDL levels associated with several risk factots including inappropriate
diet, obesity, physical inactivity, cigarette smoking and low estrogen levels,
resuits in the penetration of LDL into the arterial wall. This leads te
subendothelial lipid accumulation, which attracts macrophages and leads to their
conversion to foam cells. LDL also causes migration and multiplication of SMCs
in the subendothelial region. This hypothesis has been reinforced over the past
years by clinical studies showing a direct correlation between plasma cholesterol
levels and CHD and aIse demonstrating a reduction of cardiovascular events by
normalization of plasma lipid levels [Ito et al. 2001, Koizumi et al. 2002, Sasaki et
al. 2003].
The lipid infiltration theory alone does net explain everything about the
atherosclerotic process. Indeed, high cholesterol levels and inflammation appear
to be two essential components in the pathogenesis of atherosclerosis and both
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components seem to play a key role in the formation of the atherosclerotic lesion.
In fact, both processes interact, with oxLDL and/or its products having
proinflammatory activities [Witztum et al. 2001] (See Table 3).
Table 3. The effects 0f oxidized LDL and/or its products-oxidized phospholipids andlor oxysterols.
Mimic biological effects of platelet-activating factor.
Induce monocyte binding to endothelial ceils.
Increase tissue factor activity in endothelial celis (minimally modifïed-LDL).
Increase expression of M-CSF, monocyte chemotactic protein-1.
Increase expression 0f VCAM-1 (LPC and 1 3-HOO stea rate).
Induce apoptosis.
Inhibit nitric oxide release or function.
Induce expression of intedeukin-1 and interleukin-8.
Increase collagen synthesis in smooth muscle ceils.
lnccease intracellular calcium.
Inhibit lipooolvsaccharide-induced exDression of NFKB.
1.1.4.3. Oxidative stress hypothesis
This hypothesis proposes that many pathogenic mechanisms in
atherogenesis may resuit from increased oxidative stress. Oxidative stress is a
state in which excess reactive oxygen species (ROS) overwhelm endogenous
antioxidant system. ROS are reactive chemical entities that can be classified into
two categories: free radicals and non-radical derivatives [Kukreja et al. 1994].
Free radicals are more reactive than the corresponding non-radicals. While ROS
in low concentrations serve as signaling molecules, the excessive induction of
C ROS elicits harmful
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Figure f. Modulation of cellular function by ROS in cardiovascular diseases. [Taniyama et al. 2003)
As shown in figure 1, ROS ptay major roles in the initiation and
progression of cardiovascular dysfunction associated with diseases such as
hyperlipidemia, diabetes mettitus (DM), hypertension, ischemic heart disease,
and chronic heart failure. ROS affect many functions of the endothelium. The
most weII known ïs endothelium-dependent vasoretaxation, which is ïmpaired by
a Ioss of NO bioactivity in the vessel watt [Mugge et aI. 1991]. ROS atso cause
endothefial apoptosis [Dimmeter et aL 2000, Li et aI. 1999], increase monocyte
adhesion [Marui et al. 1993, Khan et al. 1996, Chappell et al. 1998], and play a
rote in angiogenesis fMaulik et aI. 2002, Kurokï et aI. 1996, Arbiser et al. 2002].
ROS can cause vascular SMCs growth [Rao et aI. 1992, Sundaresan et aI. 1995,
Patterson et al. 1999J and migration [Weber et al. 2002], as well as induce the
ECs
ceils
Hypertrophy
Proilferation
Migration
Matrix regulatlon
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( expression of matrix components [Rajagopalan et al. 1996] and inflammatory
mediators such as NFKB [Li et aI. 2002].
Several studies have demonstrated the ability of various antioxidant
compounds to prevent atherogenesis in animais. For example, it has been shown
that probucol inhibited the formation of atherosclerosic lesions independently of
its choiesterol-iowering properties in Watanabe hereditary hyper! ipidemic
(WHHL) rabbits [Carew et al. 1987]. This agent aiso reduces the formation of
atherosclerotic lesions in cholesterol-fed monkeys [Sasahara et al. 1994].
Moreover, vitamin E has been shown to reduce atherosclerosis both in WHHL
rabbits [Williams et al. 19921 and cholesterol-fed hamsters [Parkec et ai. 1995].
While these resuits suggest that antioxidants may protect against
atherosclerosis, human studies are less convincing. Aithough in epidemiological
studies a higher intake of antioxidant vitamins or a higher plasma concentrations
of vitamin E seem to protect patients to some extent [Riemersma et al. 1989],
clinical intervention studies in patients at high risk of cardiovascular events have
been inconciusive [Steinberg et al. 2002]. This has led to a general consensus
that antioxidant supplements are of no value in the prevention of CVD in subjects
at high risk. For examples, several large-scale, double-blind, placebo-controlled
trials have shown convincingly that neither E3-carotene [Omenn et aI. 1996,
Hennekens et al. 1996, Alpha-Tocopherol, Beta-Carotene Cancer Prevention
Study Group 1994] nor vitamin E alone in the Heart Outcomes Prevention
Evaluation (HOPE) study and the Heart Protection Study (HPS) [Yusuf et al.
Ç 2000, Heart Protection Study Collaborative Group 2002] or in combination with
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other antioxidant vitamins [Brown et al. 2001], reduces the risk of fatal or nonfatal
infarction in an unselected population of people with established CHD or at high
risk of CHD.
1.1.4.4. Hypothesis of infection
There is reasonable evidence suggesting that infection may contribute ta
the pathogenesis of atherosclerosis. Several studies have addressed the
possible raie 0f infectious agents in the development cf atherosclerosis. One
interesting candidate is Chlamydia pneumoniae (C.pneumoniae), a human
respiratcry pathogen, which has been linked in bath sero-epidemiological and
immunohistochemical studies with CHD [Saikku et aI, 1998, Elkind et aI, 2000,
Schmidt et aI, 2000]. Results of animal experiments and preliminary intervention
trials with antibiotics [Gurfinkel et al 1999] further suggest a raIe of this pathogen
in atherogenesis. A second infecticus agent is Helicobacter pylori (H. pylori), a
pathogen invoived in peptic ulcer [Danesh et al. 1997]. H. pylori DNA is found in
atherosclerotic plaques, but is absent in healthy vascular walls [Farsak et al.
2000].
1.1.4.5. Hypothesis of inflammation
Several studies have firmly established that immune mechanisms play a
key raie in the pathogenesis cf atheroscierosis. in fact, recent advances in basic
science have demcnstrated a fundamental raIe for inflammation in mediating ail
stages cf atherosclerosis from initiation thrcugh progression, and ultimately
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thrombotic complications. Whilst the inflammatory response and cell-mediated
immunity may be initially protective in atherogenesis, persistent and excessive
inflammation will fayot the progression of the disease.
Signs of inflammation accompany the eatliest accumulation of lipid within
the arterial wall. Blood leukocytes adhere poorly to the normal endothelium.
When the endothelial monolayer becomes inflamed, t expresses adhesion
moiecules that bind cognate ligands on circulating leukocytes. Once adherent to
the endothelium, the leukocytes contribute to the local inflammatory response
and simultaneously penetrate into the intima. MCP-1 is responsible for
transmigration of monocytes into the intima and a family of T-cell
chemoattractants is in charge for transmigration of lymphocytes. M-CSF is most
essential for monocyte/macrophage differentiation in the atherosclerotic lesions.
Monocyte-derived macrophages are scavenging and antigen-presenting cells.
They secrete cytokines, chemokines, growth-regulatory molecules,
metalloproteinases and other hydrolytic enzymes. These secretory products may
play a critical role in converting fibrous plaque from stable to unstable ones.
Proinflammatory cytokines such as IL-1, IL-6, IL-8, interleukin-lO (IL-10),
interleukin-12 (IL-12), and TNFŒ produced by macrophages in the arterial wall
provide chemotactic stimuli ta adherent leukocytes directing their migration into
the intima. Activated macrophages express class II histocompatibility antigens
such as HLA-DR that a!low them to present antigens ta T lymphocytes [Raines et
al. 1996]. Both CD4 and CD8 T cells are present in the lesions at aIl stages of the
atherosclerotic process, particularly CD4 subtype [Zhou et al. 1996, Hansson et
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al. 1989]. T ceils are activated when they bind antigen processed and presented
by antigen presenting ceHs including SMCs [Hansson et al. 1989], dendritic ceits
(DCs), and macrophages. Activated T ceils elaborate inflammatory cytokines
such as TNFŒ and interferoni’ (IFN-y). IFN-y is the predominant cytokine
produced by intraplaque T ceils. It activates macrophages and induces
inflammatory responses. Several in vitro and in vivo data indicate that IFN-y is
proatherogenic. Among these, it has been shown that IFN-y downregulates ABCI
a protein that regulates cholesterol effiux from macrophages [Wang et al. 2002],
antagonizes the production of collagen [Billiau et al. 1998], which is widely
believed to stabilize plaque structure and that blockage of IFN1’ resuits in an
approximately 60% reduction in atherosclerosis [Gupta et al. 1997]. Thus, in
human lesions, T ceils may play s role in both lesion development and instability.
OxLDL and heat-shock proteins are candidate antigens initiating adaptive
immunity in atherosclerosis. A third proposed autoantigen is 32-glycoprotein lb.
Some evidence also implicates microbial pathogens in atherogenesis and
bacteria may induce innate immunity and autoimmunity.
DCs arise trom a common CD34+ progenitor in the bone marrow and
constitute a family of celis that are able to induce primary immune responses
[Banchereau et al. 1998, Austyn 1998, Palucka et al. 1999]. DCs express high
levels of both class I and class Il MHC molecules and co-stimulatory moiecules,
and this thereby relates to their unique ability for activating naïve T ceils
[Banchereau et al. 1998, Austyn 1998, Palucka et al. 1999]. In the arterial wall,
DCs are present in their immature forms and become activated during
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atherogenesis [Bobryshev et al. 1995a, Bobtyshev et al. 1995b, Bobryshev et al.
1998, Bobryshev et al. 1999]. For example, immunohistochemical and
ultrastructural studies have shown that the number of DCs increased in
atherosclerotic arteries [Bobryshev et al. 1995, Bobryshev et al. 1996a,
Bobryshev et al. 1996b, Bobryshev et al. 1998]. Also, DCs have been identified
in atherosclerotic lesions in rats with experimental hypercholesterolemia and in
apoE deficient mice [Ozmen et al. 2002, Bobryshev et al. 1999a, Bobryshev et
al. 1999b]. Although vascular DCs become activated and differentiate at early
stage of atherosclerosis, advanced atherosclerotic plaques are enriched either by
adventitial vascular DCs invading directly [Bobryshev et al. 1998] or by blood
DCs invading via inflamed neovessels [Bobryshev et al. 1998, Bobryshev et al.
1999]. Although the functional significance of DCs in atherosclerotic lesions
requires clarification, it is reasonable to postulate that DCs in the arterial watt
may be involved in antigen capture and antigen processing [Bobryshev et al.
1998]. Bobryshev et al [1998] observed in the atherosclerotic lesions. DCs
frequently located in areas enriched with T cells, particularly within inflammatory
infiltrates. DCs clustering with T ceNs display ICAM-1 and VCAM-1 [Bobryshev et
al. 1998], which interact with LFA-1 and VLA-4, respectively and this co
Iocalization is thought to be essential for T celi activation. It has also been found
that inflammatory cytokines as well as heat-shock proteins [Springer 1994] are
responsible for DC activation, while chemokines control DC migration
[Banchereau et al. 1998, Lane et aI. 1999, Palucka et al. 1999, Dieu et al. 1998,
C
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G Arnold-Schild et aI. 1999, Todryk et al. 1999]. Taken together, DCs may play a
crucial role in T ceil activation in atherosclerosis.
Recent studies have provided evidence that mast celis are present in
various stages cf atherosclerotic lesions. Mast celis can assist in the recruitment
cf monocytes and lymphocytes into vascular tissues, theteby propagating the
inflammatory response.
1.11. Dïabetes mellitus (0M)
1.11.1. Definition
DM is a group of metabolic syndromes characterized by chronic
hyperglycemia, the hallmark of the disease [Olefsky et al. 1992] and disturbances
of carbohydrate, fat and protein metabolism resulting from defects in ins
ulin
secretion, insulin action or both. The effect of chronic hyperglycemia 0f diab
etes
is associated with long-term damage, dysfunction and failure cf various org
ans,
especially the eyes, kidneys, nerves, heart, and blood vessels. Sympto
ms cf
marked hyperglycemia include polyuria, polydipsia, weight loss, polyphagia, a
nd
blurred vision. In its most severe forms, ketoacidosis or a non-keto
tic
hyperosmolar state may develop and lead to stupor, coma and death in
the
absence of effective treatment.
1.11.2. Classification
The classification cf DM was brought into order by the National Diabetes
Data Group cf the USA and the second World Health Organization (WHO) Expert
2$
Committee on Diabetes MeHitus in 1979 and 1980. Apart from minor
modifications by WHO in 1985, little has been changed since that time. This
classification cf DM is shown in Table 4. In light cf the new knowledge regarding
the etiology of different forms of diabetes, an etiologic classification of diabetes is
also presented in Table 5.
1.11.2.1. Type I diabetes
Type 1 diabetes is a chtonic disease that occurs when the pancreas
ptoduces too little insulin to regulate blood sugar levels appropriately. Type I
diabetes have weak link with Class I antigens (B8 and Bis), but have stronger
link with Class Il antigens (DR3 and DR4) and subtypes cf DR4 antigens (Dw4,
10, and 14) [Braun 1992]. Approximately 95% cf white patients with type 1
diabetes have either DR3 or DR4 antigens, and around 55 to 60% have bcth
antigens. The HLA-DR3 and DR4 genes are believed to be the primary
susceptibility genes for type I diabetes. The observation that heterozygosity for
DR3/DR4 increases the risk for diabetes compared with homozygosity for other
high-risk alleles suggests a polygenic mode of inheritance [Bertrams 1984].
Although the genetic contribution is important for developing type 1 diabetes, it is
insufficient and requires an environmental factor to trigger its initiation.
Type 1 diabetes is classifled as classic autoimmune (type lA) and
idiopathic (type 1 B) diabetes [Report cf the Expert Committee on the Diagnosis
and Classification cf Diabetes Mellitus 1997, Alberti et al. 1998]. Type lA
diabetes, results from a cellular-mediated autoimmune destruction of the beta
29
ceils of the pancreas. It accounts for only 5-10% of this type of diabetes. It can
become manifest with hyperglycemia presenting in the first days of life or in
adults over the age of 60. Several evidences support that type 1 diabetes is an
immune-mediated disease [Rewers et al. 1996, Wucherpfennig et al. 2001,
Atkinson et al. 2001]: First, it is Iinked with class II HLA (D-region) antigens
known to be associated with autoimmune disease. Second, it may occur with
other forms of immune endocrinopathies and coupling of diabetes with immune
endocrinopathy may cluster in families. Third, an early lesion in experimental and
human type 1 diabetes consists of lymphocytic infiltration of the islets
Langechans (insulitis or isletitis) resembling lymphocytic infiltrations in other
autoimmune diseases. Fourth, antibodies directed against both cytoplasmic and
celi-surface determinants on islet ceils are present in many type 1 diabetic
patients at diagnosis. Finally, immunotherapy prevents overt diabetes in
experimental models of diabetes.
Markers of the immune destruction of the 3-cell are detectable in type 1
diabetes. These antibodies include autoantibodies to islet celis, insulin, glutamic
acid decarboxylase (GAD65), and tyrosine phophatases lA-2 and IA-2f3. Several
of these autoantibodies are present in 85-90% of individuals with type 1 diabetes
having impaired fasting hyperglycemia levels. In this form of diabetes, the rate of
13-cell destruction is quite variable, being rapid in infants and children and slow
in
ad u Its.
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Table 4. Classification of the Types of Diabetes. [World Health Organization 1985]
Class name Characteristcs
lnsulin-dependent diabetes Low or absent levels 0f circulating endogenous insulin and dependent on
mellitus (IDDM) injected insulin to prevent ketosis and sustain life.
Onset predominantly in youth but can occur at any age.
Associated with certain HLA and GAD antigens.
Abnormal immune response and islet ceil antibodies are frequently
present at diagnosis.
Etiology probably only partially genetic, as only —35% of monozygotic
twins are concordant for IDDM.
Non-insulin-dependent diabetes lnsulin levels may be normal, elevated, or depressed; hyperinsulinemia
mellitus (NIDDM) and insulin resistance characterize most patients; insulinopenia may
develop as the disease progresses.
Not insulin-dependent or ketosis-prone under normal circumstances,
but may use insulin for treatment of hyperqlycemia.
Onset predominantly after the age of 40 years but can occur at any age.
Approximately 50% 0f men and 70% 0f women are obese.
Etiology probably strongly genetic as 60%—90% 0f monozygotic twins
are concordant for NIDDM.
Gestational diabetes (GDM) Glucose intolerance that has its onset or recognition during pregnancy.
Associated with older age, obesity, family history of diabetes.
Conveys increased risk for the woman for subsequent progression to
NIDDM.
Associated with increased risk 0f macrosomia.
Other types 0f diabetes, including In addition to the presence 0f the specific condition, hyperglycemia at a
diabetes secondary to or level diagnostic 0f diabetes is also present.
associated with:
Pancreatic disease Causes of hyperglycemia are known for some conditions, e.g.,
Hormonal disease pancreatic disease; in other cases an etiologic relationship between
Drug or chemical exposure diabetes and the other condition is suspected.
Insu lin receptor abnormalities
Certain genetic syndromes
o
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( Table 5. Etiologic classificatïon of DM. [American Diabetes Association 20041
I. Type 1 diabetes (f3-ceII destruction, usually leading to absolute insulin deficie
ncy)
k lmmune-mediated
B. Idiopathic
J;. Type 2 diabetes (may range from predominantly insulin resistance with re
lative
insulin deficiency ta a predominantly secretory defect with insulin
resistance)
III. Other speciric type
k Genetic defects cf (13-celI function)
1. Chromosome 12, HNF-la(MODY3)
2. Chromosome 7, glucokinase fMODY2)
3. Chromosome 20, HNF-4a (MODYJ)
4. Chromosome 13, insulin promoterfactor-1 (IPF-1; MODY4)
5. Chromosome 17, HNF-113 (MODY5)
6. Chromosome 2, Neuro Dl (MODY6)
7. Mitochondrial DNA
8. Others
B. Genetic defects in insulin action
1. Type A insulin resistance
2. Leprechaunism
3. Rabson-Mendenhall syndrome
4. Lipoatrophic diabetes
5. Others
C. Diseases 0f the exocrine pancreas
1. Pancreatitis
2. Trauma/pancreatectomy
3. Neoplasia
4. Cystic fibrosis
5. Hemochromatosis
6. Fibrocalculous pancreatopathy
7. Others
D. Endocrinopathies
1. Acromegaly
2. Cushing’s syndrome
3. Glucagonoma
4. Pheochromocytoma
5. Hyperthyroidism
6. Somatostatinoma
7. Aldosteronoma
8. Others
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Table 5. Etiologic classification of 0M (Continue).
E. Drug- or chemical-induced
1. Vacor
2. Pentamidine
3. Nicotinic acid
4. Glucocorticoids
5. Thyroid hormone
6. Diazoxide
7. t3-adrenergic agonists
8. Thiazides
9. DIantin
10. a-Interteron
11. Others
F. Infection
1. Congenital rubella
2. Cytomegalovirus
3. Others
G. Uncommon forms of immunemediated diabetes
1. S tiff-man” syndrome
2. Anti-insulin receptor antibodies
3. Others
H. Other genetic syndromes sometimes associated wfth diabetes
1. Downs syndrome
2. Klinefelters syndrome
3. Turners syndrome
4. Wolfram’s syndrome
5. Friedreichs ataxia
6. Huntintons chorea
7. Laurence-Moon-Biedl syndrome
8. Myotonic dystrophy
9. Porphyria
10. Prader-WiDi syndrome
11. Others
IV. GDM
Some patients, particularly chiidren and adolescents, may present with
ketoacidosis as the first manifestation of the disease. Others have modes
t fasting
hyperglycemia that can rapidly change to severe hyperglycemia an
d/or
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ketoacidosis in the presence of infection or other stress. Aduits may retain
residual f3-cell function sufficient to prevent ketoacidosis for many years.
Unlike type lA diabetes, type lB is flot triggered by an autoimmune
response and is of unkown origin. These patients have permanent insulinopenia
and are prone to ketoacidosis. This form of diabetes is strongiy inherited, Iacks
immunological evidence for R-ceII autoimmunity, and is flot HLA associated.
Individuals with this form of diabetes suifer from episodic ketoacidosis and exhibit
varying degrees of insulin deficiency between episodes. Thus, some patients with
type 1 B require insulin repiacement therapy [Banerji et ai. 1989].
LIL2.2. Type 2 diabetes
Type 2 diabetes is characterized by a state of resistance to insulin
mediated glucose disposai in muscle, liver, and adipose tissue associated with
an absolute or relative deficiency in insuiin secretion. it accounts for 90-95% of
DM. Both genetic and environmentai factors contribute to the deveiopment of
type 2 diabetes. Obesity and insuiin resistance are major risk factors for this form
of diabetes [Haifner et ai. 2003].
Type 2 diabetes is preceded by a long period of asymptomatic
hypergiycemia and thus remains frequently undiagnosed for many years.
Persistent metaboiic derangement before the onset of frank diabetes is
responsibie for the high incidence of micro- and macro-vascular complications in
patients with type 2 diabetes. Cardiovascuiar disease is responsible for 80% of
C
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the mortality in patients with type 2 diabetes and impor
tantly preceeds overt
diabetes in more than 50% of patients.
1.11.2.2.1. Prevalence
The number of diabetic patients is increasing worldwide
. The WHO
predicts that between 1997 and 2025, the number of diab
etics will double from
150 to about 300 millions. The incidence has increased by
about 33% over the
Iast decade and is expected to increase further. However
, the greater tise in the
prevalence of type 2 diabetes is projected to occur in developing count
ries,
particularly India and China.
1.11.2.2.2. Etiology
There is no single cause of type 2 diabetes. The dev
elopment of this
disease in high-risk subjects is caused by both polygenetic and environme
ntal
factors. Factors that predispose an individual to the
development of type 2
diabetes are listed in Table 6 [American Diabetes Association. 20031.
Type 2
diabetes occurs primarily in individuals greater than 45 ye
ars of age [Harwell et
al. 2001], however an increased prevalence of childhood obesity h
as promoted a
marked increase of type 2 diabetes in adolescents and
young adults [Pinhas
Hamiel et al. 1996]. Obesity is a major tisk factor for type 2 diabetes [Chan
et al.
1994, Colditz et al. 1995]. In fact, 80% of patients with type 2
diabetes are
overweight.
35
Table 6. Diabetic risk factors.
Age > 45
Body mass index (8M I) 25kg1m2
A Family history 0f diabetes
Physical inactivity
Ethnicity
lmpaired tasting glucose (IFG) or impaired glucose tolerance (IGT)
A History 0f gestational DM, orthe delivery 0f a baby of >9 lb
Hypertension
Dyslipidemia
A History 0f vascular disease
Insulin resistance is also an essential determinant in the development of
type 2 diabetes [Goldsteln 2003]. Women with a history of GDM, and their
children, have a relatively high risk of developing type 2 diabetes. Numerous
epidemiological studies also indicate that a sedentary ifestyle is strongly and
independently related to an increased incidence of type 2 diabetes. Several of
these studies establish a dose-response relationship between physical activity
and risk cf diabetes [James et al. 1998, Astrup et al. 2001].
1.11.2.2.3. Genetic factors
There is considerable evidence that genes are important in the etiology of
type 2 diabetes [McCarthy et al. 1994]. For example, it has been shown that 1) a
history cf type 2 diabetes in a first-degree relative doubles the risk of developing
diabetes, b) identical twins of parents who have type 2 diabetes have 80-90%
chance to develop diabetes [Kenny et al. 1995, Rewers et aI. 1995]; c) patents
and siblings cf patients with type 2 diabetes, who share 50% of their genes, are
3-4 times more likely to have type 2 diabetes than subjects without diabetic
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relatives [Kenny et al. 1995, Rewers et al. 1995]. Variation in prevalence
between ethnic groups also provides evidence for the genetic component of type
2 diabetes. lndeed, migration studies show that genetic predisposition varies
markedly between races that live in s similar environment [Kenny et al. 1995].
Detailed analysis of the challenges and progress towards defining genetic
susceptibility ta type 2 diabetes has been reviewed by Elbein et al [1994]. Current
research suggests that only a small number of cases of type 2 diabetes are
caused by a single-gene defect. These cases include maturity-onset DM of youth
(mutated MODY gene), syndrome of insulin resistance (insulin receptor defect),
and maternally inherited DM and deafness (mitochondrial gene defect) [Sa et al.
2000]. The genetic component of the more typical common form of type 2 DM is
probably complex, involving the interactions of several genes and environmental
factors [So et al. 2000]. It is now well accepted that the genetic component is
subject to major influence from the environment, type 2 diabetes becoming
manifest unless the environment permits for example excess dietary intake and a
degtee of obesity.
1.11.2.2.3.1 Gene candidates
Most of major advances in understanding the genetics 0f type 2 diabetes
have been done in the tare subtypes caused by mutations of a single gene
[Hattersley 1998]. Defining the genes that predispose patients ta otdinary type 2
diabetes is considerably more difficuit than defining causal genes in tare
monogenic subgroups. Recent studies have shown that, unlike HLA genes in
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type I diabetes, there is no single major predisposing type 2 diabetes gene. To
date, more than 250 candidate genes have been investigated in type 2 diabetes
but none has been found to play a major role in the common forms of type 2
diabetes. Genetic classification of type 2 diabetes is shown in Table 7 [Unger et
al. 1998]. Recently, evidence has accumulated that a variant in the peroxisome
proliferator-activated receptor (PPAR)-y gene is protective for the development of
type 2 diabetes [Altshuler et al. 2000]. Conversely, it has been reported that
variations in the protease calpain 10 gene, is associated with susceptibility to
type 2 diabetes in Mexican Americans [Horikawa et al. 2000].
1.11.2.2.3.2. Mutations in genes involved in insulin resistance
Insulin receptor gene: As shown in figure 2 [Kahn 1994J, the insulin receptor
consists of two Œ subunits and two f3 subunits that bind the insulin f3-a-Œ-f3
heterotetramer. More than 40 mutations of the insulin receptor gene are known to
cause insulin resistance. However, mutations in the structural sequence of the
insulin receptor gene are not believed to cause insulin resistance in ordinary type
2 diabetes [Taylor et aI. 1992].
Insulin receptor substrate-1 tIRS-1): IRS-1 is the primary substrate of the
insulin receptor in most tissues (figure 2) and thus the IRS-J gene is a candidate
gene in type 2 diabetes. Although mutations in this gene have been identified in
patients with type 2 diabetes, they are common in nondiabetic subjects as well
[Stem 1995]. Genetic analysis of the IRS-1 gene has revealed several base-pair
3$
changes that result in amino acid substitutions [Almind et al. 1993, Laakso et al.
1994, 1mai et al. 1994]. The most common amino acid change is a glycine to
arginine substitution at codon 972 (G972R), which has an overali frequency of
—6% in the general population [Hitman et al. 1995]. This mutation has been
reported ta significantly impair IRS-1 function in experimental models cf diabetes
[Almind et aI. 1996]. Furthermcre, clinical studies have shown that this genetic
variant is associated with reduced insulin sensitivity. Although a variant cf IRS-1
may reinforce the negative effect cf cbesity on insulin-sensitivity, it seems
unlikely that mutations in the IRS-1 gene contribute to the pathogenesis cf type 2
diabetes.
GLUT4: Activation cf the insulin signal transduction system in insulin target
tissues leads to the stimulation cf glucose transport. GLUT4, the insulin
responsive facilitative glucose transpcrter, is expressed in insulin-sensitive
tissues such as muscles and adipocytes. GLUT4 activity was considered a prime
candidate for decreased glucose uptake in muscle and adipose tissue in cbesity
and diabetes. However, studies in large populations cf type 2 diabetics have
shown that GLUT4 polymorphisms are uncommon and occut with approximately
equal frequency in controls and patients with diabetes [Kusari, et al. 1991, Choi
et al. 1991].
39
JRas Complex
Lz:zrN
70K 56 90< 56 —d—— MAP Kinase -*---— MAPXK -*-— Rat-1
I Potoin Phtpha_
5 S6 Phos’n Nuclear Proteiri Glycogen syrdhaso Transcription Factor1 Phosn I‘1
Glucoee Proteln LIplU Glycogen Growth & Gene
Tran5port Syntheeli Synthesl Synthe5l6 Expre85lon
Figure 2. Downstream effects resulting from ïnsulin/insulin receptor interaction. [Kahn 1994]
Hexokinase II: Hexokinase Il is associated with GLUT4 and plays an important
role in intracellular glucose metabolism by catalyzing the conversion 0f glucose
to glucose-6-phosphate. Although it was considered to be a promising candidate
gene for type 2 diabetes and insulin resistance, missense mutations in the
hexokinase II gene that encodes the principal hexokinase isoenzyme occur with
equal frequency in type 2 diabetic patients and in controls [Laakso et al. 19951.
Hexokinase Il activity has been reported to be decreased in muscle of patients
with type 2 diabetes [Lehto et al. 1995].
Glucose
Insulin
Receptor
Ï
Pi 3-Kinase
GTP
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Table 7. Genetic Classification of type 2 diabetes. [Unger et al. 1998]
1. Genetically characterized forms of type 2 diabetes
A. Maturity-onset diabetes of the young (MODY)
7. MODY1— linked to chromosome 20q
2. MODY2— linked to glucokinase (7p1 3-1 5)
3. MODY3— linked to chromosome 12q
4. Others
B. Defects in the insulin gene (11 p15)
1. Famillal hyperproinsulinemia
2. Mutant insulin molecules
C. Defects in the inulin receptor flOpl3)
1. Leprechaunism
2. Type A syndrome of insulin resistance
3. Rabson-Mendenhall syndrome
D. Mutation in mitochondrial gene for tRNA
1. Maternally inherited diabetes with neurosensory deafness
2. MELAS syndrome
E. Mutation in GLUT2 glucose transporter (3q26) (one case only)
2. Genes involved in ordinary type 2 diabetes
A. Genes with some evidence for involvement
1. HLA locus-DR4 (6P21-23) — in elderly persons with type 2 only
2. Glucagon receptor gene (1 7q25)
3. Insulin receptor substrate-1 (2q76)
4. Glycogen synthase (1 9q1 3)
5. Intestinal tatty acid-binding proteins (4q)
6. RAD (2q3637)
B. Genes for which significant involvement has been ruled out
1. Insulin gene (11p15)
2. MODY genes (20q, 7p, 12q)
3. ATP-sensitive K channel (21q22)
4. Glucagon-like peptide-1 (GLP-1) receptor (6p21)
5. GLUT2 (3q36)
6. GLUT4 (17p13)
7. lnsulin receptor (1 9p1 3)
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Glycogen synthase: Glycogen synthesis and glycogen synthase are reduce
d in
type 2 diabetes. A missense mutation 0f the muscle glycogen synthase gene
(M416V) is associated with insulin resistance in the Japanese population and
may play a role in the pathogenesis of type 2 diabetes [Shimomura et al. 1997].
1.11.2.2.3.3. Mutation in genes encoding 3-ceII proteins involved in the
quality and quantity of secreted insulin (figure 3)
Pro-insulin and insulin: Mutations in pro-insulin gene have been reported
.
These mutations associated with hyperinsulinemia or hyperpro-insulinemia
do
net alter glucose homeostasis in the absence of other environmental factor
s such
as age and obesity [kahn et al. 1996]. A polymorphism in the 5’ region of insulin
gene has been described in obese women [Weaver et al. 1992]. In addition,
Olansky et al [1992] identified that an insertion in the promoter cf insulin is
responsible for decreasing promoter activation, and this alteration has
been
found to contribute to 5 to 6% in the development of type 2 diabetes in Afr
ican
Americans. A mutation in insulin gene, responsible for hyperpro-insulinemia
has
also been reported by Coilinet et ai in 199$. Final (y, a mutation cf allele 2 in
insulin gene has been shown to induce diabetes and severe dysfunc
tion cf
pancreatic 13-cells in mice [Wang et al. 1999]. Despite these resuits, it is
important to note that insulin gene mutation is unhikely ta play a major role in the
development of type 2 diabetes.
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GLUT2: GLUT2 is another glucose transporter and is also a candidate gene in
type 2 diabetes [Davies et al. 1998]. GLUT2 mRNA and protein are decreased in
diabetic animais, and this transporter is a target molecule for streptozotocin, an
agent used to induce experimental diabetes. Nevertheless, GLUT2 mutations are
not common in type 2 diabetes, although rarely they may contribute.
GLUT2 Glucoso
trans:onet GIucos Iflsulifl
:er ia.e
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rare)
Figure 3. Genetic Uefects in Beta-Ceils in type 2 diabetes. [Kahn et al. 1996].
Glucokinase: Glucokinase (hexokinase IV) is a rate-limiting enzyme in glucose
metabolism and the predominant glucose phosphorylating enzyme in pancreatic
beta celis. It induces the initial steps of glycolysis, that are ctitical for insulin
secretion. Its importance has been confirmed by the finding that mutations in its
gene cause a form of diabetes known as maturity-onset diabetes 0f the young
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(MODY), which is characterized by mild hyperglycemia, decreased glucose
induced insulin secretion, and impaired hepatic glycogen storage [Hattersley
1998]. However, structural mutations on the glycokinase gene do flot appear to
play a role in the common forms of type 2 diabetes.
ATP-sensitîve potassium (K+) channel subunit: AIP-sensitive K channels
play important roles in many cellular functions by coupling celi metabolism to
electrical activity. Studies in different diabetic populations do flot support a role
for these channels in type 2 diabetes.
Sulfonylurea receptor: One study has been reported that mutations in the
sulfonylurea receptor gene on chromosome 11 cause familial persistent
hyperinsulinemic hypoglycemia of infancy [Reis et al. 20021.
Mitochondrial Genes: Mitochondrial DNA is a circular molecule of 16569 base
pairs containing 37 genes encoding 22 transfer RNAs (tRNAs) and 13 enzymes
of oxidative phosphorylation. Many studies have established an association
between mitochondrial DNA mutation and maternally transmitted type 2 diabetes
[Kameoka et al. 1998, Xiu et al.1997, Gerbitz et al. 1996].
1.11.2.2.3.4. Mutations in genes involved in Iïpid metabolism and obesity
Lipid metabolism related gene defects: Lipoprotein lipase gene mutations may
cause high levels 0f triglycerides and reduced levels of high-density lipoproteins,
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which commonly occur in type 2 diabetes. Despite cf this, polymorphic enzymes
were not considered to explain the abnormalities cf lipid metabolism in diabetic
patients. An association between apolipoprotein D polymorphism and type 2
diabetes has been reported in Nauruan and South Indian patients [Baker et al.
1994]. Pima Indians have a polymorphism at codon 54 of the gene encoding the
intestinal fatty acid-binding protein. An Ala —> Thr substitution doubles the affnity
cf the protein for long-chain fatty acids and can increase the rate of uptake and
oxidation of fatty acids, suppressing glucose utilization. Individuals who are
heterozygous or homozygous for the Ihr allele have greater insulin resistance
and hyperinsulinemia.
Obesïty-related gene defects: In human, the f3-3-adrenoreceptor gene is
expressed in visceral adipose tissue surrounding the gastrointestinal tract and is
believed to influence both resting metabolic rate and lipolysis. A mutation in the
beta 3-AR gene (Trp64Arg) has been associated with increased tendency to gain
weight and early onset of type 2 diabetes [Sakane et al. 1998]. The product of
the ob gene is a 167-amino-acid peptide called leptin that s expressed and
secreted by adipocytes. Mutation or deletion cf the leptin gene causes massive
obesity and type 2 diabetes in ob/ob mice [Wang et al. 1998]. Reichart et al
[20001 demonstrated that leptin-receptor-defective mice might develop type 2
diabetes. Adiponectin, also referred to as AdipoQ or ACRP30, is a plasma
protein prcduced and secreted exclusively by adipose tissue. A recent study
identified that missense mutation (1164T) cf adiponectin is associated with type 2
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diabetes [Kondo et aI. 2002]. The hormone resistin has been suggested to Iink
obesity to type 2 diabetes by modulating steps in the insulin-signaling pathway
and inducing insulin resistance. However, a study of Sentinelli et aI [20021
suggests that genetic defects of the resistin gene are unhikely to play a role in the
etiology cf metabolic disorders such as type 2 diabetes.
1.11.2.2.3.5. Mutations in genes relevant to insulin action
TNFa and IL-6: IL-6 and TNFŒ modulate tissue sensitivity to insulin. In 2003,
Kubaszek et aI [2003] investigated whether polymorphisms in the TNFa (G
308A) and IL-6 (C-174G) genes predict the conversion from IGT to type 2
diabetes. They reported that the -308A allele of the promoter polymorphism (G
308A) of the TNFŒ gene is a predictor for the conversion from IGI to type 2
diabetes.
Other candidate diabetogenes: MODY are monogenic forms of type 2 diabetes
that are characterized by an early disease onset, autosomal-dominant
inheritance, and defects in insulin secretion. Genetic studies have identified
mutations in eight genes associated with different forms of MODY. The majority
of the MODY subtypes are caused by mutations in transcription factors that
include hepatocyte nuclear factor (HNF)-4 alpha [Pruhova et al. 2003], HNF-1
alpha [Prukova et al. 2003, Kim et al. 2003], PDX-1, HNF-1 beta, and NEURO
Dl/BETA-2.
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Islet amyloid deposition mainly composed of amylin, is a characteristic
pathological finding in patients with type 2 diabetes. Amylin promoter gene
mutation are known to predipose some populations such as Chinese, Japanese,
and New Zealand Maori to type 2 diabetes[Poa et al. 2003]. Interestingly, a
recent study found that S2OG mutation of the amylin gene is associated with a
lower body mass index in Korean type 2 diabetic patients [Cho et al. 2003].
Lll.2.2.4. Environmental factors
1.11.2.2.4.1. Obesity
The increased prevalence of obesity is accompanied by a parallel
increase in the prevalence of type 2 diabetes. Body weight is determined by an
interaction between genetic, environmental and psychosocial factors acting
through the physiological mediators of enetgy intake and expenditure. Numerous
cross-sectional studies on a range of Caucasian and non-Caucasian populations
have reported an association between obesity and the risk of type 2 diabetes
[Hodge et al. 2001]. In a 16-year study of nearly 85,000 female nurses, Hu et al
[2001] found that the most important determinant of diabetes risk was BMI. It s
important to note that the best predictor of diabetes is the quantity of abdominal
or visceral fat [Ronnemaa et al. 1997, Gastaldelli et al. 2002]. Abdominal fat is
also a predictor for metabolic complications of diabetes. Visceral fat can provide
an increased flow of free fatty acids (FFA) to the liver with increased formation of
VLDL triglycerides. As a consequence, hepatic steatosis and hepatic insulin
resistance can develop. EFA can also be deposited as triglycerides in muscles,
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resulting in peripheral insulin resistance. Thus, obesity s thought to predispose
to type 2 diabetes primarily by causing insulin resistance.
1.11.2.2.4.2. Diet
Several dietary factors may affect the risk of developing type 2 diabetes.
A low-fiber diet with a high glycemic index has been associated with an increased
risk of diabetes [Salmeron et al. 1997, Liu et aL 2000]. A high-fat diet and specific
dietary fatty acids have been shown to differentially affect insulin resistance and
the risk cf diabetes [Vessby et al. 2000, Hu et al. 2001]. A recent study
demonstrated that an increased dietary polyunsaturated:saturated fat ratio is
associated with a reduced risk of diabetes, independent of age, sex, family
history of diabetes, and other lifestyle factors [Harding et al. 2004]. Montonen et
al [2003] provided evidence that whole-grain consumption and cereal fiber intake
are associated with a reduced risk cf type 2 diabetes both in men and women.
I.II.2.2.43. Physical activity
Physical activity has acute and chronic effects on glucose, lipid and
protein metabolism. It has been found, in cross sectional, as well as in
prospective and longitudinal studies, to be independently associated with both
prevalence and incidence of type 2 diabetes in men and women [De Courten et
al. 1997, Tuomilehto et al. 1997, Kriska et al. 1992, Hill et al. 2004, J. Some
prospective studies found a dose response relationship between exercise and
diabetes incidence. In these studies, it was proposed that type 2 diabetes may be
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reduced by 30-50% with regular exercise [Manson et al. 1994]. Physical activity
may lower type 2 diabetes risk by reducing total body fat [Ballor et al. 1991] and
abdominally distributed fat [Ross et al. 2000], and/or through improving insulin
sensitivity by increasing GLUT4 expression in muscles [Mayer-Davis et al. 1998].
In obese diabetic patients, physical activity normalizes the levels of insulin
secretion. [Giacca et al. 1998]. Average physical activity levels have decreased
over recent years in many populations and this fact is considered as a major
contributor to the current global rise of obesity [Prentice et al. 1995] and thus also
of type 2 diabetes [Perry et al. 1995].
I.II.2.2À4. Stress
Some evidence suggest that depression may increase the risk 0f
developing type 2 diabetes mellitus [Eaton et al .1996]. A recent longitudinal,
biracial cohort study involving 11,615 nondiabetic adults aged 48-67 years, has
reported that depressive symptoms predict incident type 2 diabetes [Golden et al.
2004]. Hormonal or oxidative stress could also be determinants of type 2
diabetes.
1.11.2.3. Pathophysiology of type 2 diabetes
There are marked differences in the phenotypic expression of type 2
diabetes with affected individuals exhibiting varying levels of insulin resistance
due to the failure of peripheral tissues to respond to circulating insulin or impaired
in insulin secretion of beta cells [saltiel 2001]. This range of abnormalities
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includes metabolic detangements characterized by predominant defects in
insulin sensitivity with relative f3-cell dysfunction to metabolic derangements
characterized by severe 13-celI dysfunction accompanied by mild insulin
resistance.
1.11.2.3.1. Action of insulin
Insulin inhibits lipolysis, stimulates lipogenesis, stimulates DNA and
protein biosynthesis, inhibits protein breakdown, activates transport of glucose,
amino acids, and ions, and promotes glycogen synthesis and glycolysis. Insulin
inhibits catabolism by suppressing secretion of glucagon, the primary catabolic
hormone, and by blocking the hepatic effects of glucagon through enhancement
of hepatic phosphodiesterase activity, which inhibits cyclic AMP-dependent
protein kinase and thereby inhibits glycogenolysis and gluconeogenesis. The
anabolic/catabolic state of the organism therefore can be smoothly regulated by
the relative concentration of these two antagonistic hormones.
Insulin action begins when it binds to the Œ subunit of the insulin receptor
inducing the auto-phosphorylation of the 3 subunit of the insulin receptor. The j3
subunit 0f the insulin receptor, which has acquired tyrosine kinase activity
phosphorylates the IRS-1, thereby initiating the signaling cascade. IRS-1
stimulates phosphatidylinositol (PI) 3-kinase, the enzyme that catalyzes the
phosphorylation of PI, PI-4-P, and PI-4, and ultimately enhances protein
synthesis and glucose transport. Phosphorylated IRS-1 acts as a docking protein
that binds to and stimulates the P21 signaling pathway through its association
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with GRB2, which interacts with $0$ in the RAS complex. Ihe RAS complex
plays a rote in ceil growth and metabolism and modulates glycogen synthesis in
a pathway that activates raf-1 kinase, which in turn phosphorylates and activates
MARK.
1.11.2.3.2. Insulïn resistance
Insulin resistance can be defined as a condition of low insulin sensitivity, a
blunted effect of insulin in promoting glucose uptake in peripheral tissues, mainly
in skeletal muscles. As shown in figure 4 [Barbara et al. 2002], insulin resistance
is a major feature of type 2 diabetes and obesity. Genetic and environmental risk
factors such as obesity and physical inactivity are key determinants of insulin
resistance. Insulin resistance in visceral fat leads to increased fatty acid
production and increased cytokine secretion, which both exacerbate insulln
resistance in the liver and muscles [Saltiel. 2001]. In the livet, increased glucose
output and increased VLDL and 1G production are observed, while in the
skeletal muscle decreased uptake of glucose is well documented. The resulting
combination of chronic free fatty lipotoxicity and hyperglycemia causes f3-cell
dysfunction. Ihe consequent reductions in insulin secretion and J3-cell mass,
facilitate the progressive deterioration of glucose tolerance, and eventually
provoke the onset of type 2 diabetes.
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C111.2.32.1. Genetics and environment
The sensitivity cf target tissues to the glucoregulatory action cf insul in isgenetically determined and future risk for development cf type 2 diabetes isinversely related to the level of insulin sensitivity [Hansen et aL 2003]. Evidence
exists that 50% of first degree relatives of diabetic patients show insulin
resistance [Kahn 1994]. Abdominal obesity is the major acquired pathogenicfactor for insulin resistance [Bjorntorp 1994] and the effect of obesity on insulin
Figure 4. Pathogenesis of type 2 diabetes.
TG: Triglycerides
VLDL: Very low-density lipoproteinGlu: Glucose
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resistance is greater in members of diabetic families than in persons with no
family history cf diabetes [Gerich et al. 1998].
1.11.2.3.2.2. Hepatic insulin resistance
Type 2 diabetes with moderate fasting hyperglycemia show slight
increased production of glucose by the liver [DeFronzo 1992]. lncreased hepatic
glucose production in type 2 diabetes is probably caused by a decteased
inhibitory effect of insulin on glucagon secretion and glucose production. The
importance of increased hepatic gluconeogenesis is underlined by the fact that
when phosphoenolpyruvate carboxykinase, a regulatory enzyme of
gluconeogenesis, is overexpressed in mice hyperglycemia results [Valera et al.
1994]. However, it is unlikely that increased production of hepatic glucose plays a
primary role in the pathogenesis of human type 2 diabetes.
1.11.2.3.2.3. Insulin resistance in skeletal muscle
In normal individuals, 75% of the glucose in a carbohydrate meal is taken
up by muscle, and it is stored as glycogen. In NIDD patients glucose uptake and
glycogen synthesis in skeletal muscle is reduced [Kelly et al. 1992]. The fact that
knockout of GLUT4 gene expression does flot cause hyperglycemia in mice
indicates that total loss of insulin-stimulated glucose transport is however flot
sufficient to cause type 2 diabetes [Tsao 19991.
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1.11.2.3.2.4. Insulin resistance in adipocyte
Insulin resistance in type 2 diabetic patients is closely associated with
increased in visceral adiposity [Banerji et al. 1997]. It has been shown that
visceral obesity rather than subcutaneous or total obesity is independently
correlated with insulin resistance. The increased fat ceil mass of obesity, in
addition to being intrinsically insulin resistant due to a defect 0f GLUT4
translocation, may export insulin resistance to muscle, both by releasing FFAs
into the general circulation and by infiltrating muscles.
1) FFAs
Concomitant increase in plasma levels of FFAs and insulin reflects the
adipocyte resistance to the anti-lipolytic effect of insulin. Most obese individuals
have elevated plasma levels of FFAs, which are known to cause peripheral
muscle insulin resistance [Groop et al. 19911 by inhibiting insulin-stimulated
glucose uptake and glycogen synthesis [Roden et al. 1996, Dresner et al. 1999].
FFAs also cause hepatic insulin tesistance, through inhibiting insulin-mediated
suppression of glycogenolysis [Roden et al. 2000]. On the other hand, FFAs
support between 30 and 50 % of basal insulin secretion and potentiate glucose
stimulated insulin secretion. The insulin stimulatory action of EFAs is responsible
for the fact that the vast majority of obese insulin resistant people do not develop
type 2 diabetes. During the development of diabetes, excess in FFAs may alter
the capacity of j3 celis to respond to glucose. The strong correlation documented
between EFA concentrations and hepatic glucose production further supports
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that insulin through its regulatory effect on adipocyte lipolysis may control hepatic
glucose production.
2) Adipocytokines
IL-6 and TNFa: Recent data have revealed that the plasma concentration of
inflammatory mediators, such as TNFa and IL-6, s incteased in the insulin
resistant states of obesity and type 2 diabetes, raising questions about the
mechanisms underlying inflammation in these two conditions. These two
cytokines are both overexpressed in the adipose and muscle tissue of patients
with visceral obesity and patients with type 2 diabetes [Vozarova et al. 2001,
Hotamisligil et aI. 1995]. TNFŒ expression is also elevated in the adipose tissue
of multiple experimental models of obesity. On a cellular level, TNFŒ is a potent
inhibitor of the insulin-stimulated tyrosine phosphorylations on the beta-chain of
the insulin receptot and insulin receptor substrate-1 [Hotamisligil et al. 1996].
Anti-TNFŒ antibody significantly improved insulin resistance in obese rodents
[Ventre J, et al. 1997] but flot in humans [Ofei et al. 1996].
Adiponectîn: Adiponectin is an adipocyte-specific plasma protein. Evidence
suggests that adiponectin is associated with obesity-like metabolic disease
[Trayhurn et al. 2001]. For instance, increased serum adiponectin levels are
coupled with increased insulin sensitivity and glucose tolerance [Yamauchi et al.
20021. In a case-control study, Lindsay et al. [2002] found that subjects with low
Ç concentrations of adiponectin were more likely to develop type 2 diabetes than
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subjects with high concentrations cf this protein. In addition, it has been shcwn
that first-degree relatives cf type 2 diabetic patients have reduced adiponectin
mRNA expression in adipose tissue ccmpared te ccntrcls [Lihn et aI. 2003].
Ihese findings suggest a harmful effect cf 10w levels cf adiponectin in the
development cf type 2 diabetes.
Resistin: Resistin is a newly identified adipccyte hormone. Steppan et al [2001]
demonstrated that plasma resistin concentrations are increased in obese mice,
and that immuncneutralizaticn cf circulating resistin significantly improved insulin
action. Consistent with these findings, it has been recently repcrted that serum
resistin concentrations are elevated in bcth type 2 diabetic and obese
nondiabetic patients [Jank et aI. 2002, Savage et al. 2001]. Thus, resistin may
prcvide a crucial risk between cbesity and insulin resistance.
Leptin: Leptin is a protein produced by the adipose tissue-specific cb gene, that
appears te play an important rcle in the regulaticn cf fccd intake and energy
expenditure. Insulin resistance, cbesity and type 2 diabetes are asscciated with
hyperleptinemia. Nctably, high serum leptin levels are accompanied by increased
insulin levels [Cusin et al. 1995]. Recent studies have shcwn that leptin inhibits
insulin secretion and exeris anti-insulin effects on liver and adipose tissue. If
these effects are ccnfirmed, leptin cculd participate in the insulin resistance cf
cbesity and type 2 diabetes. It has been fcund that leptin is associated with
impaired fibrinclysis, which is a ccmmon finding in cbese humans [skurk et al.
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2002]. Recently, Kazumi et al [2003] found a positive association between CRP
and leptin. Finally, plasma leptin levels have been shown to be associated with
coronary atherosclerosis in type 2 diabetes [Waflace et al. 2001, Rahmouni et al.
2004]. Thus, leptin appears to be a novel tisk factor for CVD [Wallace et al.
20011.
1.11.2.3.3. Hyperinsulinemia and glucose intolerance
Insulin resistance, hyperinsulinemia, and IGT are common abnormalities
in individuals at high risk for type 2 diabetes [Rewers et al. 1995]. Current
knowledge suggests that development of glucose intolerance or diabetes is
initiated by insulin resistance. At the early stages, the pancreatic 13-ceil is able to
compensate for insulin resistance by increasing insulin levels, thereby
maintaining glucose levels in a normal range for a period of time (up to several
years). IGT associated with mild postprandial hyperglycemia is a transitional
period between prediabetes and mature diabetes. As insulin resistance worsens,
the progression from IGT to early type 2 diabetes is marked by a decrease in J3-
celi function and thus a decline in insulin secretion. It is the failure over time of
the f3-cell to compensate for insulin resistance with hyperinsulinemia that marks
the beginning of type 2 diabetes. As long as the pancreatic 13-celi is able to
compensate for insulin resistance by increasing insulin production and secretion,
glucose levels remain normal or near normal. However, eventually the 3-ceIl
begins to fail, and insulin secretion falis, resulting in hyperglycemia and type 2
diabetes. Factors that contribute to decreased insulin secretion are leptin and
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several agonists including norepinephrine, somatostatin, galanin, and
prostaglandins [Sharp 1996, Kieffer et al. 1997].
1.11.2.4. Complications associated with type 2 diabetes
Chronic hyperglycemia in type 2 diabetes causes Iong-term damage to
many tissues of the body, particularly to the vascular system. Vascular
complications are the leading cause of morbidity and mortality in the type 2
diabetic population [Cooper et al. 2000]. These can be divided into microvascular
and macrovascular complications. Figure 5 [Cooper et al. 20001 illustrates a
pathophysiological model of the development of diabetes and diabetic vascular
complications.
1.11.2.4.1. Macrovascular complications
Macrovascular complications of type 2 diabetes include cardiovascular,
cerebrovascular, and peripheral vasculat diseases. CVD s the most prevalent
complication of DM and the leading cause of mortality in patients with type 2
Predisposing Earfy Metabolic Currently Measured Vascular Clinical
Factors Abnormalities Risk Factors Disease Disease
Figure 5. Model of development of diabetîc vascular complications.
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diabetes. CVD is responsible for 80% of the mortality in diabetic patients,
accounts for 75% of ail hospitalization for diabetic complications [Pyorala et al.
1987, Haffner et al. 1998] and preceeds overt diabetes in more than 50% of
patients [Peters et al. 1998]. As shown in figure 6 [Libby et al. 20021, multiple
factors contribute to the accelerated atherosclerosis in type 2 diabetes. These
risk factors include excess prevalence of traditional risks such as obesity,
hypertension, smoking, and dyslipidemia along with glycooxydation of
lipoproteins and proteins, alteration of the coagulation system, inflammation,
insulin resistance, and hyperinsulinemia. These factors have been clearly
categorized into conventional and novel risk factors.
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Figure 6. Multiple cardiovascular rïsk factors in diabetes.
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1.11.2.4.1.1. Traditional risk factors
IJI.2.4.1.1.1. Dyslipidemia
Patients with type 2 diabetes have atherogenic dyslipidemia characterized
by elevated levels of VLDL trigiycerides and small dense [DL choiesterol
particles and decteased levels of HDL cholesterol. SmalI dense LDL are more
hable ta oxidation and may more readily adhere to and subsequently invade the
arterial wahI [Laakso et aI. 1995]. Although LDL are not usually increased in
diabetes, twa prevention trials clearly showed that lowering [DL cholesterol
levels stiil reduces the risk of major cardiac events in diabetic patients [Pyorala et
aI. 1997, The Long-Term Intervention with Pravastatin in Ischaemic Disease
Study Group 1998]. The prevalence of hypertriglyceridemia and 10w HDL
choiesterol levels in diabetic subjects is approximately twice as high as in the
nondiabetic groups [Garg et al. 1990]. There is increasing evidence supporting a
raie for VLDL triglycerides in macrovascular disease in patients with type 2
diabetes. The fact that type 2 diabetic patients with hypertriglyceridemia have
increased smahl dense LDL [Yudkin 1993] and increased VLDL hevels in type 2
diabetes are also associated with post-prandial hyperhipidemia that is
compounded by impaired LPL activity [Krentz 2003J. Bath smahl dense LDL and
impaired LPL activity are associated with CVD. Low HDL levels have been found
ta be often associated with high levels of total VLDL triglycerides in type 2
diabetes [Laakso et al. 1995]. The Framingham study established Iow levels of
HDL as a risk factor for CVD [Swan et al. 1999], because the reduction in
cardioprotective HDL cholesterol means a reduction of cholesterol efflux from the
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tissues, which is the first step in reverse cholesterol transport to the liver from
peripheral tissues. In addition, the antioxidant and antiatherogenic activities of
HDL cholesterol are reduced when circulating levels are low [Krentz 2003].
Overail, dyslipidemia is considered to be an independent risk factor for CHD in
type 2 diabetes.
1.11.2.4.1.1.2. Hypertension
Hypertension is an independent risk factor for CVD in type 2 diabetes and
is about 70% greater in type 2 diabetic patients than in non-diabetic subjects
[Sowers et al. 2001]. Ihe resuits from the UKPDS indicated that the risk of
myocardial infarction correlate with blood pressure in patients with type 2
diabetes [Adler et al. 2000]. Hypertension is often associated with insulin
resistance, hyperinsulinaemia [Laakso et al. 1997] and proteinuria [Stamler et al.
1993], which are also risk factors for CVD.
1.11.2.4.1.1.3. Smoking
The Multiple Risk Factor Intervention Trial (MR-FIT) [Stamler et al. 1993]
has confirmed that cigarette smoking is an independent predictor and risk factor
of CVD morbidity and mortality in persons with diabetes [Laakso et al. 1997].
Cigarette smoking appears to act synergistically with hypercholesterolemia to
accelerate CVD in diabetes, possibly by enhancing the oxidation of LDL
cholesterol [Heitzer et al. 1996].
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1.11.2.4.1.1.4. Obesïty
Obesity is an important risk factor of type 2 diabetes and is associated
with insulin resistance, dyslipidemia, hypertension, and an increased risk cf CVD
[Bonadonna et al. 1990, Rexrode et al. 19961.
1.11.2.4.1.1.5. Hyperglycemia
Several studies have reported that hyperglycemia is flot a particularly
strong determinant for developing CHD in type 2 diabetic patients. While the
UKPDS found that intensive blood-glucose control by either sulphonylureas or
insulin substantially decreases the risk of microvascular complications, this
approach did not reduce the risk of developing macrovascular disease in patients
with type 2 diabetes [UK Prospective Diabetes Study (UKPDS) Group. 1998].
These results are in contrast with others showing that glycemic control was
important in decreasing cardiovascular risk in different populations including
diabetic ones [Laakso. 1999, Gerstein et al. 1996, Fuller et al. 1983, Fuller et al.
1980, Singer et al. 1992]. Today, a debate stiil exists whether hyperglycemia per
se is an important risk factor for diabetic macrovascular complications.
Importantly, Bonora et al [Bonora et al. 2001, Bonora. 2002] recently
documented that postprandial plasma glucose is an independent risk factor for
cardiovascular disease in diabetic subjects. The mechanisms through which
hyperglycemia causes vascular injury, include nonenzymatic glycosylation of
proteins and lipids, oxidative stress, activation cf PKC and of the polyol pathway.
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1) Glycation of proteins
Definition and formation: Non enzymatic glycation is s biochemical process by
which glucose is covalently bound ta proteïn aminogroups through a series of
chemical reactions described by Maillard [Maittard et al. 1912].
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Figure 7. The formation of AGEs. [Aronson et aI. 2002]
As shown in figure 7, glucose forms chemically reversible early
glycosylation products with reactive amino groups of circulating or vessel wall
proteins (Shiif bases), which subsequently rearrange to form the more stable
Amadori-type early glycoslation products. Equilibrium levels of Schiif-base and
Amadori products are reached in hours and weeks, respectively [Brownlee et al.
1988]. Some of the early glycoslation products on long-lived proteins such as
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vessel wall collagen, continue to undergo complex series of chemical
rearrangement to form AGEs [Brownlee et al. 19881. Once formed, AGE-protein
adducts are stable and virtually irreversible. The best chemically characterized
AGEs compounds found in human are pentosidine [seli et aI. 1989] and N
(carboxymethyl)-L-lysine (CML) [Ikeda et al. 19961.
Role of AGE in diabetic macrovascular complications: There is increasing
evidence that AGE are involved in the pathophysiology of diabetic macro
angiopathies. It has been shown that CML accumulates in atherosclerotic
plaques and serum of diabetic patients [Schleicher et ai. 1997].
Immunohistochemical analysis of coronary arteries from type 2 diabetic patients,
has also documented high AGE-reactivity within the atherosclerotic plaque
suggesting a cale cf AGEs in the accelerated development of arterial disease
observed in diabetes [Nakamura et al. 1993].
AGEs can accelerate the atheroscierotic process by diverse mechanisms,
which can be classified as non-receptor dependent and receptor-mediated. AGE
binding ta its specific receptors on endothelial ceils quenches nittic oxide and
increases vascular permeability, procoagulant activity, adhesion moiecule
expression and monocyte influx, and oxidative stress and thereby contributes to
vascular injury [Aronson et ai. 2002]. In addition, AGE aiso interact with
macrophage receptors to induce cytokine and growth factor release, [Tanaka et
al. 1988]. In the atherosclerotic lesion, iinking of AGE to extracellular matrix
C enhances synthesis cf extracetiular matrix components and trapping of LDL in
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the subendothelium [Brownlee et al 1986, Brownlee et al. 1985]. Evidence also
suggests that AGE-modified LDL is Iess susceptible to LDL receptors, but more
susceptible to macrophage scavenger receptors [Steinbrecher et al. 1984].
2) PoIyoI pathway
Ihere are a number of tissues in which glucose uptake is not dependent
on insulin, including the kidney, neural tissue, and the lens of the eye. In such
tissues, hyperglycemia-induced tissue injury is associated with the activation of
the polyol pathway, which is a two-step enzymatic process. First, intracellular D-
glucose is reduced to sorbitol, coupled to oxidation of NADPH to NADP by
aldose reductase. The second step is the subsequent oxidation of sorbitol to
fructose, which is coupled to reduction of NAD to NADH by sorbitol
dehydrogenase. Evidence indicates that an increased free cytosolic NADH/NAD
ratio is observed in a variety of tissues of diabetic animais. This change was aiso
found in celis and tissues exposed to eievated glucose levels in vitro [Obrosova
et al. 2001, Tilton et al. 1992, Williamson et al. 1993]. The biochemical
mechanisms responsible for a further reduced cytosolic state in diabetic tissues
are flot completely understood.
3) PKC activation
Activation of PKC, an intracellular second messenger, is reported in many
diabetic tissues including the retina, kidney, heart, and aorta [Inoguchi et al.
1992] In particular, the glucose-sensitive PKC32 isoform is activated in diabetic
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vascular tissues [Inoguchi et aL 1992]. Evidence has been provided that
LY333531, a specific PKCf32 inhibitor, blocks various diabetes-related
abnormalities in the retina and kidney [Ishii et al. 1996]. Moreover, ACE inhibitors
and aminoguanidine have been shown to reduce renal PKC activity [Russo et al.
2000]. These findings suggest a tole for PKC in mediating vascular injury in
diabetes. Potential changes induced by hyperglycemia-induced activation of the
DAG-PKC pathway are shown in figure 8.
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Figure 8. Hyperglycemia-induced activation of the DAG-PKC pathway. [Koya et aI. 1998]
4) Oxidative stress
Oxidative stress may play a crucial role in the pathogenesis of diabetic
complications [Evans et al. 2002]. Indeed, diabetes is characterized by a chronic,
growing increase in oxidative stress-favoring stimuli as well as by a progressive
decrease in the efficacy of the antioxidant system. Ihis imbalance in the
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oxidative stress equilibrium may underlie the much higher incidence of
cardiopathy [Cal et aI. 20011 and vasculopathy [Inoguchi et al. 2000] in diabetes.
The theoretical importance of oxidative stress in diabetes is highlighted by its
potential double impact on metabolic as well as vascular dysfunction in this
disease [Wiernsperger 2003J. For example, oxidative stress can decrease insulin
internalization by endothelial celis [Bertelsen et al. 2001] and therefore potentially
interfere with the hormone transfer from plasma to tissues. In target cells,
oxidative stress can reduce GLUT4 translocation, therefore limiting the capacity
to transport glucose into muscle celis [Rudich et al. 1998].
Many studies have demonstrated the presence of oxidative stress in
diabetic patients, as reflected by increased levels of indicators of oxidative stress
and antioxidants [Vessby et al. 2002, Seghrouchni et al. 2002]. Oxidative stress
in diabetes may originate from an exaggerated production of ROS, overcoming
the antioxidant capacity, a breakdown of the antioxidants in front of a relatively
normal ROS production, or a combination of both. As shown in figure 9, varlous
sources of ROS exist. In particular, mitochondria are considered to be a
privileged source of ROS due to the production and transport 0f electrons.
Hyperglycemia, FFAs, and leptin have been shown to induce ROS generation
from mitochondria [Evans et al. 2002, Wojtczak et al. 1993, Bakker et al. 2000,
Yamagishi et al. 2001]. Hyperglycemia can also increase ROS via transition
metal-catalyzed autoxidation [Wolff 1993, Evans et al. 2002]. In addition, since
AGEs and Iipids are constantly produced in overt diabetes, carbonyl stress has
been proposed as a major source of oxidative stress in this disease [Baynes et
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al. 2000, Taniguchi et al. 1996]. While high glucose level, FFA, insulin, and
angiotensin Il stimulate NADfP)H oxidase to produce ROS [Griendiing et al.
2000, Kashiwagi et al. 1999, Inoguchi et al. 2000, Griendling et al. 2000], high
cholesterol, by activating xanthine oxidase, stimulates endothelial superoxide
production [Ohara 1993J. Finally, oxidative stress-inducing carbonyl compounds
are found in food [Cai et al. 2002].
Figure 9. Exogenous and endogenous stimuli leading to ROS generation. [Evans et al. 2002]
The implication of oxidative stress in diabetes is a major concern for the
development of therapeutics aimed at improving the metabolic and/or vascular
dysfunctions of this burdening disease. However, there are currently no
recommendations for antioxidant supplementation in diabetic patients. While an
Q
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endless number cf in vitro and in vivo studies in both animais and humans have
shown clearcut positive effects on individuai metabolic or vascular parameters,
there is stili missing proof for a beneficial effect of antioxidant therapy in large
scale ciinicai studies. For exampie, antioxidants such as NAC remarkabiy protect
retinal pericytes against AGE-induced apoptosis in vitro [Denis et aI. 20021 and
various antioxidants ameliorate diabetic neurophathy in animais. However human
studies have faiied to demonstrate a ciear beneficiai effect cf antioxidant therapy.
For exampie, whereas severai reports exist showing improvements in surrogate
endpoints such as endothelial reactivity, no effect has been found in ail major
ciinicai triais examining the iong-term outcome of vitamin E on cardiovascular
events [Yusuf et ai. 2000, Lonn et ai. 2001]. Very recentiy the vitamin E
atherosclerosis prevention study (VEAPS) triai has reported that vitamin E
reduces LDL oxidation but does flot reduce atheroscierosis [Hodis et al. 2002].
Ihe possible causes cf apparent clinicai faiiure of antioxidants may be due to the
wrong conclusion about the relevance of vitamin E antioxidant effect and the
effect of vitamin E as prooxidant. Let’s hope that vitamin E is an unlucky choice
and that the use cf other antioxidants, aione or in combination, may contradict
the actual pessimistic conclusion for antioxidants therapy. More promising
approaches should be based on drugs preventing the ROS generation rather
than their scavenging. This notion is supported by the resuit from a recent triai
showing an improvement both in biood pressure and in giycemic controi by
administration cf Coenzyme Q [Baynes et ai. 19961.
C
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1.11.2.4.1.2. Novel risk factors
Many studies have shown that assessment of conventional risk factors
only partly account for the excessive risk of developing CVD in the diabetic
population. More importantly, there is yet no definitive evidence that controlling
hyperglycemia reduces macrovascular disease in type 2 diabetes. The
recognition of these facts has led to the identification of novel tisk factors that are
commonly associated with insulin resistance, hyperinsulinemia and
hyperglycemia. These factors include insulin resistance, inflammation,
endothelial dysfunction, oxidative stress, and alteration of the coagulation.
1.11.2.4.1.2.1. Insulin resistance
Today, evidence exists that much of the increased risk of developing CVD
in diabetes is re!ated to insulin resistance. Insulin resistance is the hallmark of
type 2 diabetes and preceeds the disease for several years [Plutzky et al. 2002,
Erkelens 2001]. Insulin resistance is related and is the preceeding factor of both
traditional and nontraditional CV risk factors, including hyperglycemia,
hypertension, and obesity, linking ail these abnormalities to the development of
CVD [Haffner et al. 1999]. For such reasons, insulin resistance might be
regarded as an accomplice in the pathogenesis of CV disease in type 2 diabetes.
lmportantly, it bas been proposed that insulin resistance might also contribute to
CVD in a direct and independent pathway [Bonora et al. 2002]. For example, it
bas been demonstrated that both insulin and proinsulin can augment the
expression of PAl-1 in vivo [Nordt et al. 1998, Nordt et al. 1995].
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1.11.2.4.1.2.2. Homocysteine
Elevated biood level of homocysteine is strongly reiated ta an increased
risk for atherosclerosis and cardiovascuiar disease [Bostom et al. 1999, Romm et
al. 1998]. A high prevaience 0f hyperhomocysteinemia ïs found in patients with
type 2 diabetes [Smulders et al. 1999, Hoogeveen et al. 1998, Munshi et ai.
19961 and high serum levels cf homocysteine are significantiy associated with
coronary events in type 2 diabetes, independently of traditionai cardiovascular
risk factors [Becker et ai. 2003]. Plasma leveis of homocysteine are aiso eievated
in hypertensive diabetic patients [Qureshi et aI. 2003].
1.11.2.4.1.2.3. Microalbuminuria
Microalbuminuria is defined as persistent elevation of aibumin in the urine.
Use of the aibumin/creatinine ratio is recommended as the preferred screening
strategy for ail diabetic patients. Microalbuminuria is an independent risk factor
for the development of CVD and a predictor cf cardiovascular mortality in the
diabetic population. It has been documented that microalbuminuria is associated
with insulin resistance, dysiipidemia, centrai obesity, and hypertension [Bianchi et
aI. 1995, Sowers et al. 1999, Feldman et ai. 1999]. Miroalbuminura is also related
ta endothelial dysfunction and increased oxidative stress, and thus is an
important risk factor for CVD in diabetic persons [Kuusisto et aI. 1995, Dinneen et
ai. 1997, Sowers et ai. 1999].
C
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1.11.2.4.1.2.4. Abnormal fibrinolysis and hypercoagulation
Recent studies have identifled defects in the coagulation and fibrinolytic
cascade as important pathological mechanisms leading to CAD. Type 2 diabetes
is a state cf increased plasma coagulability, increased platelet aggregability, and
ceduced fibrinolytic capacity [colweli 2001]. Diabetes is aise associated with
increased levels cf von Willebrand factor, factor VII, factor VIII, platelet factor 4,
and PAl-1 levels [Giuseppe et al. 2003]. PAl-1 predicts type 2 diabetes
independently cf insulin resistance and other known risk factors for diabetes
[Festa et al. 2002]. Diabetic and hyperinsulinemic patients typically exhibit
increased production of PAl-1 from visceral abdominal adipocytes. It is Iikely that
elevated levels of TF and PAl-1 and reduced levels of tissue-type plasminogen
activator are associated with increased production of proinflammatory cytokines
such as IL-6 from adipocytes in type 2 diabetes [Giuseppe et al. 2003].
1.11.2.4.1.2.5. Inflammation
A decade age, elevated systemic markers of inflammation were found ta
predict adverse CV events in patients with severe unstable angina [Liuzzo et al.
1994]. Since then, in view cf the persuasive evidence indicating a raie for
inflammation in atherogenesis, several investigators have examined whether
circulating markers cf inflammation may predict CV risk in a variety cf clinical
settings. Results of their studies have supported a potential role for several
biochemical markers cf inflammation as predictors cf the development cf CHD as
wetl as adverse CV-related outcomes in patients with known coronary
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syndromes. Markers of inflammation appear to offer risk prediction information
that is independent of, and possibly complementary to traditional risk factors for
the dev&opment of CVD. Among these markers, elevated concentrations of
CRP, IL-6, fibrinogen, adhesion molecules, serum amyloid A protein, leucocyte
count have shown to be markers for incteased risk of CVD [Altman et al. 2002,
Liuzzo et al. 1994, Blake et al. 2001, Libby et al. 2002, Wu et al. 2003]. It should
be noted that the notion that CRP may reptesent a ptedictor of CV risk
has
recently been challenged by Danesh et al [2004]. This point will be discussed
further at section 1.IV.11. Recently, chronic subclinic inflammation has emerged
as a new risk factor for the development of type 2 diabetes and as a can
didate
mechanism underlying the common soil hypothesis linking type 2 diabe
tes and
atherosclerosis. Indeed, it has been demonstrated that circulation mackers
of
subclinical inflammation, in particular CRP and IL-6, are powerful indepen
dent
predictors of both diabetes and CVD [Ridker et al. 2000, Pradhan et al.2001,
Festa et al. 2002]. (see section 1.1V. for details).
1.11.2.4.1.2.6. Endothelial dysfunction
Patients with type 2 diabetes exhibit endothelial dysfunction as determine
d
by the assessment 0f vascular reactivity and/or the measurement of
plasma
mackers of endothelial activation/dysfunction. Endothelial dysfunction can al
so be
detected in obese patients, in relatives without diabetes as well as in
the
spectrum of insulin resistance before the detection of any distinct carbohy
drate
intolerance. Thus insulin cesistance appears to be associated with endothe
lial
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dysfunction. Some components of the metabolic syndrome, such as
hypertension, dyslipidemia and increased uric acid, likely contribute to alterations
in endothelial function. Evidence that markers 0f endothelial dysfunction are
associated with CRP indicates the link existing between endotheHal dysfunction
and inflammation. Increasing evidence has revealed that endothelial celis play an
important role in development and progression of atherosclerosis. Insulin
resistance is clearly associated with increased cardiovascular risk. Therefore
endothelial dysfunction builds s link between insulin resistance and
atherosclerosis. Endothelial dysfunction is now considered as a new risk factor
for type 2 diabetes.
1.11.2.4.1.3. Inflammation: the Iink between obesity, insulin resistance, type
2 diabetes and atherosclerosis.
The recent concept that type 2 diabetes is an inflammatory condition is an
exciting and novel apptoach to beffer understanding of this condition
.
Inflammation is implicated both in terms of pathogenesis and complications
of
type 2 diabetes.
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o1.11.2.4.1.3.1. Inflammation and obesity
Physical inactivity
High-fatdiet
It is now we established that obesity is a chronic inflammatory disorde
r.
Consistent with this notion, elevated plasma concentrations 0f CRP [Yudkin et al.
1999], IL-6 [Mohamed-Ali et al. 1997], TNFŒ [Hotamisligil et al. 1993], and PAl-1
Obesity
Genetic factors
Figure 10. Inflammation the link between obesity, insulin resistan
ce, diabetes, and atherosclerosis.
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[Lundgren et al. J 996] have been found to be associated with obesity. Increa
sing
evidence indicates that adipose tissue is an important sou
rce 0f cytokines
including TNFŒ, leptin, PAl-1, IL-6, IL-1, resistin and angiotensin
ogen [Ahima et
al. 2000] and that adiposity contributes to a proinflammatory milieu [Yudk
in et al.
1999]. High secretion rate of these proinflammatory cytokines is associa
ted with
decreased insulin release and action [Ahima et al. 2000]. As shown in figu
re 11
there is also some evidence that beside adipocytes, macrop
hage infiltration into
adipose tissue can also take part in the inflammatory chang
es associated with
obesity [Xu et al. 2003, Weisberg et al. 2003].
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1.11.2.4.1.3.2. Inflammation and insulin resistance
As mentioned above, proinflammatory cytokines such as TNFŒ and IL-6
secreted from adipose tissue induce insulin resistance. Growing evidence has
pointed to a correlative and causative relationship between inflammation and
insulin resistance/type 2 diabetes. TNFŒ is overexpressed in white adipose
tissue both in obese and insulin-resistant states and mediates insulin resistance
in rodent obesity models [Hotamisligil et al. 1993, Hotamisligil et al. 1994].
Conversely, mice lacking the TNFŒ ligand or the p55 TNF receptor are partially
protected from obesity-induced insulin resistance [Uysal et al. 1997, Uysal et al.
1998, Ventre et al. 1997, Moller 2000]. High secretion of IL-6 s associated with
decreased insulin release and action. Plasma IL-6 levels are elevated in diabetic
patients with features of the insulin resistance syndrome and serum IL-6 is
associated with insulin resistance in men and women. Interestingly, low
production capacity cf IL-10, a cytokine with anti-inflammatory properties, is
associated with the metabolic syndrome and type 2 diabetes [van Exel et al.
2002]. Elevated expression of SAA3, an acute phase teactant has also been
recently documented in adipose tissue of mice, this fact being especially
remarkable in the diabetic state [Lin et aI. 2001]. The Insulin Resistance
Atherosclerosis Study (IRAS) bas clearly shown that CRP is independently
related to insulin insensitivity [Festa et al. 2000]. In the liver, insulin seems to be
one of the main regulators of the cytokine-associated acute-phase response. It
attenuates cytokine stimulation of most acute phase protein genes in human
hepatoma cells. Thus, Iack of significant insulin action, as found in type 2
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diabetes, or unsubstituted insulin deficiency, would result in Ioss of this anti
inflammatory effect.
Beside adipocytes, activated macrophages in the arterial wall also secrete
numerous cytokines and chemokines such as TNFŒ, IL-1, IL-6, and MCP-1,
which aIl cause insulin resistance in adipocytes [Hotamisligil et al. 1994, Grimble
et al. 2002, Amrani et al. 1996, Fried et aI. 1998]. As a consequence of sustained
inflammation in the vascular waII, insulin signaling in adipocytes can become
increasingly impaired.
1JL2.4.1.3.3. Inflammation and type 2 diabetes
Ihat type 2 diabetes may represent an inflammatory condition has been
first suggested by Ctook et al. [1993] then by Pickup et al in 1997. These
investigators reported that type 2 diabetes is an inflammatory condition,
characterized by elevated plasma concentrations of acute phase inflammatory
reactants such as sialic acid and IL-6. Later on, an association between white
blood celI count [Schmidt et aI. 1999], CRP [Prahan et aI. 20011, PAl-1 and type
2 diabetes [Festa et al. 2002] has also been documented. lnterestingly, in 2002
elevated plasma levels of PAl-1 [Festa et al. 2002] and CRP [Prahan et al.2001J
have been found to predict the development of type 2 diabetes independently of
fat mass and BMI. These studies again add to the notion that low-grade
inflammation s important in the pathogenesis of type 2 diabetes.
Although, type 2 diabetes is associated with chronic 10w-grade
inflammation, the underlying mechanism(s) responsible for this inflammatory
7$
response ïs flot well understood. A recent study indicates that serum
concentration cf AGEs is an independent determinant 0f plasma CRP levels
suggesting that subclinical inflammation in these patients may be partly due to
activation of the inflammatory response by AGEs [Tan et al. 2004]. Considering
the sttong correlation between insulin resistance, inflammation, and type 2
diabetes, it is also possible that the association cf type 2 diabetes with
inflammation may be due to the state of insulin resistance. Alternatively, elevated
levels of inflammatory markers in diabetes, may be the result of preexisting
atherosclerosis.
1.11.2.4.1.3.4. Inflammation in endothelial dysfunction and atherosclerosis
Endothelial dysfunction predicts CV events and is documented in type 2
diabetes. If is also detected in obese and insulin resistant subjects. Thus, insulin
resistance itself appears to be related to endothelial dysfunction. Insulin
resistance may contribute f0 endothelial dysfunction through systemic defect cf
the P13 kinase pathway and decreased insulin-mediated endothelial NO
production. Endothelial dysfunction may also be induced by proinflammatory
cytokines such as IL-13 and TNFŒ, and by the acute-phase protein CRP. lndeed,
recent studies indicate that human recombinant CRP, at concentrations known to
predict vascular disease, elicits a multitude of effects on endothelial biology
favoring a proinflammatory and proatherosclerotic phenotype.
The activation cf proinflammatory mechanisms and the accumulation cf
monocytes and macrophages in the intima (in addition to lipid infiltration) are
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characteristic of atherosclerosis. The cytokine, IL-6, has proinflammatory activity
by itselt and through increasing the levels 0f IL-1 and TNFa. AH cf these
cytokines have been implicated in atherogenesis [Yudkin et aI. 2000].
Importantly, IL-6 stimulates liver production cf CRP. Serum CRP is an important
marker cf vascular inflammation and predictor of atherosclerosis [Ridker et al.
2003, Ridker et al. 2001, Ridker et al. 2000, Van Der Meet et al. 2002,
Hashimoto et aL 2001]. Recent data suggest that CRP also promotes
atherosclerosis. These findings together with the fact that CRP is present in the
intima and media layers of human atherosclerotic arteries [Torzewski et al. 2000,
Reynolds et al. 1987] and on the surface of foam cells [Torzewski et al. 1998],
further suggest the involvement of CRP in atherosclerosis. Besides the
production cf CRP by the liver, macrophages and smooth muscle-Iike cells
present in the atherosclerotic lesion also secrete CRP [Yasojima et al. 20011.
1JL24.2. Microvascular complications
The major diabetic microvascular complications include retinopathy,
nephropathy, and neuropathy [Greene. 1986]. As shown in figure 4, the Diabetes
Control and Complications Trial (DCCT) [The Diabetes Control and
Complications Trial Research Group. 1993], the UKPDS [UK Prospective
Diabetes Study (UKPDS) Group. 1998], and the study by Ohkubo et al. [Ohkubo
et al. 1995] studies point te a definite association between the severity and
duration cf hyperglycemia and microvascular complications in patients with type
$0
2 diabetes. Specially evidence exists that patients with hemoglobin Aic levels
greater than 8 %, are at high risk for these complications [Peters et al. 1998].
1.11.2.4.2.1. Retinopathy
Diabetic retinopathy is one of the earliest signs of the effects of sustained
hyperglycemia on the microvasculature and the leading course of adult
blindness. While 20% of patients had retinopathy at the time cf diagnosis [Peters
et al. 19981, more than 60% of type 2 diabetic patients wiH develop some degree
of diabetic retinopathy during the course of the disease [American Diabetes
Association. 1998]. The retinopathy is usually categorized as background or
proliferative. Notably, the UKPDS demonstrated that a significant dectease in the
progression of retinopathy could be achieved in patients, treated with intensive
insulin therapy compared to conventional therapy [The Diabetes Control and
Complications Trial Research Group. 1993].
1.11.2.4.2.2. Nephropathy
Diabetes mellitus is the most common single cause 0f end-stage renal
disease (ESRD) and accounts for about half cf the patients receiving long term
renal dialysis in the USA. When type 2 diabetes is diagnosed, the presence of
nephtopathy ïs already present in 8% of patients [Peters et al. 1998]. The earliest
clinical evidence of nephropathy in type 2 diabetes is microalbuminuria.
Progression to ESRD is associated with persistent proteinuria and hypertension.
$1
In type 2 diabetes, high levels of glucose and glycohemoglobin are strongly
associated with microalbuminuria [Alzaid et al. 1996].
1.11.2.4.2.3. Neuropathy
Diabetic neuropathy is classified as either peripheral or autonomic.
Peripheral neuropathy is the most common manifestation of diabetic neurophathy
[Singh et al. 1995], with symptomatic disease occurring in approximately 25% of
patients with diabetes millitus [Koda-Kimble et al. 1995]. The clinical presentation
of peripheral neuropathy can range from mild-to-severe pain to decreased
sensation primarily in the lower extremities [Koda-Kimble et al. 1995]. Autonomic
neuropathy can manifest as impotence, gastroparesis, urinary retention, and
diarrhea [Koda-Kimble et al. 1995]. Neuropathies can develop anytime during the
progression of type 2 diabetes.
1.11.2.5. Diagnosis
The diagnostic criteria for diabetes mellitus have been modified from those
formerly recommended by the NDDG [National Diabetes Data Group 1979] or
WHO [World Health Organization 1985]. The revised criteria for the diagnosis of
diabetes are shown in Table 8 [American Diabetes Association 2004]. Three
ways to diagnose diabetes are possible, and each must be confirmed, on a
subsequent day, by any one of the three methods given in Table 8. For example,
one instance ofsymptoms with casual plasma glucose 200 mg/dl (11.1 mmol/l),
confirmed on a subsequent day by 1) fasting plasma glucose (FPG) 1 26 mg/dl
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(7.0 mmol/l), 2) an oral glucose tolerance test (OGU) with the 2-h postload value
200 mg/dl (11.1 mmol/l), or 3) symptoms with a casual plasma glucose 200
mg/dl (11.1 mmolll), warrants the diagnosis of diabetes.
Table 8. Criteria for the diagnosis of DM.
1. Symptoms of diabetes plus casual plasma glucose concentration 200 mg/d
l (11.1 mmol/L).
Casual is deflned as any time of day without regard to time since last meal. The cl
assic
symptoms of diabetes include polyuna, polydipsia, and unexplained weight loss
.
or
2. FPG 126 mg/dl (7.0 mmol/L). Fasting is deflned as no caloric intake toc at least 8 h.
or
3. 2-h postload glucose 200 mg/dl (11.1 mmol/L) during an OGH. The test should be
performed as described by WHO, using a glucose load containing the equivalent
0f 75 g
anhydrous glucose dissolved in water.
In the absence of unequivocal hyperglycemia, these critena should be confirme
d by repeat testing
on a different day. The third measure (OGH) is not recommended for routine clinical use.
1.11.2.6. Treatment
1.11.2.6.1. Diet and physical activity
1.11.2.6.1.1. Weight Ioss
Ihe study by Long et al. [1994] indicated that weight loss in patients with
severe clinical obesity prevented more than 30-fold, the progression of IGT
to
diabetes.
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1.11.2.6.1.2. Life style changes
Changing lifestyle is the primary target in the prevention of type Il
diabetes. In a Swedish unccntrolled study, Eriksson et al. [Eriksson et aI. 1991]
initially reported that an increase in physical activity and a moderate loss of body
weight, reduces the incidence of type 2 diabetes by 50% in middle-aged men
with IGT. A Chinese study in patients with IGT, conflrmed that a 6-year
intervention with diet and physical activity leads, both in overweight and normal
weight individuals, to an approximate 30-40% reduction risk of developing
diabetes [Pan et al. 1997]. In the Finnish Diabetes Prevention Study (FDPS)
[Tuomilehto et al. 2001], reduction in the incidence cf diabetes in patients with
IGI, was directly associated with their changes cf lifestyle. Data from this study
showed that lifestyle changes resulted in a 58% reduction cf diabetic risk.
Recently, the Diabetes Prevention Program (DPP) group performed the first
study comparing the effects cf lifestyle modification vs pharmacological therapy
on the reduction cf diabetic risk. This study found that lifestyle modification
reduced diabetic risk by 58% and that compared to placebo, metfcrmin treatment
reduced diabetic risk by cnly 31 % [DPP Group 2002]. This study also fcund that
losing even 5-7 kg of body weight, reduced diabetic risk. This beneficial effect
was accompanied by lower cholesterol levels as well as by a reduction in other
cardiovascular risk factors [DPP Group 2002]. Liac et al [2002) recently repcrted
that modification cf Iifestyle could influence BMI and fat distribution in Japanese
American with IGT.
C
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Although it is clear from these data that lifestyle changes may reduce the
development cf type 2 diabetes, substantial lifestyle modification stiil cannot be
achieved in many developed countries. Additionally, in these countries, healthy
individuals do flot maintain long-term lifestyle changes and are subject to the
danger of dietary carelessness and sedentary lifestyle. Due to the limitations of
lifestyle modification in the prevention cf type 2 diabetes, use of pharmacological
agents is often required in type 2 diabetes.
1.11.2.6.2. Oral hypoglycemïants
Since type 2 diabetes is defined as a syndrome characterized by insulin
deficiency, insulin resistance, and increased hepatic glucose output, medications
used to treat type 2 diabetes are designed to correct one or more of these
metabolic abnormalities. Currently, there are five distinct classes of hypoglycemic
agents, including sulfonylureas, meglitinides, biguanides, thizaolidinediones, and
alpha-glucosidase inhibitors. Each class cf these agents displays unique
pharmacological properties.
1.11.2.6.2.1. Sulfonylureas
Sulfonylureas derived from sulfonic acid and urea have remained the
mainstay of antidiabetic therapy about five decades. Glyburide, glipizide,
glimepiride, and gliclazide are the second-generation sulfonylureas, which are
more potent than the first-generation sulfonylureas in the therapy cf type 2
$5
diabetes and in the prevention cf diabetic vascular complications [Luna et al.
1999J.
The suiphonylureas act by triggering insulin release from the pancreatic
beta ceil and may slightly improve insulin resistance in peripheral target tissues
such as muscle and fat. A specific site on the adenosine triphosphate-sensitive
potassium channels is occupied by sulphonylureas leading to closure of the
potassium channels and subsequent opening of calcium channels resulting in
insulin secretion [Zimmerman et al. 1997]. The over clinical efficacy of
sulfonylureas in patients with type 2 diabetes is related to the pre-treatment
levels of fasting plasma glucose and HbAjc. The higher the fasting glucose level,
the greater the effect will be [DeFronzo et al. 1999, Feinglos et al. 1999, Luna et
al. 1999]. Hypoglycemia is the most worrisome side effect of the sulfonylureas. It
S 0f particular concern with agents that are metabolized to an active metabolite
with significant renal excretion. These agents are long-acting compounds
including chlorpropamide and glyburide, both of which should be avoided in the
setting of impaired renal function and used with caution in elderly patients. Thus,
shorter-acting compounds like tolbutamide and gliclazide have been relatively
well tolerated and appear to be the best choice to treat elderly patients [Graal et
al. 1999]. Glimepiride is associated with a lower incidence of hypoglycemia
[Langtry et al. 1998].
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1.11.2.6.2.2. Meglitinide
Meglitinides are rapid-acting insulin secretagogues targeting postprandial
hyperglycaemia. This class cf drugs is useful for patients who are at risk of
hypoglycaemia with Jonger-acting sulfonylurea dtugs [Loh et al. 2002].
Repaglinide is the first meglitinide analogue to become available for use in
patients with type 2 diabetes. Neteglinide, the newest member of the class, has
recently became available. Repaglinide achieves similar overail glycemic control
to that provided with glyburide [Plosker et al. 2004]. Meglitinides rapid onset and
relatively short duration of action allow for flexible meal schedules.
1.11.2.6.2.3. Mefformin
Metformin is an insulin-sensitizing biguanide, widely used in the treatment
cf patients with type 2 diabetes. Metfocmin has a wide volume of distribution to
the targeted organs because it is net protein bound [Davidson et al. 1997].
Moreover, metformin undergoes no modifications in the body, and is in its
unchanged form rapidly excreted by the kidneys [Davidson et al. 1997].
Metformin improves hyperglycemia by reaching high concentrations in the small
intestine [Wilcock et al. 1994, Wiernsperger et al. 1999] and decreasing intestinal
absorption of glucose [Ikeda et al. 2000, Wilcock et al. 1991]. This action may
contribute to decreased postprandial blood glucose levels [Wu et al. 1990].
Several reports indicate an antihypertensive effect of metformin in animaIs
[Petersen et al. 1996, Katakam et al. 2000, Bhalla et al. 1996, Verma et al. 2000]
and humans [Landin et al. 1991, Giugliano et al. 1993]. Potential mechanisms cf
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antihypertensive action of metformin are complex and include both insulin
dependent and insulin-independent vasodilatory actions [Kirpichnikov et al.
2002].
Metformin was recommended in a single drug therapy especially for obese
subjects [Hermann et al. 1994, Johansen 1999]. In conjunction with diet,
metformin reduces fasting glucose concentrations, and hemoglobin Aic values
[Davidson et al. 1997, Hermann et al. 1994, DeFronzo et al. 1995]. The
effectiveness of metformin monotherapy on lowering glucose has been shown to
be independent of age, body weight, ethnicity, insulin and C-peptide levels
[Hermann et al. 1994, Johansen 1999]. Treatment with metformin also
significantly reduces both total and visceral fat [Pasquali et al. 2000]. In the liver,
metformin only partially suppresses gluconeogenesis. It did flot however,
stimulate insulin production [DeFronzo et al. 1999, Wiernsperger et al. 1999].
Studies demonstrated that metformin achieved 10% to 30% reduction of
free fatty acid oxidation [Wiernsperger et al. 1999, Perriello et al. 1994]. Based
on the decreased levels of free fatty acids by metformin treatment, this drug
could not only improve insulin secretion but might also help to correct impaired
insulin secretion by f3-cell [Patane et al. 2000]. Several pieces of evidence
showed that metfomin reduced both hepatic glucose and VLDL production
through an activation of the hepatic AMP protein kinase pathway [Zhou et al.
2001]. Besides increasing insulin sensitivity in diabetic and nondiabetic subjects,
metformin also lowers plasma insulin levels [Cusi et al. 1996, Bailey et al. 1996].
C
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Importantly, the DPP study showed that metformin may directly delay or
prevent the onset of type 2 diabetes by 31% [DPP Group 2002]. This study
invoived more than 3000 participants from 26 centers, using patients with IGT
tested at 6-month intervals. These findings suggest that metformin may decrease
the risk of deveiopment of type 2 diabetes. This beneficial effect may be related
to the ability of metformin to decrease CRP [Arbar et al. 20031 and PAl-1 [Seli et
aI, 2002], two predictors of the deveIopment of diabetes.
Compared to other antidiabetic agents, metformin has severai advantages
such as iowering body weight, causing reduction leveis of triglycerides and LDL
cholesterol, avoiding hypoglycemia, and improving fibrinolysis. These
advantages of metformin accompanied by its good toIerabiiity profile, place
metformin as a first-line agent in the prevention and treatment of type 2 diabetes.
IJI.2.6.2.4. Thiazolïdinediones
Thiazolidinediones act as insulin sensitizers and decrease peripherai
insulin resistance by enhancing insuiin-mediated glucose uptake by muscles.
They have a lesser effect on insulin action in the liver. Thiazolidinediones play a
beneficial role in the prevention of type 2 diabetes in individuals with IGI and
other risk factors for diabetes [Nolan et al.1994]. Studies demonstrated that
troglïtazone improved E3-cell function in subjects with I GI [Ehrmann et al. 1997].
In the Troglitazone in Prevention of Diabetes (IRIPOD) study [Azen et al. 1998],
a 56% reduction in diabetes risk was obsecved following troglitazone treatment.
Thiazolidinediones have rapid anti-inflammatory effects [Garg et al. 2000, Aljada
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et al. 2001, Ghanim et al. 2001, Mohanty et al. 2001] and these effects may
contribute to their beneficial action on insulin sensitivity. Troglitazone reduces
ROS generation, NFKB binding activity, and plasma CRP concentrations
[Ghanim et al. 2001]. Troglitazone can cause fatal hepatic toxicity and has been
withdrawn from the market, therefore alternatives such as piogiitazone and
rosiglitazone are now being used in the clinical intervention trials.
1.11.2.6.2.5. Acarbose
Acarbose is a Œ-glucosidase inhibitor, which can improve insulin
sensitivity, as well as decrease postprandial hyperglycemia through reducing the
digestion of oligosacharides. Thus, it may help reduce the hyperglycemic stress
on the 13-ceils [Chiasson et al. 1996]. In the STOP-NIDDM trial [Chiasson et al.
2002], obese adults with IGT were treated with acarbose. Resuits of this study
demonstrated that this drug induces in a 25-36% reduction of type 2 diabetic risk.
The same study found that acarbose has anti-hypertensive effect, reduces
postprandial glucose levels, and lowers insulin concentrations [Chiasson et al.
2002]. The specific advantages cf acarbose can be summarized as follows
[Levovitz et ai. 2002]. It specifically lowers postprandial plasma glucose levels; lts
action is independent of, and additive to, ail other forms of pharmacologic
therapy; It does not cause weight loss or gain, and it is relatively nontoxic
[Lebovitz et al. 1998, Raptis et al. 2001].
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1.11.2.6.2.4. Other medications that may reduce the risk of type 2 diabetes
Data obtained in a recent multi-centered international trial, have shown
that the use cf angiotensin converting enzyme (ACE) inhibitors such as Enalapril
or Ramipril may prevent the onset of diabetes in people at risk cf coronary heart
disease [Simpson et al. 2003]. Other drugs such as angiotensin teceptor
blockers (ARB5) have been shown te reduce macrovascular complications in
diabetes [Dahlof et al. 2002]. Because angiotensin Il is a proinflammatory
peptide, these drugs may exert their beneficial effects by reducing inflammation
[Brasier et al. 2002, Phillips et aI. 2002].
1.11.2.6.3. Insulin therapy
As J3-cell function detetiorates during the course cf type 2 diabetes, insulin
secretagogues eventually become ineffective. At that stage, the patient needs
insulin administration. Many studies have shown that insulin therapy greatly
improves insulin secretion in patients with type 2 diabetes, presumably by
reducing hyperglycemia [Della Casa et al. 1991, llkova et al. 1997]. Some studies
have also demonstrated an improvement in peripheral insulin sensitivity after
insulin thetapy in type 2 diabetes [Garvey et al. 1985, Groop et aI. 1989, Yki
Jàrvinen et al. 199, Foley et al. 1983]. Even short-term insulin therapy appears te
result in long-term improvement in blood glucose control, especially when
administered in the earliest stages cf diabetes [Skyler et al. 1997, llkova et al.
1997]. Based on these observations, some diabetes experts have advocated
initiating intensive insulin therapy early in the course cf type 2 diabetes, or
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immediately after a diet on exercise regimen fails, in an effort to preserve the
remaining 3-cell function and improve long-term glycemic control [Skylec et al.
1997, Glaser et al. 1999].
Lll.3. Gestational diabetes (GDM)
GDM is defined as any degree of glucose intolerance developing with the
onset or discovered during pregnancy. Approximately 7% of ail pregnancies are
complicated by GDM, resulting in more than 200,000 cases annually. The
prevaience of this disease may range from I to 14% of pregnancies, depending
on the population studied [American Diabetes Association 2004]. Women with
marked obesity, personai history of GDM, glycosuria, or a strong family history of
diabetes are at high risk to develop GDM. GDM is associated with insulin
resistance and endothelial dysfunction, and 60% of patients with GDM will
develop diabetes within 15 years.
1JL4. Other type of diabetes
This is a large inclusive group of less common and diverse disorders
causing or associated with hyperglycemia. These probably account for 1 to 2 ¾
of the cases of DM. They are listed in Table 4.
o
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1.111. Lectin-like oxidized Iow density lipoprotein receptor-1 (LOX-1)
1.111.1. General
LOX-1 is a type Il membrane protein belonging to the C-type lectin family
of molecules. it is a newly identified endothelial receptor for oxLDL, which is also
expressed by other vascular ceil types, such as macrophages and SMCs
[Sawamura et al. 1997]. LOX-1 expression is induced by various
pathophysiological stimuli relevant to atheroscierosis and inflammation, includin
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cytokines such as INFa [Kume et al. 19981 and TGFJ3 [Minami et ai. 2000], fluid
shear stress, oxidative stress [Murase et al. 19981 and homocysteine [Nagase et
al. 2001], oxLDL [Aoyama et al. 1999, Dayan et al. 2000], angiotensin II [Li et al.
1999, Morawietz et al. 1999], endothelin [Morawietz et al. 2001], and AGE [Chen
et al. 2001]. More importantly, studies demonstrate that LOX-1 is expressed in
vivo in the vessels of hypertensive [Nagase et al. 1997], diabetic [Chen et ai.
2001] and hyperlipidemic [Chen et al. 2000, Kakutani et ai. 2001] animais and is
upregulated in early human atherosclerotic lesions [Kataoka et aI. 1999],
suggesting that LOX-1 may be involved in the initiation 0f atherosclerosis
.
1.111.2. LOX-1 properties
1.111.2.1. Structure of LOX-1 gene
1.111.2.1.1. Human LOX-1 gene
The length of the LOX-1 gene is more than 7 kb with 6 exons and 5
introns. The organization of the human LOX-1 gene is shown in figure 12.
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1.111.2.1.2. 5’-flanking region 0f the LOX-1 gene
As shown in figure 12, a number of potential transcription-factor-binding
sites are Iocated in the 5’-flanking region of the gene. The GATA-2-binding sites
are present at —180 and —1676 bp and are known to mediate endothelium
specific expression cf endothelin-1 [Lee et aI. 1999]. c-ets-1 is present at —2274
bp and is expressed in endothelial celis during angiogenesis and tumour
vascularization. It is also involved in the regulation cf vascular endothelial
growth-factor receptor [Macleod et aI. 1992, Morishita et al. 1995]. 12-0-
Tetradecanoylphorbol 13-acetate-Responsive Elements (TREs) are present at —
60, -984 and —1714 bp. These elements are the binding sites for AP-1 and are
responsible for the induction cf transcription cf related genes by protein kinase C
or phorbol ester [Angel et al. 1987]. A shear-stress responsive element (SSRE,
GAGACC) is present at —1447 and —1011 bp. SSRE may be involved in the NF
KB-mediated induction cf LOX-1 gene expression [Collins et al. 1995, Khachigian
et aI. 1995]. The TATA box is located at —29 bp while the CAAT box is Iocated at
-99 bp. Sequence analysis of Rat LOX-1 5’-flanking region performed by
computer analysis finds that there are six AP-1 sites, four AP-2 motifs, one NFiB
site, and one SSRE site [Nagase et aI.1998]. The consensus cf NFKB sequence
presented in the promoter of rat LOX-1 gene is encoding as “gggattttac”. The
presence cf these elements in the LOX-1 promoter suggests that LOX-1 is an
inducible regulated gene.
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1.111.2.2. Structure of LOX-1 protein
As shown in figure 12, a Ca2-dependent carbohydrate-recognition domain
(CRD) is present in C-type animal lectins. Based on the overali architecture 0f
proteins, the position of the CRD domain, and the degree cf homology of their
CRD domains, C-type animal lectins have been classified into seven groups
[Aoyama et aI. 1999]. Group f includes proteoglycans, group II type-II membrane
proteins including hepatic lectins, the Kupper ceIl receptor and the CD23
lymphocyte-activation antigen. Group III includes collectins with mannose-binding
proteins, the pulmonary surfactant apoprotein and conglutinin. Group IV includes
L-, P-, and E-selectins. Group V is a second group of type-II membrane proteins
including NKR-P1, Ly49 and CD69. Group VI is the mannose receptor family.
Group VII is the free CRD. LOX-1 belongs to the group V of the C-type lectin
family [Dirckamer. 1988]. It has a type II membrane protein structure with a short
N-terminal and a long carboxy-terminal hydrophilic demains separated by a
hydrophobic domain of 26 amino acids [Sawamura et al. 1997].
1.111.2.2.1. The domain structures and functions of LOX-f
As shown in figure 12, the LOX-1 protein consists cf four domains
including the short N-terminal cytoplasmic demain, the transmembrane domain,
the neck demain, and the C-type lectin-like domain [Sawamura et al. 1997].
Several potential phosphorylation sites including Thr 21 and Ser 28 (for PKC)
and Thr 2 (for casein kinase II) have been found in the N-terminal cytoplasmic
demain. Phosphorylation cf these sites is involved in signal transduction and
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LOX-1 regulation. Six repeats cf cysteines in the lectin-like demain are totaliy
conserved among ail species. Truncation or deleticn cf the lectin domain cf LOX
1 results in loss cf cxLDL binding [Chen et al. 2001], as weH as in lcss of
aged/apototic ceil and negatively charged phospholipid binding ability [Chen et
al. 20011 indicating its function as a ligand-binding domain, and initiator cf the
processes cf internalizaticn and phagccytcsis [Chen et al. 2001].
1.111.2.2.2. Post-translational modification of LOX-1
As shown in figure 12, several potential N-linked glycosylation sites Iccate
in the extracellular C-termina! demain cf the LOX-1 protein [Sawamura et al.
1997]. Evidence indicates that LOX-1 is first synthesized as a 40-kDa precursor
(pre-LOX-1) with N-linked high mannose carbohydrates, and then is
subsequently glycosylated and prccessed into a 50-kDa mature LOX-1 protein,
which is then transpcrted te the celI surface [Katacka et al. 2000]. Treatment cf
LOX-1 with N-glycanase reduces the molecular mass te 32 kDa, which is the
predicted molecular size cf LOX-1 lacking ail the N-linked cligcsaccharide
moieties [Katacka et al. 2000, Shi et al. 2001]. It has been prcposed that N-linked
glycosylation cf LOX-1 regulates, in part, its intracellular transpcrt and ligand
binding activity. Altered glycosylation cf LOX-1 may thus affect its biclogical
functions in vivo.
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I.Ill.2.23. Soluble forms of LOX-1
Many membrane proteins can be converted into soluble molecules by
proteolytic cleavage [Ehiers et al. 1991, Rose-John et aI. 1994, Hooper et al.
1997]. LOX-1 is one of these trans-membrane proteins which, can also be
cleaved at the juxtamembrane region 0f the extracellular domain. The secreted
soluble form of LOX-1 [Kume et al. 2001], has a molecular weight of 35 kDa.
Because phenylmethylsulfonyl fluoride inhibits the release of soluble LOX-1 in
vitro, a phenylmethylsulfonyl fluoride-sensitive serine proteasefs) may be
involved in the process of soluble LOX-1 secretion. Examination of the serum
levels of LOX-1 in vivo may be a novel diagnostic strategy for the evaluation and
prediction of atherosclerosis and vascular disease [Kume et al. 20011.
1.111.2.3. LOX-1 tissue distributions
LOX-1 is expressed not only in cultured vascular cells such as endothelial
cells, macrophages, SMCs, fibroblasts, and platelets, but also in various tissues
in vivo [Sawamura et al. 1997, Draude et al. 1999, Moriwaki et al. 1998, Yoshida
et al. 1998]. For example, LOX-1 is expressed in vivo in aortic, carotid, thoracic,
and coronary arteries and veins. It is mainly expressed in aortic intima and
vascular-rich organs, such as placenta, lungs, brain and liver.
1.111.3. LOX-1 binding Iigands
Q LOX-1 demonstrates binding activity for multiple ligands, which can be
classified into five groups. Group 1 contains modified lipoproteins including ox
9$
LDL, acetylated LDL, and hypocNorite-modified HDL [Marsche et aI. 2001,
Moriwaki et al. 1998, Sawamura et al. 1997]. Group 2 contains polyanionic
chemicals including polyinosinic acid and carrageenan. Group 3 contains anionic
phospholipids including phosphatidylsecine (PS) and phosphatidylinositol
[Moriwaki et al. 1998, Oka et al. 1998]. Group 4 contains cellular ligands
including apoptotic/aged ceils, activated platelets, and bacteria [Kakutani et al.
2000, Oka et aI. 1998, Shimaoka et al. 2001]. Group 5 includes AGEs [Jono et
al. 2002].
Study cf Kakutani’s research team found that s novel sandwich enzyme
immunoassay system utilizing anti-apolipoprotein B antibody and recombinant
soluble LOX-1 can detect the lipoprotein LOX-1 ligand in vivo [Kakutani et al.
2001 J. The same research team also evaluated the level of the lipoprotein LOX-1
ligand in plasma under some pro-atherogenic conditions. Their data
demonstrated that plasma cf WHHL rabbits shows increased levels of lipoprotein
of LOX-1 ligand and that supplementation with antioxidants can attenuate the
rapid increase cf the lipoprotein LOX-1 ligand [Chen et aI. 2002]. Taken together,
this method may suggest a convenient approach for quantitative measurement of
the lipoprotein LOX-1 ligand in routine clinical tests. This assay determining the
level of modified [DL in the plasma in vivo may be useful for predicting ischemic
heart diseases.
C
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1.111.4. Regulation of LOX-1 expression
1.111.4.1. Inducing Factors
LOX-1 expression can be upregulated by pro-inflammatory factors stimuli,
markers cf oxidative stress, and under various pathological conditions.
1.111.4.1.1. Pro-inflammatory cytokines
LOX-1 expression is induced by the pro-inflammatory cytokine TNF-Œ in
both endothelial cells and macrophages [Moriwaki et al. 1998, Kume et al. 1998].
It can also be upregulated by other proinflammatory cytokines including
interleukin-1f3 [Nakagawa et al. 20021 and endothelin-1 [Morawietz et al. 2001,
Morawietz et al. 2002] in endothelial ceils.
1.111.4.1.2. Pro-atherosclerotic stimuli
Besides pro-inflammatory cytokines, multiple pro-atherosclerotic stimuli
regulate LOX-1 expression in vascular celis in vitro. For example, TGF-f31 has
been reported to upregulate LOX-1 expression in endothelial ceNs, macrophages,
and SMCs [Draude et al. 2000, Chen et al. 2001, Minami et al. 2000]. Fluid
shear stress has been shown to modulate various endothelial functions, including
the expression of several genes such as endothelin-1 [Malek et al. 1993, Kuchan
et al. 1993], TGF-f31 [Ohno et aI. 1995], and MCP-1 [Shyy et al. 1994]. Murase et
al [1998] provided evidence that fluid shear stress transcriptionally induces LOX
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1 expression in vascular endothelial ceils thus suggesting a role for LOX-1 in the
localized formation of atherosclerotic lesions in vivo.
LOX-J expression is also upregulated by phorbol 12-myristate 13-acetate
(PMA) [Yoshida et al. 1998, Kume et al. 1998], lipopolysaccharide [Kume et al.
1998], and angiotensin II [Morawietz et aI. 1999, Li et aI. 1999]. PPAR Œ ligands,
such as fenofibrate and WY14643, also enhance LOX-1 expression in cultured
bovine aortic endothelial ceils (BAECs) [Hayashida et al. 2001].
1.111.4.1.3. Oxidative stress
As mentioned before, oxidative stress is firmly implicated in the
pathogenesis of atherosclerosis. Evidence exists that LOX-1 expression is not
only upregulated by oxLDL, but also by the atherogenic Iipid constituent of
oxLDL, Iysophophatidylcholine [Aoyama et al. 2000, Mehta et aI. 1998]. In
addition, LOX-1 expression is induced by many stimuli associated with oxidative
stress, such as 8-iso-prostaglandin F2Œ (8-iso-PGF2Œ), a marker of oxidative
stress in vivo [Morrow et al. 1992]. Elevated formation of 8-iso-PGF2Œ is
associated with cardiovascular risk factors such as hypercholesterolemia and
diabetes mellitus [Patrono et al. 1997]. Halvorsen et aI [20011 demonstrated that
8-iso-PGF2Œ increases LOX-1 expression both at the gene and protein levels in
human JAR ceils. Importantly, it has also been shown that AGEs, which are weIl
known inducers of oxidative stress, bind to LOX-1 [Jono et aI. 20021 and increase
LOX-1 expression in human aortic endothelial ceils (HAECs) [Chen et al. 2001].
Superoxide anions, as well as hydrogen peroxide, also inctease LOX-1 mRNA
‘o’
expression in cultured aortic endotheliai cefls [Nagase et al. 2001]. Finally,homocysteine, an atherogenic substance which exerts its effects throughoxidative stress, enhances endothelial LOX-1 gene expression, an effectinhibited by N-acetylcysteine (NAC) [Nagase et al. 2001, Holven et aI. 2003].Overali, these results suggest a redox-sensitive regulation of LOX-1 expression.
1.111.4.1.4. Pathological conditions
LOX-1 expression is increased in experimental hypertension. Indeed,Nagase et al [1997] reported that Dahi sait-sensitive hypertensive ratsspontaneously expressed high levels of LOX-1 mRNA in the aorta. Importantly,treatment of rats with the AT1 receptor blocker, iosartan, not only decreasesatherosclerosis, but also reduces endothelial LOX-1 expression. Morawietz et al[1999] demonstrated that endothelial LOX-1 is upregulated by angiotensin II invivo and in vitro. The induction of LOX-1 expression is mediated by angiotensin IIAT1 receptor. High LOX-1 expression is also documented in hyperlipidemia, asrefiected by the upregulation of LOX-1 expression in the aorta of Watanabeheritable hyperlipidemic rabbits and in high cholesterol-fed New Zealand whiterabbits [Chen et al. 2000]. This augmented expression is primarily Iocalizedwithin the intima of eariy atherosclerotic lesions. Finaiiy, increased LOX-1expression has been observed in experimental diabetes, with increased LOX-1expression in the endothelium and aorta of the diabetic rat [Chen et al. 20011.
C
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1.111.4.2. Inhibitory factors
Li et a [2002] demonstrated that the 3-Hydroxy-3-methyglutaryl-coenzyme A reductase inhibitors, simvastatin and atorvastatin, significantlyreduce oxLDL-induced LOX-1 expression with consequent reduction of 0xLDL-mediated activation of the redox-sensitive NF-KB. Simifar resuits were obtainedby Mehta et af [20011 who reported that these drugs significantly reduced 0xLDL-induced LOX-1 expression as weB as eNOS expression. These resufts alsoprovided evidence that both statins attenuated oxLDL-mediated activation ofMAPK, and uptake of 0xLDL by human coronary artery endothefial cefis(HCAECs). Li et aI [2001] reported that the effect of statins on LOX-1 expressionis associated with an increase in PKB activity in HCAECs. Among other inhibitoryfactors of LOX-1 expression, Tempo, a superoxide dismutase and Iosartan, anACE inhibitor, have been shown to reduce LOX-1 expression induced byangiotensin II [Nagase et aI. 2001]. PPARy Iigands including the natural ligand15-deoxy-Delta (12,14)-prostaglandin J (2) (15d-PGJ(2)), and thethiazolidinediones, piogliazone and troglitazone, have also been reported todecrease TNFŒ-induced LOX-1 mRNA expression in cultured BAECs [Chiba etal. 2001]. Finally, s recent study provided evidence that L-arginine was effectivein decreasing LOX-1 expression in the donor organ after organ transplantation[Kosaka et aI. 2003].
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1.111.5. Role of LOX-1 in atherosclerosis
Uptake of oxLDL by vascuiar ceits is considered a crucial step in theinitiation and progression of atherosclerosis. As mentioned above, LOX-1 isexpressed by vascular ceiis and is expressed in vivo in the vesseis ofhypertensive [Nagase et ai. 1997], diabetic [Jono et ai. 2002, Chen et ai. 2001],and hyperiipidemic animais [Chen et ai. 2000, Kakutani et ai. 2001]. lmportantiy itis aiso upreguiated in human atheroscierotic iesions [Kataoka et ai. 1999]suggesting a roie of LOX-1 in atherogenesis. The potentiai roie of LOX-1 inatheroscierosis is shown in figure 13.
1.111.5.1. Role of LOX-1 in endothelial dysfunction
Numerous studies support a role of LOX-1 as a potentiai mediator ofendotheliai dysfunction. First, 0xLDL binding to LOX-1 in endotheiiai ceNsgenetates superoxide anions, decteases NO, activates NF-KB pathway[Cominacini et ai. 2000, Cominacini et ai. 2001], and induces the production of
endotheiin-1 and MCP-1 [Li et ai. 2000]. Second, binding of 0xLDL to LOX-1induces apoptosis, a process invoived in endotheiiai dysfunction [Li et ai. 2000].Third, LOX-1 is an adhesion moiecuie, favoring monocyte adhesion toendothelium [Honjo et ai. 2003, Li et ai. 2002]. Finaiiy, it has been documented in
a hyperchoiesteroiemic rabbit modei, that endotheiiai LOX-1 expression is
upreguiated during the early stage of atherogenesis i.e. before intimai
accumulation cf macrophage foam ceiis, thus suggesting a roie for LOX-1 inÇ endotheiiai activation during eariy atherogenesis [Chen et ai. 2000].
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1.111.5.2. Rote of LOX-J in the progression of the atherosclerotic lesion
Even though LOX-1 ïs a major receptor for oxLDL by endothelial celis,
foam cefl formation stil) has flot been identified in endothelial celis either in vitro
or in vivo. While uptake of 0xLDL via LOX-1 in vascular endothelial ceHs may flot
resuit in massive lipid accumulation, this process may eaU to endothelial
activation and/or dysfunction, monocyte adhesion, and celi injury in the early
stage of atherosclerosis. LOX-1 is flot only expressed in endothelia) ceHs but also
in macrophages and SMC5 [Yoshida et al. 1998, Draude et aI. 1999]. Uptake of
oxLDL by macrophages and subsequent foam ceil formation play key roles in
atherogenesis. It has been shown that LOX-1 expression is more prominent in
macrophages and SMCs that have accumulated in the intima [Kataoka et al.
1999], thus suggesting a rote for LOX-1 in foam cet) transformation of
macrophages and SMCs. Furthermore, Mehta et al [2002] have documented
LOX-1 expression in the intima of advanced human atherosclerotic lesions,
where LOX-1 co-localizes with apoptotic ceils.
1.111.5.3. Rote of LOX-1 in atherosclerotic plaques stability
It has been suggested that the composition of the atherosclerotic plaque is
the most important determinant of plaque distuption and development of acute
coronary syndromes [Libby. 1995]. MMPs are an endogenous family of enzymes
that are responsible for vascular remodeling [Newby et al. 1994, Li et al. 2000].
Release of MMPs and enhanced collagenase activity may degrade various
components of the fibrous cap and contribute to the vulnerability of plaques to
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rupture. Recent studies have shown that increased activity and expression of
MMPs play a crucial role in the composition of atherosclerotic plaques [Silence et
al. 2001, Lemaitre et al. 2001]. Ihe finding that 0xLDL upregulates the
expression of MMP-1 and -3 via LOX-1 activation strongly supports a role for
LOX-1 in vasculature remodeling and plaque rupture [Li et al. 2003].
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Figure 13. Role of LOX-1 in atherosclerosis. LOX-1 is expressed in endothelial cells,
macrophages, and SMCs. LOX-1 is an adhesion molecule, involved in endothelial
dysfunction and initiation and progression of atherosclerosis. LOX-f is upregulated by
multiple inflammatory cytokines and pathological stimuli. AGE and oxLDL are ligands for
LOX-1.
1.111.6. Role of LOX-1 in type 2 diabetes
Elevated blood glucose levels can adversely affect the vessel wall through
various mechanisms. Diabetes is characterized by a state of increased oxidative
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stress, endothelial dysfunction, up-regulated expression of endothelial cell
adhesion molecules, and glycosylation of virtually every protein in the body. It
Ieads to enhanced oxidative modification of lipoproteins and AGEs formation. It
has been shown that LOX-1 expression is increased in the aorta of STZ-induced
diabetic rat [Chen et aI. 20011. In the same study, it was further demonstrated
that diabetic rat serum and AGEs, which bound to LOX-1 [Jono et al. 2002]
induce endothelial LOX-1 expression and that ligand activity is increased in the
serum of diabetic rat. Our resuits showing that macrophage LOX-1 expression is
increased in human type 2 diabetes, further support a role for LOX-1 in human
diabetic vascular complications [Li et al. 2004].
1.1V. CRP
CRP was discovered in the plasma of patients during the acute phase of
pneumococcal pneumonia. Its name was derived from a protein that binds to the
C-polysaccharide of the pneumococcal celI wall [Tillett et al. 1930]. CRP is
considered as a prototypical APP, although it accompanies both acute and
chronic inflammatory disorders.
CRP is secreted by the liver in response to a variety of inflammatory
cytokines including IL-6, IL-113, TNFŒ, interferon-’y, TGF-13, and possibly IL-8
[Wigmore et al. 1997]. A variety of other cell types including adipocytes ptoduce
these cytokines, but its most important sources at the inflammatory site are
macrophages and monocytes [Wigmore et al. 1997].
o
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Evidence suggests that CRP is a part of the innate immune system where
it acts as a pattern recognitïon molecule to activate the adaptive immune
response [Du Clos. 2000]. CRP is a member of the pentraxin family is composed
of five identical 23-kDa subunits arranged in a calcium-dependent cyclic
pentamer shape [Shrive et al. 1996]. Each subunit binds to phosphocholine (PC)
with high affinity [Anderson et al. 1978]. The five ligand-binding sites cf CRP are
ail on the same face cf the pentamer [Du Clos. 2000]. On the opposite side cf
each subunit is an effector molecule-binding site that mediates the protein’s
interaction with Clq, FcyRI and FcyRII [Agrawal et al. 1994, Marnell et al. 1995,
Bharadwaj et al. 1999]. Ligand recognition and binding by CRP may thus
contribute to a range cf metabolic, scavenging and host-defense functions.
Besides CRP, there are many other plasma proteins named APPs, which
have been defined as those whose plasma concentration increases (positive
APP5) oc decreases (negative APPs) by at least 25 percent during inflammatcry
disorders. Among these are serum amyloid A (SSA), fibrincgen, albumin,
transfercin, and many cthers [Du Clos. 2000]. After a mcderate inflammatccy
stimulus, CRP and SSA levels increase rapidly up ta 1000-fcld within 1-2 days,
whereas other APPs increase only by 50- to 200-fold in a slow response lasting
several days [Du Clos. 2000].
Conditions that lead to substantial changes in plasma concentrations of
APPs, include infection, trauma, surgery, burns, tissue infarction, and varicus
immunolcgical-mediated and crystal-induced inflammations [Gabay et al. 1999].
C Because CRP decreases just as rapidly with the resolution cf these conditions,
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shows long-term stability during storage, has a very long half-life about 18-20
hours, does not show diurnal, age, and sex variations [Edward et al. 2003], its
measurement appears a convenient biomarker to monitor various inflammatory
states.
I.IV.J. CRP and Atherosclerosis
As discussed earlier, inflammation is considered as a major contributor to
the pathogenesis of atherosclerosis. In this regard, the predictive association
between markers of inflammation and CV events has been extensively
confirmed. The interplay between the inflammatory process, cardiovascular risk
factors, and atherothrombosis is complex [Liuzzo et aI. 1994]. Since each step in
atherogenesis involves cytokines, bioactive molecules, and inflammatory ceils,
the relationship between CRP and each parameter must be examined.
I.IV.f.1. CRP as a predictive risk marker of CV events
Numerous epidemiological studies have provided evidence that CRP is a
predictive risk marker of CVD. Initially, in a large dyslipidemic population,
Blackburn et al [1962] found that elevated CRP is an independent predictor of
advanced carotid plaques in male subjects. Later on, Liuzzo et al [1994] and
Haverkate et al [1995] established the prognostic usefulness of CRP in the
setting of angina. Then, Iracy R et al [1997] identified CRP as an independent
prospective CVD risk factor in healthy elderly men and women. Paul et al [1997]
showed that men in the quartile with highest CRP values had three times the risk
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of myocardial infarction and two times the risk of ischemic stroke compared to
men in the lowest quartile. In 1999, Koening et al reported that CRP predicts
CHD in initially healthy middle-aged men in the Monitoring Trend and
Determinants in CVD (MONICA) Augsburg cohort study. A recent prospective
study provided evidence that CRP levels correlate with sudden cardiac death
[Albert et aI. 2002]. Taken together, these findings indicate that CRP is a
powerful predictive marker 0f CV events. This notion has recently been
challenged by resuits from a large study showing that the predictive value of CRP
measurement in the serum adds relatively littie to that provided by assessments
of traditional risk factors [Danesh et al. 2004], suggesting that the clin ical value of
measuring CRP as a major predictor for the risk of CVD needs to be further
evaluated.
As mentioned above, CRP bas now emerged as one of the most powerful
predictors of cardiovascular risk. CRP levels should be below 1g/mL in an
individual without inflammation. Patients with bacterial infections, autoimmune
diseases, and cancer may have CRP levels higher than 100 .tg/mL. As shown in
figure 14, CRP levels in healthy individuals of less than 1, 1 to 3, and greater
than 3 1.tg/mL correspond to 10w-, moderate-, and high-risk groups respectively,
for future CV events [Edward et al. 2003, Ridker. 2003]. If CRP levels show
above lojig/mL, CRP testing should be repeated to exclude other pathological
processes [Edward et al. 2003, Ridker. 2003]. Even though CRP levels correlate
minimally with lipid levels, CRP levels should be intetpreted in conjunction with
( the lipid profile. In 2000, Ridker et al reported that CRP is a better predictor of
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risk of CV events than LDL cholesterol in a study comprising 28,000 women and
the same authors reported that CRP adds prognostic information at ail ieveis cf
the Framingham Risk Score [Ridker. 2003]. For exampie, the Aduit Treatment
Panel III (ATP III) cut-points for LDL ievels on coronary risk prediction were iess
than 130, 130 to 160, and greater than 160 mg/dL. Studies with [DL choiesteroi
beiow 130 mg/dL who have CRP leveis greater than 3 igImL represent a high
risk group often missed in ciinicai practice.
CRP level Interpretation
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Figure 14. CRP level and CV rïsk. CRP levels are Iisted on the Ieft and interpretatïons are on the right.
[Yeh et al. 2003J
I.IV.1.2. Role of CRP in atherosclerosis
As mentioned above, inflammation piays a pivotai role in ail stages of
atherogenesis, and 10w-grade chronic inflammation as measured by high
sensitivity CRP is thought to predict future risk of acute coronary syndrome
independent of traditionai cardiovascuiar risk factors. increasing evidence
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Ç suggests that CRP may be directly involved in atherothrombogenesis that
extends beyond its previously accepted role as an inflammatory marker. CRP is
present in the intima and media layers of human atheroslcerotic arteries. It is
produced by macrophages and SMCs [Yasojima et al. 2001] and expressed on
surface of foam celis [Torzewski et al. 1998], and serum CRP correlates with
macrophage accumulation in coronary arteries of hypercholesterolemic pigs
[Turk et al. 2003].
I.IV.1.2.1. Role of CRP on monocyte adhesion/recruitment
Monocyte adhesion to the endothelium and subsequent migration into the
subendothelium, where they differentiate into monocyte-derived macrophage
foam cells is believed to be the very early step in the inflammatory process of
atherosclerosis. Evidence has been provided that CRP promotes chemotaxis of
monocytes and increases expression of ceil adhesion molecules and
chemokines in human endothelial celis [Woollard et al 2002], thereby favoring
monocyte-endothelial cell adhesion and monocyte recruitment into the vessel
wall. Importantly, CRP deposition preceeds the appearance of monocytes in
early atherosclerotic lesions. CRP binds to monocytes through FcyRI/cd64 with
low affinity [Marneil et al. 1995], as well as FcyRlla/CD32 with high affinity
[Bharadwaj et al. 1999]. Interaction of CRP with monocytes leads to enhanced
release of proinflammatory cytokines including TNFa, IL-1 f3 and IL-6.
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I.IV.f.2.2. Role of CRP on foam ceil formation
Macrophages are key proinflammatory celis, which secrete abundant
proatherosclerotic cytokines. After uptake of CxLDL through specific scavenger
receptors, macrophages become foam ceils, the hallmark of early
athecosclerosis. It has been shown that CRP binds to apolipoprotein B —
containing LDL and VLDL at their Ca2+-dependent PC binding sites and
mediates LDL uptake by macrophages. These data suggest that foam ceil
formation in atherogenesis may resuit in part from this CRP effect. Further
evidence for a raie of CRP in early atherogenesis is the finding that CRP
decreases eNOS expression and increases ET-1 expression. Importantiy, Paul et
aI [2004] recently demonstrated that human CRP transgenic expression causes
accelerated aortic atherosclerosis in apo E mice. These resuits provide final
proof of the proatherogenic effects of CRP in vivo.
CRP may contribute ta the deveiopment of atherosclerosis through
several mejchanisms. First, it may do sa, by activating macrophage and SMC
function leading ta increased release of proinflammatory mediators and growth
factors. Second, it may promote atherosclerotic lesion by activating the
complement system. Through its ability to increase TF and PAl-1, it may also
favor the progression of thrombosis and have a negative impact on vascular
remodeling. Recently, Danenberg et al [2003] have provided the first in vivo
evidence that arterial injury in CRP-transgenic mice resuits n an expedited and
higher rate of thrombotic occlusion. These data suggest that CRP is s risk factor
C
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and possible causal agent rather than metely a risk marker for increased rate of
arterial thrombosis.
I.IV.1 .3. Comparison of CRP to other risk factors
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0 1.0 2.0 4.0 6.0
Figure 15. Direct comparison 0f CRP to several other Iipid and non-Iipid risk factors for CVD.
CRP is not the only inflammatory biomarker that has been shown to
predict CV events. Many novel risk factors are also elevated among individuals
at increased vascular risk [Blake et al. 2001]. Unfortunately, the assays required
for their assessment are either inappropriate for routine clinical use or the protein
of interest has too short halflife for clinical evaluation. For example,
measurements of fibrinogen, a biomarker involved in both inflammation and
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thrombosis remain poorly standardized. Comparison of CRP to other risk factors
for CVD demonstrated that CRP is a stronger predictor of risk for CVD than ail
other markers as shown in figure 15 [Paul et aI. 1997].
I.IV.1 .4. Goal of screening and therapeutic options
The first goal of CV screening programs should be the identification of
high-risk individuals. This group of individuals can be targeted for smoking
control programs, improved diet and exercise regimes, and blood pressure
control techniques. Even though there is currently no definitive evidence that
lowering CRP will reduce CV event rates, many interventions known to reduce
CV risk have been linked to lower CRP levels.
The benefits of statin drugs to decrease CRP levels to iess than 3.6jiglmL
and to decrease the number of CV events have been extensiveiy demonstrated
[Paul et al. 1997]. The peroxisome proliferator-activated receptor y ligand,
rosiglitazone has been found to reduce CRP levels in MI patients [Haffiner et al.
2002]. Aspirin was also shown to reduce CRP levels in the primary prevention of
CVD. Finally, the PPARŒ agonists, fibrates, have also been found to decrease
CRP levels [Kleemann et al. 2003J.
I.IV.2. CRP and Diabetes
Many studies have demonstrated eievated serum levels of CRP among
individuals with both features of the metabolic syndrome and overt type 2
diabetes. McMillan [1989] first reported that CRP increases markedly in both
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O diabetic and glucose intolerant subjects. Later, Rodriguez-Moran et al [1999]
and Inukai et al [1999] reported that hyperglycemia is related to increased serum
CRP levels in non-controlled type 2 diabetes. lmportantly, Pradhan et al [2001]
and Freeman et al [2002] recently demonstrated that CRP is a strong
independent predictor of incident diabetes in large nationwide cohort studies.
CRP has been shown to be associated with body mass index, fasting glucose
levels, hyperinsulinemia and insulin resistance. In contrast to IL-6 whom effect
was considerably attenuated aftet adjustment for BMI, the relation between CRP
and the incidence of diabetes was still observed after adjustment of ail risk
factors. Ouchi et al [2003] recently demonstrated that elevated CRP levels are
negativeiy correlated with the Ievel of plasma adiponectin, an adipocyte-specific
plasma protein associated with obesity-related metabolic and vascular diseases
[Trayhurn et al. 2001]. It is important to note that CRP concentrations are
significantly reduced by loss of body weight [Heilbronn et al. 2001, Tchernof et al.
2002].
O
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I.V. Hypothesis and objectives
Endothelial dysfunction predicts CV events and is documented in patients
with type 2 diabetes. Endothelial dysfunction can also be detected in obese
patients, in relatives without diabetes as weIl as in the spectrum of insulin
resistance. Thus, insulin tesistance itself appears to be associated with
endothelial dysfunction. Multiple interrelated mechanisms may contribute to
endothelial dysfunction in insulin resistance. First insulin resistance may induce
endothelial dysfunction through elements of the insulin syndrome, such as
hypertension, dyslipidemia, and hyperglycemia. Insulin may also exert this effect
independently cf classic risk factors. One candidate mechanism underlying the
effect of insulin resistance on endothelial dysfunction is low-grade inflammation.
lndeed insulin resistance is closely associated with chronic subclinical
inflammation and each component of the insulin resistance syndrome has been
linked to the inflammatory cascade. In this regard, increased CRP levels have
been shown to correlate significantly with features of the insulin resistance
syndrome. Recently, CRP has been found to promote atherosclerosis and to
predict the development of type 2 diabetes.
Endothelial LOX-1 is a novel identified receptor for 0xLDL and a potential
key mediator of oxLDL-induced endothelial dysfunction. LOX-1 is overexpressed
in endothelium and aortas of diabetic rats, thus supporting a role cf LOX-1 in
human diabetic vasculopathy. In addition to endothelial cells, macrophages also
express LOX-1. Expression of LOX-1 at the macrophage celI surface may favor
( foam celI formation. The nature cf the metabolic and inflammatory factors
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responsibie for vascular LOX-1 upregulation in diabetes is unknown. Thus, the
working hypothesis of our proposai was that human diabetes is assaciated with
increased vascuar LOX-1 expression and that this alteration contributes ta the
accelerated atheroscierosis associated with this disease.
The specific objectives of this study were:
1). Ta determine the direct in vitro effect of high glucose on LOX-1 expression in
human endotheiiai ceiis and macrophages.
2). Ta determine the direct in vitro effect af CRP an LOX-1 expression in human
endatheiial ceiis.
3). Ta demanstrate the raie of LOX-1 in glucose- or CRP-induced monocyte
adhesion to endothelium as weii as in oxLDL uptake by macrophages or
endatheiial ceiis.
4). Ta characterize the moiecular mechanisms involved in the upregulation of
endotheiiai and macrophage LOX-1 expression by glucose.
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ABSTRACT
Endothelial dysfunction is an early and key determinant cf diabetic vascular
complications that is elicited at least in part by oxidized low-density lipoprotein (oxLDL).
The recent observation that lectin-like oxLDL receptor-1 (LOX-1) expression is
increased in the vascular endothelium of diabetic rats suggests a role for LOX-1 in the
pathogenesis of diabetic vascular dysfunction. Recause postprandial plasma glucose
has been recently proposed as an independent risk factor for cardiovascular diseases in
patients with diabetes, we evaluated, in the current study, the in vitro effect cf high
glucose on LOX-1 expression by human aortic endothelial cells (HAEC5) and the role cf
this receptor in glucose-induced human monocyte adhesion to endothelium. Exposure
of HAECs to high D-glucose concentrations (5.6-30m moliL) enhanced, in a dose- and
time-dependent manner, LOX-1 expression, both at the gene and protein levels. The
stimulatory effect cf glucose on LOX-1 gene expression in HAECs was abolished by
antioxidants as well as by inhibitors cf nuclear factor-KB (NE-KB), protein kinase C
(PKC) and mitogen-activated protein kinases (MAPK). Electrophoretic mobility shift
assay data demonstrated that high glucose enhanced, in HAECs, the nuclear protein
binding to the NFKB regulatory element cf the LOX-1 gene. Finally, our resuits showed
that incubation cf HAECs with high glucose increased human monocyte adhesion to
endothelium through a LOX-1-dependent signaling mechanism. Overall, these resuits
demonstrate that high glucose induces endothelial LOX-1 expression. This effect
appears to be exerted at the transcriptional level through increased oxidant stress and
NF-KB, PKC and MAPK activation. The study aise suggests a role for LOX-1 as
Ç mediator cf the stimulatory effect of high glucose on monocyte adhesion.
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INTRODUCTION
Atherosclerotic cardiovascular disease is the leading cause cf death and the
major complication of diabetes (1-5). Endothelial dysfunction is a key, early and
potentially reversible event in atherogenesis that is commonly present in human
diabetes (6-8) and plays a key role in the pathogenesis cf diabetic vasculopathies (9).
Several mechanisms may cause or contribute te endothelial dysfunction in diabetes
mellitus. These include hyperlipidemia, oxidative stress, oxidized low-density lipoprotein
(0xLDL), insulin resistance, formation cf advanced glycated end products (AGE),
activation cf protein kinase C (PKC) and hyperglycemia (10-16). Recently, a role for
lectin-like oxLDL receptor-1 (LOX-1), a novel endothelial ceil receptor for oxLDL and
AGE (17-18), in vascular celI dysfunction and monocyte adhesion has been proposed
(19-20). The finding that LOX-1 expression is increased in the vascular endothelium cf
diabetic rats (21) suggests a rote for this receptor in endothelial dysfunction associated
with diabetes. The mechanisms responsible for the upregulation cf vascular LOX-1 in
diabetes are unkncwn. Pathcphysiological stimuli relevant te atherosclerosis in diabetes
that may contribute te this alteration include oxLDL, tumcr necrosis factor-a (TNF-Œ)
and advanced glycation end products (AGEs) (21-23). Since postprandial plasma
glucose has recently been proposed as an independent risk factor for cardiovascular
disease in patients with diabetes (24), we sought te investigate in the present study the
regulaticn cf endcthelial LOX-1 expression by high glucose and the mclecular
mechanisms involved in this effect. On the basis cf previcus observations showing that
hyperglycemia increases leukocyte-endothelial interaction (25-28) and that LOX-1
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supports adhesion cf leukocytes to endothelium (19-20), we further examined the role
for LOX-J in glucose-induced monocyte adhesion.
©
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MATERIALS AND METHODS
Reagents
Fetal caif serum (FCS) was purchased from Wisent (St Bruno, Quebec). RPMI 1640
medium, phenylmethylsulfonyl fluoride (PMSF), Nonidet-P-40 fNP-40), Hank’s balanced
sait solution (HBSS), lymphoprep, penicillin-streptomycin, glycine, sodium dodecyl sulfate
(SDS) and Trizol reagent were obtained from Gibco BRL (Burlington, Ontario, Canada).
Human aortic endothelial cells (HAECs), endothelial growth culture medium (EGM) and
EGM bullet kit were obtained from Clonetics (San Diego, CA, USA). D-glucose, L-glucose,
mannitol, bovine setum albumin (BSA) fraction V, dianisinine dihydrochioride,
hexadecyltrimethylamine ammonium bromide (HTAB), dithiothreitol (Dfl),
dimethylsulphoxide (DMSO), Vitamin E and vitamin C were purchased from Sigma.
Monoclonal antibodies against 3-actin, p50, and p65 were bought from Santa Cruz
Biotechnology (Santa Cruz, CA). Recombinant human TNF-Œ, lgG1 neutralizing antibody
and monoclonal antibodies to human intercellular adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule-1 (VCAM-1), and E-Selectin were purchased from R&D Systems
(Minneapolis, MN). Monoclonal antibody to human LOX-1 was kindly provided by Dr.
Sawamura (National Cardiovascular Centec Research Unit, Osaka, Japan). Caiphostin C,
BAYI 1-7085, N-acetyl-L-cysteine (NAC) and PD98059 were obtained from Calbiochem
(La Joua, CA). LY379196 was kindly provided by Eh Lihly (Indiana, USA).
Endothehial ceils.
HAECs were grown to confluence in EGM under recommended conditions. The
EGM was supplemented with 2% fetal bovine serum (FBS) containing 0.2jig/ml cupric
sulfate, 0.01ig/ml human epidermal growth factor, 0.1% gentamicin sulfate
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amphotericin-B, 1ig/mI hydrocortisone and 12ig/mI bovine brain extract protein
content. Final LDL concentration in the EGM was around 40ig/mI. Determination of
TBARS content in the EGM demonstrated that LDL oxidation occurred in the
supernatants of HAECs cultured in normoglycemic (IBARS content: I .4nmol/mg
protlml) and hyperglycemic conditions (TBARS content:4.4nmollmg proUml). Confluent
cells were used in ail experiments at passages 3-5. Evidence that these ceils express
Von Willebrand factor, adhesion molecules and cytokines and demonstrate PAl-I
activity supports the relevance of these cells as model for the study of native vascular
endothelium.
Human monocytes.
Human monocytes were isolated as previously described (29). Briefly, peripheral
blood mononuclear cells were isolated from heaithy control subjects by density
centrifugation using Ficoil, allowed to aggregate in the presence of FCS, then further
purifled by the rosetting technique. After density centrifugation, highly purified
monocytes (85-90%) were recovered. Human monocyte putity was assessed by flow
cytometry (FACScan, Becton Dickinson) using phyco-erythrin-conjugated anti-CD14
monoclonal antibody (Becton Dickinson).
Analysis of mRNA expression
Expression of the LOX-1 gene in human HAECs was measured by polymerase
chain reaction (PCR) technique. Total RNA for use in the PCR reaction was extracted
from celis by an improvement of the acid-phenol technique of Chomczynski (30). Briefiy,
cells were lysed with TRizol reagent and chloroform was added to the solution. After
centrifugation, the RNA present in the aqueous phase was precipitated and
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resuspended in diethyl pyrocarbonate water. cDNA was synthesized from RNA by
incubating total cellular RNA with 0.1 pg oligodl (Pharmacia) for 5 min at 98°C then by
incubating the mixture with reverse transcription buffet for 1h et 37°C. The cDNA
obtained was amplified by using 0.8pmoIIL 0f two synthetic primers specific for human
LOX-1 (5’-TTACTCTCCATGGTGGTGCC-3’) (5’-AGCTTCTTCTDCTTGTTGCC-3’) and
human glyceraldehyde-3-phosphate deshydrogenase (GAPDH) (5’-
CCCTTCATTGAC CTCAACTACATGG-3’) (5’-AGTCHCTGGGTGGCAGTGATGG-3’),
used as internaI standard in the PCR reaction mixture. A 193-base pair human LOX-1
cDNA fragment and a 456-base pair human GAPDH cDNA fragment were amplified
enzymatically by 30 and 20 repeated cycles, respectively. An aliquot cf each reac
tion
mixture was then subjected to electrophoresis on 1% agarose gel containing ethidium
bromide. Ihe intensity 0f the bands was measured by an image analysis scann
ing
system (Alpha I mager 2000, Packard Instrument Company). Titrating the cDNA
samples ensured that the signal lies on the exponentiel part of the standard curve.
To
achieve better quantification of LOX-1 mRNA expression, levels of LOX-1 mRNA
were
also measured in some experiments by Northern blot analysis. Ten millions
HAECs
were plated in plastic petri dishes (lOOx200mm) (Falcon, Lincoln Park, N]). After
treatment, celis were Iysed with Trizol reagent. Total RNA was isolated and se
parated
in a 1.2% agarose gel containing 2.2 mol/I formaldehyde. The blots were prehyb
ridized
for 6h. The mRNA expression was analyzed by hybridization with [32P]dCTP-Iabeled
human LOX-1 cDNA probe. Hybridization was detected by autoradiography with
Kodak
X-Omat-AR films (Rochester, NY). mRNA expression was quantified by high resolution
optical densitometry (Alpha Imager 2000, Packard Instruments, Meriden, CI).
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DNA binding assay
The isolation of the nuclei was performed as previously described (31). Briefly, 5
x i07 HAECs were collected, washed with cold phosphate-buffered sait solution (PBS),
and lysed in 1 ml ice-cold buffer A (15 nmol/L KCL, 2 mmol/L MgCI2, 10 mmol/L
HEPES, 0.1 % PMSF, and 0.5% NP-40. After a 10-min incubation on ce, Iysed celis
were centrifuged, and the nuclei were washed with buffer A NP-40. Ihe nuclei were
then Iysed in a buffer containing 2 moi/L KCL, 25 mmol/L HEPES, 0.1 mmol/L EDTA,
and 1 mmol/L DTT. After a 15-min incubation period, a dialysis buffer (25 mmol/L
HEPES, I mmol/L Dfl, 0.1 % PMSF, 2 jig/ml aprotinin, 0.1 mmoi/L EDTA, and 11%
glycerol) was added to the nuclei preparation. Nuclei were collected by centrifugation
for 20 min at 13,000 rpm. Aliquots (50 pi) of the supernatants were frozen at -70°C, and
protein concentration was determined. DNA retardation (mobility shift) electrophoresis
assays were performed as previousiy described by Fried and Crothers (32). Briefly, 5 ig
nuclear extracts were incubated for 15 min in the presence of 5 X binding buffer (125
mmol/L HEPES, pH 7.5, 50 % glycerol, 250 mmol/L NaCI, 0.25 % NP-40, and 5 mmol/L
Dfl) in the presence or absence of 200ng anti-p50 and anti-p65 antibodies. End
iabeled double-stranded consensus sequences of the LOX-J promoter AP-1 -enhancing
elements (20,000 cpm pet sampie) were then added to the samples for 30 min.
Sampies were analyzed on a 4% nondenaturating poiyacryiamide gel (PAGE)
containing 0.01 % NP-40. The specifïcity of the nuclear protein binding was assessed
by incubating the nuclear proteins isolated from HAECs with a labeled DNA probe in the
presence of a 1 ,000-molar excess of uniabeled DNA probe.
Q
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ONA probes
Double-stranded olïgonucleotides containing the NF-KB (5’-
C GTCTGCCCHTCCCCCTCT-3’; 5’-GAGAAGAGGGGGWGG-3’) consensus
sequence of the human LOX-1 gene promoter (33) were synthesized with the aid of an
automated DNA synthesizer. After annealing, the oligonucleotides were Iabeled with [y
32PJ ATP using the Boehringer-Mannheim 5’ end-labeling kit (Indianapolis, IN).
Western-BIot
HAEC protein extracts (15[Jg) were applied to 10% SDS-PAGE and transferred
to a nitrocellulose membrane using a Bio-Rad transfer blotting system at 100 V for 1h.
Non-specific binding was blocked with 3% BSA for 1h at room temperature. After
washing with PBS-Tween 0.1%, btots were incubated overnight at 4°C with anti-LOX-1
or anti-f-actin antibody. After further wash, membranes were incubated for 1 h at room
temperature with a horseradish peroxidase-conjugated donkey anti-mouse IgG
(1/5000). Antigen detection was performed with an enhanced chemiluminescence
detection system (Amersham).
Adhesion assay
Confluent HAECs were exposed for 72h to 5.6 or 3Ommol/L glucose, then treated
for 1h in the presence of antibodies to IgG1, LOX-1, ICAM-1, VCAM-1 or E-Selectin.
HAECs were then washed twice with HBSS and incubated for 2h with freshly purified
human monocytes (280,000 cells/weII) resuspended in serum-free RPMI medium. At
the end of this incubation period, non-adherent monocytes were removed by washing
the celis wîth PBS (pH 6.0). Monocyte adhesion to HAECs was quantitated by
measuring monocyte myeloperoxidase (MPO) activity (34).
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Statistical Analyss
AIl values were expressed as the mean ± SEM. Data were analyzed by one-way
analysis cf variance (ANOVA) followed by the Tukey test. A P value less than 0.05 was
considered statistically significant.
RESULTS
Effect of D-glucose on endothelial celi LOX-J mRNA expression.
Incubation cf HAECs for 24 to 96h with D-glucose (5.6-30 mmol/L) enhanced, in
a time-dependent manner, LOX-1 mRNA levels in these cells. Maximal effect w
as
observed from 48 ta 96h (Fig. lA-a). Glucose-induced expression LOX-1 mRNA levels,
normalized to the levels cf GAPDH mRNA (Fig. lA-b) are presented in Fig. lA-c.
Incubation cf HAECs for 48h with increasing D-glucose concentrations (5.6-30 mmol/L)
enhanced, in a dose-dependent manner, LOX-1 mRNA levels in these celis (Fig. J B-a).
Maximal effect was observed with a concentration cf 30mmol/L glucose. LOX-1 mRN
A
levels, normalized to the levels of GAPDH mRNA (Fig. J B-b) are presented in Fig. 1 B-c.
Incubation cf HAECs with L-glucose or mannitol (30mmol/L) did not induce LOX-1
mRNA expression (LOX-1 mRNA expression [% cf control valuesj: L-glucose: 102±7,
mannitol: 97± 9). Quantification cf LOX-1 mRNA levels by Northern blot analysis in
HAECs exposed for 48h ta 5.6 or 3OmmoI/L glucose is presented in Fig .1 C.
Effect of D-glucose on endothelial celi LOX-1 protein expression.
Treatment cf HAECs for 24 to 96h with 5.6 or 3OmmoI/L glucose increased LOX
1 protein expression in these cells. Maximal effect was observed from 72 te 96h
(Fig.
2A-a). LOX-1 protein levels normalized to the levels of J3-actin (Fig.2A-b) are illustrated
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in Fig. 2A-c. Incubation cf HAECs for 72h with increasing D-glucose concentrations
(5.6-30 mmol/L) enhanced, in a dose-dependent manner, LOX-1 protein expression in
these ceils (Fig. 2B-a). Maximal effect was observed with a concentration cf 3Ommol/L
glucose. LOX-1 protein levels normalized to the levels cf j-actin (Fig.2B-b) are
illustrated in Fig. 2B-c. No stimulatory effect cf mannitol (3OmmolIL) on endothelial LOX
1 protein expression was observed (LOX-1 protein expression [% cf control values]:
mannitol: 105±10).
Since TNFŒ is increased in diabetes and enhances endothelial LOX-1
expression in vitro, we next measured the levels cf LOX-1 protein elicited by this
cytokine in 10w or high glucose conditions. As shown in Fig.3, TNFŒ-treated endothelial
cells cultured under normoglycemic conditions express similar LOX-1 levels than high
glucose-treated celis. Levels cf LOX-1 protein elicited by this cytokine were reduced in
HAECs exposed to high glucose concentrations (Fig.3A). Under these experimentai
conditions, no modulation cf the f3-actin protein levels, used as internai control, was
observed (Fig.3B). LOX-1 protein levels normaiized to the levels cf f3-actin are
illustrated in Fig. 3C.
Rote of PKC, mitogen-activated protein kinases (MAPK) and NF-icB in the
upregulation of endothelial celi LOX-1 gene expression by glucose.
To determine whether glucose induces endothelial LOX-1 gene expression via
PKC- and/or MAPK-dependent pathways, HAECs were pretreated for 1h in the
presence or absence cf the pan specific PKC inhibitor, calphostin C (0.1ig/ml), the
PKCf3 inhibitor, LY379196 (3OnM) or the MAPK inhibitor, PD98059 (501iM) prior
exposure te high glucose. As shown in Fig.4A-a, incubation cf HAECs with these
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inhibitors totally prevented the stimulatory effect of high glucose
on LOX-1 mRNA
expression. The inhibitory effect 0f LY379196 was still observed
when celis wete
exposed to 20 mmolIl glucose (LOX-1 mRNA expression [% of control values]: Glucose
(2Ommol/l): 150±9; glucose+LY379196: 113± 8, P<0.05). Undet these experimental
conditions, no modulation of the mRNA expression of GAPDH, used
as internaI control,
was observed (Fig. 4A-b). LOX-1 mRNA levels, normalized to the levels cf GAPD
H
mRNA are presented in Fig. 4A-c. Similar suppressive effect was o
bserved when these
cells were incubated with BAY 11-7085 (4OjiM), an inhibitor of the oxidative stress-
sensitive transcription factor N F-KB (Fig.4A).
Role of oxidative stress in high glucose-stimulated endothelial
ceV LOX-1 gene
expression.
Because vascular cells respond to high glucose by altering the intrac
ellular redox
state, we next determined the role 0f oxidative stress in glucose-i
nduced LOX-1 mRNA
expression. HAECs were pretreated for 1 h in the presence or ab
sence of NAC (lOmM)
DMSO (0.5%), vitamin C (10tM) or vitamin E (5OjiM) and then incubated for 48h w
ith
30 mmol/L glucose. As shown in Fig 4B-a, these antioxidants pr
evented the stimulatory
effect of high glucose on HAECs LOX-1 gene expression. L
OX-1 mRNA levels,
normalized to the levels of GAPDH mRNA (Fig. 4B-b) are presented in Fig. 4B-c
.
Effect of high glucose concentrations on the binding of nu
clear proteins to the
regulatory N F-KB sequences of the LOX-1 gene promoter.
We next determined whether incubation of HAECs in the pre
sence of high
glucose concentrations might induce changes at the level of
LOX-1 gene promoter
binding proteins. We found that a 24-h exposure cf HAEC
s to a high glucose
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environment resulted in a dramatic increase in the binding of nuclear proteins to the NF
KB consensus sequence of the human LOX-1 promoter. (Fig.5). This binding was
speciflcally competed in the presence of a 1 ,000-fold molar excess cf the unlabeled NE-
KB oligonucleotide and was totally abrogated by BAY 11-7085 and antibodies against
p50 andlor p65 (Fig. 5). Inhibition cf high glucose-induced NE-kB binding was further
observed after treatment of the celis with NAC, PKC and MAPK inhibitors (Fig.5).
Role for LOX-J as mediator of the stimulatory effect of high glucose on monocyte
binding to endothelial celis.
Treatment of HAEC5 for 72h with 3OmmoI/L glucose significantly increased
monocyte adhesion to these celis (Fig.6). This effect was totally suppressed by
preincubating HAECs with anti-LOX-1 antibody (Monocyte adhesion [% of control
values]: 30 mmol/L glucose: 180.±16 PcO.05, anti-LOX-1: 83±10 P<0.001, anti-IgG:
191±24) (Fig.6). To test the involvement of selectins and integrins in glucose-induced
monocyte adhesion to endothelium, HAECs were also preincubated with antibodies to
ICAM-1, VCAM-1, and E-Selectin prior exposure to glucose. Our results demonstrate
that under our experimental conditions, exposure of the celis to these antibodies did not
inhibit glucose-induced monocyte adhesion to endothelial ceils (Monocyte adhesion [%
of control values]: 30 mmol/L glucose: 180±16 P<0.05, anti-ICAM-1: 167±33, anti
VCAM-1: 163±16, anti-E-Selectin: 156±23).
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O DiSCUSSION
Evidence that LOX-1 expression is increased in the vascular endotheiium of
diabetic rats (21) supports a raie for this receptor in endothelial dysfunction associated
with diabetes. The factors responsible for vascular LOX-1 upregulation in diabetes are
unknown but may include atherogenic lipoproteins and AGE (21). In the present study,
we demonstrated that high glucose enhances LOX-1 expression, bath at the gene and
protein levels, in cultured HAECs and that this effect requires glucose metabolism by
endothelial celis since the nonmetabolized glucose isomer failed ta produce similar
effects. These resuits suggest that hyperglycemia per se may contribute ta LOX-1
induction in diabetes. In contrast to our data, Chen et al recently ceported that contrai rat
serum, along with high glucose concentrations, did not enhance LOX-1 mRNA
expression in cuitured bovine aortic endotheliai ceils (21). Because bath studies differ in
many experimental aspects, inctuding the ceti type tested and the stimulatory conditions
used, these conflicting results may oniy be apparent. Our findings that glucose-induced
LOX-1 expression is comparable to that elicited by TNFŒ and that glucose and TNFŒ do
not synergize for LOX-1 induction support the possibility that these factors may regulate
LOX-1 expression through one major and possibly identical pathway. Glucose and
TNFŒ are bath well known activators of NFK-B (35-39) and the 5’ flanking region of the
LOX-1 gene contains a consensus NE-KB binding site-like sequence (33). While
evidence has been provided that TNFŒ activates the transcription of the LOX-1 gene
(23), we found that high glucose increases endothelïal LOX-1 mRNA levels and
enhances nuclear protein binding ta the NE-KB regulatory sequence of the LOX-1
promoter. In agreement with previous studies showing that high glucose and TNFŒ
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stimulate the p50 and p65 subunits of NE-KB in monocytic cells (39), we found that the
p50 and p65 are critical components cf the transacting NF-KB complex stimulated by
high glucose in endothelial cells. laken together, these results suggest that
transcriptional regulation cf the LOX-1 gene mediated by p50 and p65 may be involved
in LOX-1 induction by glucose and TNFŒ. Another interesting finding cf this study is that
culturing endothelial celis in high glucose medium reduces the responsiveness cf these
cells ta further TNF-Œ stimulation. One possible explanation for this observation is that
high glucose may stimulate the release of TNF-Œ by endothelial cells and that
accumulation of this cytokine into the culture medium may contribute, at least in part, in
decreasing TNFŒ -responsiveness of these cells. Although the eftect cf high glucose on
TNFŒ secretion by endothelial cells has net been studied yet, evidence exists that these
cells secrete TNFŒ in response to endotoxin and hydrogen peroxide (40-41). The
possibility that glucose may stimulate TNFŒ release by endothelial cells is currently
examined.
It is well demonstrated that vascular cells, including endothelial cells, respond to
high glucose by altering the intracellular redox state (37,39, 42-43) and incteasing PKC
and MAPK activation (44). The clear link established between oxidative stress evoked
by glucose and PKC/MAPK activation (37,39,45-46) as well as the documented ability
cf these kinases ta regulate NE-kB activity (47-48) suggest that glucose-stimulated
LOX-1 gene expression in HAECs could involve increased oxidative stress and
activation of PKC and MAPK-dependent pathways. Dur resuits which demonstrate that
antioxidants and inhibitors of PKC and MAPK prevented the activation cf NF-KB and the
induction of endothelial LOX-1 mRNA expression by glucose confirm this possibility.
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Ç Evidence that the PKCI3 isoform-specific inhibitor, LY379196, effectively inhibits
glucose-induced LOX-1 mRNA levels further indicate a role for PKCJ3 in this effect. On
the basis of these resuits, we elaborate a tentative model in which reactive oxygen
species (ROS) generated by glucose metabolism induces the coordinate activation cf
PKC and MAPK as upstream kinases and NF-KB as downstream transcription factor
leading thereby to the induction cf LOX-1 gene expression.
One major adverse vascular consequence associated with endothelial
dysfunction in diabetes is increased monocyte adhesion to endothelium. Evidences that
endothelial LOX-1 supports adhesion of monocytes and is upregulated in diabetes (19-
21), suggest a role for this receptor in the enhanced binding of monocytes documented
in patients with diabetes (28, 49-50). Previous studies have shown that glucose may
contribute to the increased monocyte adherence to endothelium in diabetes (25-28). It
has been proposed that the effect cf glucose on monocyte adhesion may occur via
mechanisms involving the upregulation cf endothelial and/or leukocyte adhesion
molecules (25, 26, 28, 51-52), the activation of NE-KB and the generation of ROS (27).
Our results showing that blockade of LOX-1 totally abolished glucose-induced monocyte
adhesion te endothelial cells demonstrate a new role for LOX-1, that cf mediating the
stimulatory effect of glucose on monocyte adhesicn. In contrast, our flndings that
blocking antibodies to ELAM-1, ICAM-1 and VCAM-1 did not signiflcantly affect glucose
induced monocyte adhesion to HAECs clearly indicate that, under our experimental
conditions, these adhesicn molecules are not key determinants cf glucose-induced
monocyte binding te endothelium. Besides glucose, hypertriglyceridemia has been
documented te enhance monocyte binding te endothelial ceils in type 2 diabetes (49).
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Because VLDL fractions of diabetic serum induce endothelial LOX-1 expression (21), a
possible role for this receptor as mediator of hypertriglyceridemia-induced monocyte
endothelial adhesion may be proposed. Experiments aimed at testing this possibility are
under way.
One limitation of this study is the use of high glucose concentrations. While
plasma glucose concentrations around 2OmmolIL are flot seen in patients with diabetes
chronically, 3Ommol/L glucose is virtually incompatible with human life in chronic
diabetes. In contrast, hyperglycemic excursions are frequent in patients with diabetes
and peak glucose concentrations reaching 15 to 2Ommol/L are documented in poorly
controlled diabetic patients. Whether in vitro exposure of vascular cells to high glucose
concentrations may replicate, to some extent, the conditions experienced by the celis of
patients with diabetes during short-lived hyperglycemic excursions is unknown.
In conclusion, our data indicate that high glucose concentrations enhance LOX-1
expression in endothelial ceils. They also demonstrate a new role for LOX-1 as
mediator of glucose-induced monocyte adhesion. A better understanding of the
mechanisms of hyperglycemia-induced endothelial dysfunction may unmask new
strategies to reduce diabetic vascular complications.
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Fig.1. Time- and dose-dependent effect of high glucose on LOX-1 mRNA
levels in HAECs. Cultured HAECs were incubated for 24 to 96h (A) or 48
hours (B, C) with 5.6 to 30 mmol/L glucose. At the end of the incubation
period, celis were Iysed and LOX-1 mRNA was analyzed by RT-PCR (A-
B) or Northern Blot analysis (C). LOX-1 mRNA levels (a) were normalized
b the levels of GAPDH mRNA (b). Data illustrated on the graph bar (c)
represent the mean ± SEM of 6 (A-B) or 3 (C) different experiments. ,
p<0.05, , p<O.01 p<0.001 vs 5.6 mmol/L glucose.
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protein expression in HAECs. HAECs were cultured for 24 to 96h (A) or
72 hours (B) with 5.6 to 30 mmol/L glucose. At the end of the incubation
period, cells were lysed and LOX-1 membrane protein expression was
determined by Western blot analysis fa). LOX-1 protein levels were
normalized to the levels of 3—actin protein (b). Data illustrated on the
graph bar represent the mean ± SEM of 4 (A) and 3 (B) different
experiments (c). * p<O.05, p<0.Olvs 5.6 mmol/L glucose.
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expression. HAECs were cultured for 48h in Iow (5.6mmol/L) or high
(3Ommol/L) glucose environment, then treated for an additional 24h
time period with TNF-Œ (5OngIml). At the end of the incubation period,
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normalized to the levels of 13—actin protein (b). Data illustrated on the
graph bar represent the mean ± SEM of 4 different experiments (c).
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GAPDH mRNA (b). Data illustrated on the graph bar represent the mean ± SEM
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Fig.5. Effect 0f high glucose on the bnding of nuclear proteins extracted from
HAECs to the NE-KB sequence of the LOX-1 gene promoter. HAECs were
pretreated or flot for 1h with NAC f lOmM), calphostin C (O.lj..tg/ml), PD98059
(501iM) or BAY 11-7085 (401iM) then exposed for 24h to 5.6 or 30 mmol/L
glucose. Nuclear protens isolated from these celis were incubated with end
labeled double-stranded oligonucleotide containing the NF-icB sequence of the
LOX-1 promoter in the presence or absence of 1 000-fold molar excess of
unlabeled DNA probe (competitor). In some experiments, nuclear proteins
were incubated in the presence of anti-p50 and/or anti-p65 antibodies.
Retardation was assessed by gel electrophoresis. A. Data represent the result
of one representative experiment out of 4. B. Graph bar showing the results of
4 independent experiments. , p<0.01 vs 5.6 mmol/L glucose.
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ABSTRACT
Lectin-like oxidized low-densïty lipoprotein (0xLDL) receptor-1 (LOX-1) is a newly
identified receptor for 0xLDL that is expressed by vascular cells. LOX-1 is upregulated
in aortas of diabetic rats and thus may contribute to the pathogenesis cf human diabetic
atherosclerosis. In this study, we examined the regulation of human monocyte-derived
macrophage (MDM) LOX-1 expression by high glucose and the role of LOX-1 in
glucose-induced foam celI formation. Incubation of human MDM with glucose (5.6-30
mmol/L) enhanced, in a dose- and time-dependent manner, LOX-1 gene and protein
expression. Induction cf LOX-1 gene expression by high glucose was abolished by
antioxidants, protein kinase C (PKC), mitogen-activated protein kinases (MAPK), NF-B
and AP-1 inhibitors. In human MDM cultured with high glucose, increased expression of
PKCf32 and enhanced phosphorylation of extracellular signal-regulated protein kinase
(ERK) 1/2 was observed. Activation of these kinases was inhibited by the antioxidant,
N-acetyl-L-cysteine (NAC) and by the PKC3 inhibitor, LY379196. High glucose also
enhanced the binding of nuclear proteins extracted from human MDM to the NF-icB and
AP-1 regulatory elements of the LOX-1 gene promoter. This effect was abrogated by
NAC and PKC/MAPK inhibitors. Finally, high glucose-induced human macrophage
derived foam cell formation through a LOX-1-dependent pathway. Overall, these results
demonstrate that high glucose concentrations enhance LOX-1 expression in human
MDM and that this effect is associated with foam cell formation. Pilot data showing that
MDM of patients with type 2 diabetes overexpress LOX-1 support the relevance of this
work to human dia betic atherosclerosis.
r
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INTRODUCTION
The prevaience, incidence and mortaiity from aH forms of cardiovascuiar
diseases are increased in diabetic patients.1 Among the cardiovascuiar risk factors
documented in diabetes, hypergiycemia appears as an independent risk factor for
diabetic macrovascuiar complications.2 Mechanisms through which hyperglycemia may
promote the deveiopment cf diabetic cardiovascuiar disease inciude glycoxidation and
lipoxidation, increased oxidative stress and PKC activation.38 One of the earIiest events
in atherogenesis is the accumulation of oxidized low-density lipoprotein (0xLDL) in the
intima and the subsequent uptake cf this modified iipoprotein by macrophages leading
to foam cefl formation.9 One limiting factor for 0xLDL uptake by endothelial ceils is
lectin-iike 0xLDL receptor-1 (LOX-1), a newiy identified vascular receptor for oxLDL.’°12
Accu muiating evidence indicates a key role for LOX-1 in atherogenesis. First, uptake of
oxLDL by endothelial ceils through LOX-1 induces endotheliai dysfunction. Second,
the two main LOX-1 Iigands, 0xLDL and advanced glycation end product (AGE), are
impiicated in the pathogenesis of atheroscierosis.59 Third, expression cf LOX-1 by
vascuiar ceNs, inciuding endotheliai ceils and macrophages is enhanced by pro
atherogenic factors.138 Finaiiy, LOX-1 is expressed in vivo in the aortas of animais with
pro-atherogenic settings’6’192° and is upreguiated in eariy human atheroscierotic
iesions.2’
LOX-1 expression is increased in the endothelium and sortas cf diabetic rats16
and thus may play a role in atherogenesis associated with diabetes. Evidence that AGE
induce LOX-1 expression in cuitured endotheliai ceiis16 and macrophages22 supports a
primary roie for these products in modulating vascular LOX-1 expression in diabetes.
4
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On the basis of these resuits and given the key role for macrophages as
precursors of foam ceils in the vascular wa1179 the present study was aimed at
investigating the regulation of human macrophage LOX-1 expression by hyperglycemia
and the role of this receptor in glucose-induced macrophage foam celi transformation.
o
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MATERIALS AND METHODS
Reagents
(see “Onhne Data Supplements” for detas).
Ceil cutture
Freshly isolated human monocytes23 or THP-1 monocytes were differentiated
into macrophages in vitro and treated with high glucose (see “Online DataSupplements” for details).
Analysis of mRNA expression
-Northern Blot Analysis:
LOX-1 and glyceraldehyde-3-phosphate deshydrogenase (CAP DH) mRNAexpression in THP-1 monocyte-derived macrophages fMDM) (10x1 06/ml) was analyzedby hybridization with [32P] UCTP-labeled human LOX-1 and GAPDH cDNA probes. (see“Online Data Supplements” for details).
-Polymerase Chain Reaction (PCR) Analysis:
Total RNA for use in the PCR reaction was extracted from human MDM(2x106/ml) by an improvement of the acid-phenol technique of Chomczynski.24 cDNAwas synthesized from RNA and amplified by synthetic primers specific for human LOX-1and GAPDH (see “Online Data Supplements” for details).Western blot
LOX-1, MAPK and PKC-f32 expression in human MDM was analyzed by westernblot analysis using specific antibodies (see “Online Data Supplements” for details).DNA binding assay
C
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Nuclear proteins were isolated from THP-1 MDM and their binding to consensus
sequences of the LOX-1 promoter N F-KB and AP-J -enhancing elements was assessed
by DNA retardation electrophoretic mobility shift assay (EMSA)2526 (see “Online Data
Supplements” for details).
DNA probes
(see “Online Data Supplements” for details).
Uptake of DiI-oxLDL by human MDM
Native LDL (density, 1.019 to 1.063) was isolated from plasma obtained from
healthy donors by sequential ultracentrifugation27 and extensively dialyzed for 24h at
4°C against 5 mmol/L TrisI5O nmol/L NaCI to remove EDTA. Oxidation of [DL was
performed by incubating native LDL (2mg prot/ml) at 37°C for 20h in serum-free RPMI
1640 containing 7.5 jig/ml CuSO4. Oxidation of LDL was monitored by measuring the
amount of thiobarbituric acid-reactive substances and by electrophoretic mobility on
agarose gel. OxLDL was labeled with Dil as described previously.28 Uptake of Dil-0xLDL
by human MDM was assessed by fluorescence microscopy and determination of
fluorescence at 520/564 nm (see “Online Data Supplements” for details). Results were
normalized to total celI protein concentrations.29
Quantification of cytosolic AGE in MDM
The total AGE content present in the cytosolic extracts of glucose-treated MDM
was determined by competitive ELISA. Results were expressed as B/Bo (see “Online
Data Supplements” for details).
Patients
C
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The study group comprised 7 patients with type 2 diabetes and 12 healthy control
subjects. The diabetic patients were tecruited from the Notre-Dame Hospital outpatient
clinic and gave written consent to participate in this study. Their mean (±SE) age was
65±3 years, BMI 32±2 kglm2, fasting glucose 9.4±1.2 mmol/L, triglyceride 3.26±1.21
mmol/L, LDL cholesterol 3.08±0.31 mmol/Land serum glycated hemoglobin 0.072±0.006.
Ail the patients were treated with glyburide and metformin. None of the patients was
primarily insulin-dependent. One patient was hypertensive and was treated with enalapril,
one had macroangiopathy and microalbuminuria. Control subjects were recruited from the
hospital staff and relatives. Their mean (1- SE) age was 38+4 years, BMI 23+1 kglm2,
fasting glucose 5.0± 0.1 mmol/L, triglyceride 1.30±0.20 mmol/L, [DL cholesterol 3.50±0.40
mmol/L. Subjects who had infectious or inflammatory conditions or cardiac, renal or
pulmonary decompensated diseases or who were treated with anti-inflammatory or
antioxidant drugs were excluded from the study.
Determination of celi viability
CelI viability after treatment with the different agents under study was assessed
by trypan blue exclusion and was consistently found to be> 90%.
Statistical Analysis
Values were expressed as mean ± SEM. Data were analyzed by one-way
analysis of variance (ANOVA) followed by the Tukey test. A P value less than 0.05 was
considered statistically significant.
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RESULTS
Effect of D-glucose on human MDM LOX-J mRNA expression.
Incubation cf human MDM for 24 to 72h with 5.6 or 30 mmol/L D-glucose
increased, in a time-dependent manner, macrophage LOX-1 gene expression. Maximal
effect was observed from 48 to 72h (Fig. lA-a). Under these experimental conditions,
no modulation of the mRNA expression of GAPDH, used as internai control, was
observed (Fig. lA-b). LOX-1 mRNA levels, normaiized to the levels cf GAPDH mRNA
are shown in Fig. lA-c. The stimulatory effect of D-glucose on human MDM LOX-l
mRNA expression was dose-dependent with maximal effect occurring between 20 and
3OmM glucose (Fig. I B-a). Under these experimentai conditions, no modulation cf the
mRNA expression of GAPDH was observed (Fig. I B-b). LOX-I mRNA levels,
normaiized to the levels of GAPDH mRNA are shown in Fig. I B-c. Incubation of human
MDM with L-glucose or mannitol (30 mmol/L) did not enhance LOX-l mRNA expression
(LOX-1 mRNA expression [% cf control values]: L-glucose: 98±5, mannitol: 107±6).
Effect of D-glucose on human MDM LOX-J protein expression.
Treatment of human MDM with 30 mmol/L D-glucose enhanced LOX-1 protein
expression in these celis. This effect was obsetved from 72 to 96 h (Fig. 2A-a). Under
these experimentai conditions, no modulation of 13-actin, used as internai control, was
observed (Fig. 2A-b). LOX-l protein levels normalized to the Ievels of 3-actin protein are
illustrated in Fig. 2A-c. Incubation of human MDM for 72h with increasing D-glucose
concentrations (5.6-30 mmol/L) enhanced, in a dose-dependent manner, LOX-1 protein
expression in these celis (Fig. 2B-a). LOX-1 protein levels normalized to the levels of f3-
J actin (Fig.2B-b) are illustrated in Fig. 2B-c. No stimulatory effect of mannitol (30 mmol/L)
163
on macrophage LOX-1 protein expression was observed (LOX-1 protein expression [%
cf contraI values]: mannitol: 109±9).
Role for AGE in the induction of MDM LOX-1 by high glucose.
To evaluate whether intracellular AGE formation may play a role in the induction
cf MDM LOX-1 expression by high glucose, the levels cf cytosolic glycated proteins
present in MDM exposed to high glucose for 24 to 48h were determined. Regardless of
the glucose concentrations used, levels cf glycated proteins in MDM ccnsistently felt
below the minimum concentration of AGE detected by this assay, i.e. less than 0.25ng
AGE/pg protein. (BIBo: Glucose 24h (mmol/L) 5.6: 2.5 ± 0.7$ 10: 3.9 ÷ 1.3$ 20: 3.4 ±
0.8$ 30: 3.9 ± 0.7; Glucose 48h (mmolIL) 5.6: 3.7+1.7; 10: 2.9±1.2; 20: 3.3±0.3; 30:
2.3÷0.5). While non glycated BSA (5Ong/ml), used as negative control, failed to inhibit
antiserum binding (BIB0: 1.1), competition for antibody binding was observed with
methylglyoxal- and glucose-derived AGE-BSA (5Ong/ml) used as positive controls.
(BIBO: 0.53 and 0.57, respectively).
Effect of high glucose on TNFŒ-induced MDM LOX-1 expression.
One pathophysiological stimulus relevant to atherosclerosis in diabetes is tumor
necrosis factor alpha (TNFŒ).3031 Because this cytokine stimulates LOX-1 expression in
vascular cells13”7 and is released by monocytic cells in response ta high glucose and
AGE,3235 we determined the modulatory effect of TNF-Œ on human MDM LOX-1
expression under normal and high glucose conditions. As shown in Fig. 3A and B,
TNFŒ-treated human MDM cultured under normoglycemic conditions express similar
levels of LOX-1 gene and protein expression than high glucose-treated cells. Levels of
LOX-1 expression elicited by this cytokine did not differ when human MDM were
164
cultured in hïgh glucose conditions. The effect of TNFŒ alone on LOX-1 protein
expression was blocked by anti-TNF-Œ antibodies (Fig.38).
Signaling pathways involved in glucose-induced human MDM LOX-1 gene
expression.
To identify the signaling pathways involved in the stimulatory effect of high
glucose on LOX-1 gene expression, human MDM were pretreated for 2h with PKC,
MAPK, tyrosine kinase, NF-KB or AP-1 inhibitors, prior exposure to glucose. As shown
in Fig.4A, the pan specific PKC inhibitor, calphostin C (0.1 jiglml) and the PKCf3
inhibitor, LY379196 (30 nmmol/L) totally abrogated glucose-induced macrophage LOX
1 gene expression. A similar effect was observed when the cells were pre-incubated
with the MAPK inhibitor, PD98059 (50 imolIL), the AP-1 inhibitor, curcumin (10 .tmol/L)
or the NF-KB inhibitor, BAY 11-7085 (40 1imol/L)36 (Fig.4A). In contrast, tytosine kinase
inhibitors did flot affect this parameter (data flot shown). Under these experimental
conditions, no modulation of the mRNA expression of GAPDH was observed (Fig. 4A-
b). LOX-1 mRNA levels, normalized to the levels of GAPDH mRNA are presented in
Fig. 4A-c. Because diabetes and high glucose induœ increased oxidative stress,37 we
next determined the role cf oxidative stress in the regulation cf LOX-1 gene expression
by glucose. As shown in Fig 4B, preincubation cf human MDM with various
antioxidants, including NAC (10 mmol/L), vitamin E (50 1imolIL), vitamin C (10 imol/L)
and DMSO (0.5%), totally prevented the stimulatory effect cf high glucose on LOX-1
gene expression. Involvement of these signaling events was confirmed in THP-1 MDM
by demonstrating that PKC and MAPK inhibitors as well as antioxidants abolished
glucose-induced LOX-1 mRNA expression in these ceils (Fig.4C,D). Having established
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the relevance cf THP-1 ceils to human MDM, we next assessed using these ceils the
sequential events leading to glucose-induced PKC/MAPK activation. As shown in Fig 5,
treatment of THP-1 ceNs for 48h with high glucose induced PKCf32 (Fig.5A) and ERK1I2
(Fig.5B) activation as assessed by western blot analysis. Glucose-induced activation cf
these kinases was abrogated by NAC (Fig.5A,B). Furthermore, ERKI/2 activation in
glucose-treated macrophages was inhibited by LY379196 (Fig.5B), thereby identifying
MAPK as downstream targets cf PKC.
Effect of high glucose concentrations on the binding of nuclear proteins to the
regulatory NF-icB and AP-1 sequences of the LOX-1 gene promoter.
Exposure cf THP-1 MDM te a high glucose environment increased the binding cf
nuclear proteins te the NF-KB (Fig.6) and AP-J (Fig.7) consensus sequences cf the
human LOX-1 promoter. These binding complexes were specifically competed in the
presence cf a 1 ,000-molar excess cf the unlabeled NF-KB or AP-1 oligonucleotides and
were significantly decreased by BAY 11-7085 (Fig.6) or curcumin (Fig.7). Nuclear
protein binding was further inhibited in presence cf antibodies against p50 and p65
(Fig.6) or c-fcs and c-Jun (Fig.7). In ccntrast, irrelevant antibodies or competitors did not
alter glucose-induced NE-KB and AP-1 activation, thus confirming the specificity cf the
inhibition documented in these EMSA assays (Fig.6,7). Preincubation cf THP-1 cells
with NAC, PKC and MAPK inhibitors also suppresses the nuclear binding te the NE-KB
and AP-1 sequences cf the LOX-1 gene promoter (Fig.6,7).
Role of LOX-J in mediating glucose-induced human MDM foam celi formation.
To evaluate whether increased expression cf LOX-1 by high glucose resulted in
enhanced uptake cf 0xLDL by human MDM, these cells were treated for 48h with 5.6 or
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30 mmmol/L glucose, then incubation was pursued for an additional 24h period in the
presence of saturating amounts (20 jig/mI) of antibodies to CD36, SR-A, LOX-1 or IgG1.
At the end of the incubation period, ceNs were exposed for 3h to DiI-0xLDL (80 jig/mI) in
the presence or absence of excess unlabeled 0xLDL. Incubation cf human MDM with
high glucose in the presence of anti-CD36 and anti-SR-A antibodies led to enhanced
uptake of oxLDL by these celis as assessed by fluorescence microscopy (Fig 8A) and
measurement of extracted Dil-oxLDL (Fig8B). This effect was abrogated by incubating
human MDM with excess unlabeled oxLDL or with anti-LOX-1 antibody. In contrast,
exposure cf these cells to anti-lgG1 did flot affect glucose-induced MDM foam celI
formation (Fig.8A, B).
Levels of LOX-1 mRNA in MDM of diabetic patients.
MDM of patients with type 2 diabetes demonstrated a significant increase in
LOX-1 mRNA levels compared with those isolated from control subjects. (LOX-1 mRNA
levels (%): controls: 100±7; diabetic patients: 169+25, P<0.01).
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DISCUSSION
Despite the recent evidence Iinking experimental diabetes with increased
vascular LOX-1 expression,16 only few studies have examined the regulation of LOX-1
by metabolic factors dysregulated in diabetes. The ptesent study demonstrates, for the
first time, that high glucose increases human macrophage LOX-1 expression, both at
gene and protein levels. These results together with our preliminary observations that
MDM of diabetic patients exhibit increased LOX-1 gene expression suggest a role of
hyperglycemia in the regulation of vascular LOX-1 in human diabetes. In macrophages
which do express multiple scavenger receptors,38 over 50% of the uptake of 0xLDL
seems to occur via CD36,39 whereas SR-A shares the rest with several other scavenger
receptors, including LOX-1. Because high glucose enhances macrophage CD36
expression,”° it is tempting to postulate that upregulation of macrophage scavenget
teceptors in response to glucose may play a role in the pathogenesis of atherosclerosis
in human diabetes.
It has been previously shown that AGE enhance LOX-1 mRNA expression in
cultured aortic endothelial celis and human macrophages.1622 On the basis of the time
course and concentration of glucose required to modulate macrophage LOX-1
expression, we speculated that generation of AGE might be responsible for LOX-1
induction in glucose-treated MDM. However, arguing against this hypothesis, we did flot
ascertain the presence of AGE in these cells over the time course required to modulate
LOX-J gene expression. Considering the short incubation period of macrophages with
high glucose, lack of intracellular AGE detection may be related to this in vitro variable.
Alternatively, characteristics relating to the sensitivity of the ELISA and the specificity of
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the anti-AGE-Rnase antiserum used in this assay41 may account for these negative
resuits.
Interestingly, we found that the extent of stimulation cf macrophage LOX-1
expression achieved by glucose was comparable to that elicited by TNF-Œ and that
these two stimuli did flot synergize for macrophage LOX-1 induction. Because glucose
and AGE stimulate TNFŒ secretion3235 one possible explanation for this observation is
that induction of LOX-1 by glucose involves TNFŒ. However, this hypothesis is not
supported by our finding that immunoneutralization of TNFŒ does flot affect glucose
induced LOX-1 expression. Alternatively, glucose and TNFŒ may regulate macrophage
LOX-1 through one major and possibly identical pathway. Like TNFŒ, glucose is a well
known activator cf NF-kB and AP-1426 and may therefore induce, through the activation
0f these factors, the transcription of the LOX-igene. Consistent with this, we found that
glucose increases the LOX-1 mRNA levels in macrophages and enhances the binding
cf nuclear proteins to the NE-kB and AP-1 regulatory sequences of the LOX-1
promoter.47 Although final proof for a rote for NF-kB and AP-1 as functional responsive
elements involved in the transcriptional activation of the LOX-1 gene would require
promoter-reporter gene assays, these data support a role for these transcriptional
factors in the regulation of LOX-1 gene expression by glucose.
Regulation of LOX-1 gene expression is redox sensitive.’4 Therefore, reactive
oxygen species (ROS) generated by glucose in vascular cells6’7’46 may represent key
intermediates in the regulation of LOX-1 gene expression by this metabolic factor.
Evidence linking glucose-induced oxidative stress with activation cf PKC and MAPK in
t
vascular ce11s68’4849 further supports a role of these kinases in the control of LOX-1
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expression by hyperglycemia. In une with these hypotheses, we found that antioxidants
and PKC/MAPK inhibitors abolish glucose-induced macrophage LOX-1 mRNA levels,
thus implicating ROS and kinases as signaling molecules in this effect. Our flndings that
antioxidants suppressed glucose-induced P KC/MAPK activation and that P KC inhibition
abolished glucose-induced MAPK activation, support the hypothesis that glucose
induced kinase activation involves oxidative stress and that MAPK act in this signaling
cascade as intermediate molecules transducing signal from PKC to macrophage LOX-1.
Convincing data also indicate a role cf oxidative stress and kinases in NF-kB and AP-1
activation.7’42’46’5052 In accordance with these resuits, we found that antioxidants as well
as PKC/MAPK inhibitors block glucose-induced NE-kB and AP-1 activation, thus
identifying these transcriptional factors as downstream ROS and kinase targets. Taken
together, these resuits indicate that increased production cf intracellular ROS and
activation cf PKC/MAPK pathways are initial signaling events in the regulation of LOX-1
gene by glucose that are required for subsequent activation cf NE-kB and AP-J.
Accumulation cf cholesterol-loaded foam ceils in the arterial intima is a hallmark
and key event of early atherogenesis. Evidence that incubation cf macrophages in high
glucose conditions leads to increased intracellular accumulation cf cholesterol ester53
suggests a role for hyperglycemia in foam cell formation. Like other scavenger
receptors, LOX-1 is highly expressed in macrophages present in human atherosclerctic
Iesicns2’ and thus may play a role in macrophage foam celi formation. The present
study demonstrates, for the first time, that increased LOX-J surface expression in
glucose-treated macrophages is associated with enhanced uptake cf cxLDL by these
cells, suggesting thereby a new role for LOX-1, that cf mediating gluccse-induced foam
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celi formation. Importantly, such a role for LOX-1 in foam ceIl formation was only evident
after functional blockade of CD36. It is widely believed that much of the 0xLDL uptake
by human macrophages occurs via CD36.39 Although the quantitative contribution of
CD36 in glucose-induced foam ceil formation is unknown, it has been shown that
glucose-induced macrophage CD36 expression correlates with a 1O-fold increase in
CD36-mediated 0xLDL uptake,4° thus suggesting a major role of this receptor in
glucose-induced foam celi formation. In the present study, we reported a 2-fold increase
in non-C D36/non-S R-A-mediated oxLDL uptake in gi ucose-treated macrophages that
was only parfly reduced by an anti-LOX-1 antibody. While these resuits demonstrate a
role of LOX-1 in glucose-induced foam ceil formation, they do not argue for a major
contribution of LOX-1 in this process. Consistent with this idea, one recent study failed
ta demonstrate a key role of LOX-1 in the progression cf macrophages to foam celis in
vitro.54 Nevertheless, extrapolation cf in vitro resuits to the in vivo situation is hazardous
and further studies are needed to assess the functional significance cf increased LOX-1
expression on foam celI formation in vivo.
In summary, the present study demonstrates that high glucose enhances human
MDM LOX-1 expression in vitro and that this effect is associated with foam ceIl
formation. Our preliminary results showing increased MDM LOX-1 expression in human
diabetes support the relevance cf this work to the human setting.
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Fig.1. Time- and dose-dependent effect of high glucose on LOX-1
mRNA levels in human MDM. Cultured human MDM were incubated
for 24 to 72h (A) or 48 hours (B) with 5.6 to 30 mmol/L glucose. At the
end cf the incubation period, ceNs were lysed and LOX-1 mRNA was
analyzed by RT-PCR (A-B). LOX-1 mRNA levels (a) were normalized
to the levels 0f GAPDH mRNA (b). Data illustrated on the graph bar (C)
represent the mean ± SEM of 6 (A-B) different experiments. , p<O.05,
p<0.01, p<O.00l vs 5.6 mmol/L glucose.
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Fig.2. Time- and dose-dependent effect 0f high glucose on LOX-1 protein
expression in human MDM. Human MDM were cultured for 48 to 96h (A) or
72 hours (B) with 5.6 to 30 mmol/L glucose. At the end of the incubation
period, cells were lysed and LOX-1 membrane protein expression was
determined by Western bot analysis (a). LOX-1 protein levels were
normalized to the levels of f3-actin protein (b). Data illustrated on the graph
bar (c) represent the mean ± SEM of 6 (A) and 3 (B) different experiments.
* p<0.05, p<0.01, , p<0.00l vs 5.6 mmol/L glucose.
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Fig.3. Effect of high glucose on TNF-Œ-induced macrophage LOX-1 mRNA and
protein expression. Human MDM were cuftured for 24h (A) or 48h (B) in 5.6
mmol/L or 30 mmol/L glucose environment, then treated for an additional 24h-time
period with TNF-tx (5 ng/ml) in the presence or absence of anti-TNFŒ antibodies
(10 .ig/ml) (B). At the end of the incubation period, cells were lysed and LOX-1
mRNA (A) and membrane protein expression (B) were determined by RT-PCR and
Western blot analysis, respectively. LOX-1 mRNA and protein levels were
normalized to the levels of GAPDH mRNA (A-b) or f3—actin protein (B-b). Data
illustrated on the graph bar (A-c and B-c) represent the mean ± SEM of 4 different
experiments. ** p<O.01, , P<0.001 vs 5.6 mmol/L glucose.
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Fig.4. Effect 0f PKC, MAPK, NE-KB, AP-J inhibitors (A and C) and antioxidants
(B and D) on glucose-induced LOX-1 mRNA levels. Human (A and B) and THP
1 (C and D) MDM were pretreated for 1h with the PKC inhibitor caiphostin C
(0.1 p.glml), the specific PKCf3 inhibitor LY379196 (30 nmmol/L), the MAPK
inhibitor PD98059 (50 1imol/L), the NF-icB inhibitor BAY 11-7085 (40 p.mol/L),
the AP-1 inhibitor curcumin (10 imol/L) or the antioxidants NAC (10 mmol/L),
vitamin E (50 jimmol/L), vitamin C (10 p.mmol/L) and DMSO (0.5 %), then
exposed for 48h to 30 mmol/L glucose. At the end of the incubation period, cells
were lysed and LOX-1 mRNA was analyzed by RT-PCR (A-a and B-a) or
Northern-Blot analysis (C-a and D-a). LOX-1 mRNA levels were normalized to
the levels of GAPDH mRNA (b). Data illustrated on the graph bar represent the
mean ± SEM of 7 (A-c and B-c) and 6 (C-c and D-c) different experiments .
p<0.O1, p<O.00l vs 5.6 mmol/L glucose.
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Fig.5. Effect of high glucose on PKC and MAPK activation in THP-1 MDM.
Modulatory effect 0f NAC and PKC/MAPK inhibitors. IHP-1 MDM were
pretreated for 1h with NAC (10 mmol/L), LY379196 (30 nmmol/L), or
PD98059 (50 p.moliL) then incubated for 48h with 30 mmol/L glucose. A.
Membrane ta) and cytosolic (b) fractions wete assayed for PKC132
expression by western blot analysis. CeIls stimulated with PMA (0.5
iimol/L) for 30 min were used as positive control. B. Phosphorylation of
ERKJI2 was assessed by western blot using phospho-specific ERKI/2
antibody fa) or specitic ERK112 antïbody (b). Representative blots are
shown.
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Fig.6. Effect of high glucose on the binding 0f nucleac proteins extracted
from IHP-1 MDM ta the NF-KB sequence of the LOX-1 gene promoter.
THP-1 MDM were pretreated or flot for 1h with NAC (10 mmol/L),
caiphostin C (0.1 ig/ml), PD98059 (50 p.mol/L), BAY 11-7085 (40
tmmol/L), then exposed for 24h ta 5.6 or 30 mmol/L glucose. Nuclear
proteins isolated from these celis were incubated with end-labeled
double-stranded oligonucleotide containing the NF-KB sequence cf the
LOX-1 promoter in the presence or absence of 1000-fold molar excess
of unlabeled NE-kB or CRE DNA probe (competitor). In some
experiments, nuclear proteins wete incubated in the presence cf anti-
p50, -p65, -lgG1 or —c-fos antibodies. Retardation was assessed by gel
electrophoresis. A. Data represent the resuit of one representative
experiment out 0f 4. B. Graph bar showing the resuits of 4 independent
experiments. p<0.001 vs 5.6 mmol/L glucose.
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Fig.7. Effect of high glucose on the bnding of nuclear protens extracted
from THP-1 MDM to the AP-1 sequence cf the LOX-1 gene promoter.
THP-1 MOM were pretreated or flot for 1h with NAC (10 mmol/L),
caiphostin C (0.1 jig/ml), PD98059 (50 .tmol/L), or curcumin (10 immol/L),
then exposed for 24h to 5.6 or 30 mmol/L glucose. Nuclear proteins
solated from these cells were incubated wth end-labeled double-stranded
oligonucleotide containing the AP-J sequence of the LOX-1 promoter in the
presence or absence 0f 1000-fold molar excess of unlabeled AP-1 or CRE
DNA probe (competitor). In some experiments, nuclear proteins were
incubated in the presence of anti-c-fos, c-Jun, -IgG1 or —p50 antibodies.
Retardation was assessed by gel electrophoresis. A. Data represent the
resuit of one representative experiment out 0f 4. B. Graph bar showing the
results cf 4 independent experiments.
, pc0.00l vs 5.6 mmol/L glucose.
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Fig.8. Effect of high glucose on oxLDL uptake by human MDM. Role for
LOX-1. Human MDM were treated for 48h with 5.6 or 30 mmoIIL
glucose, then incubation was pursued for an additional 24h period in the
presence of saturating amounts (20 tgIml) of antibodies te CD36, SR-A,
LOX-1 or IgG1. At the end of the incubation period, cells were exposed
for 3h to Dil-oxLDL (80 igIml) in the presence or absence cf excess
unlabeled oxLDL. Aftet washing, fluorescence cf Dii was detected in
cytoplasm cf MDM by fluorescence microscopy (A) or measured at
520/564nm (B). Data illustrated on the graph bar represent the mean +
SEM cf 4 independent experiments. , Pc0.05 vs 5.6 mmol/L glucose.
191
11.3. The third article
192
Circulation Research 2004,(submitted).
C-reactive protein fCRP) enhances lectin-like oxidized Iow-density lipoprotein
receptor-1 (LOX-f) expression in human aortic endothelial ceils. Relevance 0f
LOX-1 to CRP-induced endothetial dysfunction.
Ling Li’, Nadia Roumeliotis3, Tatsuya Sawamura2and Geneviève R
enier3
From the Department of Biomedical Sciences
1 and Medicine , University cf Montreal,
Centre Hospitalier de l’Université de Montréal (CHUM) Research Centre, Notre-Da
me
Hospital, Montreal, Quebec, Canada and the Department of Bioscience2, Nationa
l
Cardiovascular Center Research Institute, Fujishirodai, Suita, Osaka, Japan.
Total wotd count: 4977
Abstract word count: 226
Total figures: 5
Keywords: C-reactive protein, endothelium, lectin-like oxidized low-
density lipoprotein
receptor-1, inflammation.
Short title: C-reactive protein increases endothelial LOX-J expres
sion
Address correspondence and reprint requests to:
Dr. Geneviève Renier
CHUM Research Centre
Notre-Dame Hospital
J.-A. De Seve Pavilion, Door Y 3622
1560 Sherbrooke Street East
Montreal, Quebec, H2L 4M1
E-MAIL: genevieverenierumontreal.ca
ABSTRACT
Background— C-reactive protein (CRP), a characteristic inflammatory marker, is
s
powerful predictor of cardiovascular events. Recent data suggest th
at CRP may aiso
promote atherogenesis through inducing endotheliai dysfunction. L
ectin-like oxidized
low-density lipoprotein (0xLDL) receptor-1 (LOX-1) is s newly identified endothelia
i
receptor for 0xLDL that piays a pivotai role in oxLDL-induced endo
theliai dysfunction.
Whether CRP may regulate endotheliai LOX-1 and induce en
dothelial dysfunction
through this receptor is unknown.
Methods and Results—In the present study, we studied the in vitro eff
ect of CRP on
LOX-1 expression in human aortic endothelial cefls (HAECs) and the role ot LO
X-1 in
CRP-induced human monocyte adhesion to endothelium a
nd oxLDL uptake by
endothelial ceils. Incubation of HAECs with CRP enhanced,
in a dose- and time
dependent manner, LOX-1 mRNA and protein levels. Induction of
LOX-1 protein was
already present at 5 j.tg/mi CRP and reached a maximum at 25 p.g/mI. This effect wa
s
reduced by antibodies against CD321CD64, endothelin-1 and int
erleukin-6 (IL-6). The
extent of stimulation of LOX-1 achieved by CRP was comparable
to that elicited by high
glucose and IL-6 and remained unchanged in presence of these fac
tors. Finally, CRP
increased, through LOX-1, both human monocyte adhesion to
endothelial celis and
0xLDL uptake by these cells.
Conclusions—We conclude that CRP enhances endotheli
al LOX-1 expression and
propose a new mechanism by which CRP may promote endo
thelial dysfunction, that of
inducing LOX-1.
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INTRODUCTION
Atherosclerosis is an inflammatory process that takes place in the art
erial waiI
and is accompanied by a systemic response. Since the concept of an
inflammatory sou
of atherosclerosis has been validated13, serum markers of inflamm
ation have been
identified as risk markers for cardiovascular (CV) disease. Among these, C-reactive
protein (CRP) has been proven to be the strongest predictor cf CV events.’5 Beside
s
being a risk marker, CRP may further play a pivotai role in promoting
atherogenesis.
Arguing for this hypothesis, it has been shown that CRP increa
ses the release 0f
inflammatory cytokines6, enhances the binding cf monocytes to endot
helium7 and favors
macrophage foam ceil formation.8 CRP also decreases endothelial n
itric oxide synthase
activation while increasing the expression cf endothelial cell ad
hesion molecules,
chemokines, endotheiin-1 (ET-1), and plasminogen activator inhibitor-1 (PAl-1
)•9.13
Unregulated uptake cf oxidized low-density lipoprotein (0xLDL) by vascular cells
is a crucial step in athercgenesis. Endothelial LOX-1 is the major receptor cf 0xLDL’4
and accumulating evidences indicate that 0xLDL uptake through
this teceptor induces
endotheliai dysfunction. Indeed, oxLDL binding to endothelia
l LOX-1 generates
superoxide anions, decreases nitric oxide (NO) production and activates nuclear f
actor
KB (NF-KB).1516 Furthermore, inhibition cf LOX-1 reduces ox-LDL-medi
ated up
regulation cf monocyte chemoattractant protein-1 (MCP-1) and monocyte adhesio
n te
endothelial cefls.17 Endothelial LOX-1 expression is induce
d by various pro
inflammatcry cytokines, such as tumor necrosis factor Œ (TNFŒ)’8 and trans
forming
growth factor 3 (TGF3)19 as well as by pro-atherogenic factors, such as 0xL
DL and
advanced glycation end products (AGEs) in vitro.20 This receptor is expressed in
the
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aortas of hypertensive,21 diabetic,2° and hyperlipidemic22 animai
s and is upregulated in
eariy human atheroscierotic iesions.23 In the present study, we hy
pothesized that CRP
induced endothelial dysfunction may be mediated in part via LOX-1.
Thus we tested the
effect of CRP on endothelial LOX-1 expression and the role of
this receptor in CRP
induced monocyte adhesion and 0xLDL uptake by endotheliai c
eils.
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MATERIALS AND METHODS
Reagents
Phenylmethylsuifonyl fluoride (PMSF), Hank’s balanced sait solution (HBSS),
penicillin-streptomycin, glycine, sodium dodecyl sulfate (SDS) and Trizol reagent were
obtained from Invitrogen life technologies (Burlington, Ontario, Canada). Human aortic
endothelial ceils (HAECs), endothelial growth culture medium (EGM) and EGM bullet kit
were obtained from Cedarlane Laboratories Limited (Hornby, Ontario, Canada). D-
glucose, bovine serum albumin (BSA) fraction V, dianisinine dihydrochloride,
hexadecyltrimethylamine ammonium bromide (HTAB), isopropanol and E-TOXATE kit
were purchased from Sigma. END-X B15 endotoxin removal affinity resin kit was obtained
trom Seikagaku America (Falmouth, MA02540, USA). Ficoil and horseradish peroxidase
conjugated anti-mouse lgG were obtained from Amersham Biosciences. Monoclonal
antibody against J3-actin was bought from Santa Cruz Biotechnology (Santa Cruz, CA).
Recombinant human interleukin-6 (IL-6), IgG1 neutralizing antibody, and antibodies
against intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), E-Selectin, IL-6, ET-1 were purchased from R&D Systems (Minneapolis, MN).
Monoclonal antibody to human CD32 was purchased from MEDICORP (Montreal, QC,
Canada). Monoclonal antibodies to human LOX-1 and human CD64 were kindly provided
by Dr. Sawamura (National Cardiovascular Center Research Unit, Osaka, Japan) and Dr.
Sarfati (CHUM Research Center, Montreal, Canada), respectively. Recombinant human
CRP and actinomycin D were obtained from Calbiochem (La Jolla, CA). 1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindocarbocyanine perchlorate (Dii) was bought from Molecular Probes.
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t Ceils
HAECs wete grown to confluence in EGM under recommended conditions. The
EGM was supplemented with 2% fetal bovine serum (FBS) containing 0.01 ig/ml human
epidermal growth factor, 0.1% gentamicin sulfate amphotericin-B, 1ig/mI
hydrocortisone and 12 p.gIml bovine brain extract protein content. Ceils were used at
passages 3 to 5. Confluent HAECs were exposed for different time periods to various
concentrations cf endotoxin-free CRP. Endotoxin was removed from CRP using END-X
B15 endotoxin removal affïnity resin kit at 4°C overnight. After removal cf endotoxin,
CRP contained less than 3 pg/ml endotoxin, as detected by E-TOXATE kit. In some
experiments, celis were pretreated with antibodies against CD32, CD64, ET-1 or IL-6 or
co-incubated with CRP in the presence or absence cf glucose (30mmol/L), or IL-6.
Human monocytes were isolated as previously described.24 Briefly, peripheral
blood mononuclear cells were isolated from healthy control subjects by density
centrifugation using FicolI, allowed to aggregate in the presence cf fetal calf serum
(FCS), then further purified by the rosetting technique. After density centrifugation,
highly purified monocytes (85-90%) were recovered. Human monocyte purity was
assessed by flow cytometry (FACScan, Becton Dickinson) using phyco-erythrin
conjugated anti-CD14 monoclonal antibody (Becton Dickinson).
Analysis of mRNA expression
Expression 0f the LOX-1 gene in human HAECs was measured by polymerase
chain reaction (PCR) technique. Total RNA for use in the PCR reaction was extracted
from ceils by an improvement cf the acid-phenol technique cf Chomczynski.25 Briefly,
ceils were lysed with TRIzol reagent and chloroform was added to the solution. After
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centrifugation, the RNA present in the aqueous phase was ptecipitated and
tesuspended in diethyl pyrocarbonate water. cDNA was synthesized from RNA by
incubating total cellular RNA with 0.1 pg oligodT (Pharmacia) for 5 min at 98°C then by
incubating the mixture with reverse transcription buffer for 1h at 37°C. The cDNA
obtained was amplified by using 0.8 .jmol/L of two synthetic primers specific for human
LOX-1 (5’-TTACTCTCCATGGTGGTGCC-3’) (5’-AGCHCHCTDCHGTTGCC-3’) and
human glycera!dehyde-3-phosphate deshydrogenase (GAPDH) (5’-
C CCTTCATTGACCTCAACTACATGG-3’) (5’-AGTCTTCTGG GIGGCAGTGATGG-3’),
used as internai standard in the PCR reaction mixture. A 193-base pair human LOX-1
cDNA fragment and a 456-base pair human GAPDH cDNA fragment were amplifled
enzymatically by 30 and 25 repeated cycles, respectively. An aliquot of each reaction
mixture was then subjected to electrophoresis on 1 % agarose gel containing ethidium
bromide. The intensity of the bands was measured by an image analysis scanning
system (Alpha Imager 2000, Packard Instrument Company). Titrating the cDNA
samples ensured that the signal lies on the exponential part of the standard curve.
Western-BIot
HAEC protein extracts (12 .ig) were applied to 10% SDS-PAGE and transferred
to a nitrocellulose membrane using a Bio-Rad transfer blotting system at 100 V for 1
hour. Non-specific binding was blocked with 5% BSA for 1 hour at room temperature.
After washing with PBS-Tween 0.1%, blots were incubated overnight at 4°C with anti
LOX-1 or anti-f3-actin antibodies. After further wash, membranes were incubated for 1
hour at room temperature with a horseradish peroxidase-conjugated donkey anti-mouse
q
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igG (1/5000). Antigen detection was performed with an enhanced chemiluminescence
detection system (Amersham).
Adhesion assay
Confluent HAECs were exposed for 15 hours to 25 .ig/ml CRP, then treated for
J hour in the presence of antibodies to igG1 or LOX-1. HAECs were then washed twice
with HBSS and incubated for 2 hours with freshly purified human monocytes (280,000
cells/well) re-suspended in serum-free RPMI medium. At the end of this incubation
period, non-adherent monocytes were removed by washing the celis with PBS (pH 6.0).
Monocyte adhesion to HAECs was quantified by measuring monocyte myeloperoxidase
(MPO) activity.26
Determinatïon of endotheliai ccli associated adhesion molecule expression
Endothelial celi surface expression of ICAM-1, VCAM-1 and E-Selectin was
determined by the cellular-enzyme-Iinked immunosorbent assay (ELISA) method. After
treatment with CRP for 15 hours, HAECs were washed with PBS. b block non-specific
binding, endothelial ceils were treated for 1 hour at room temperature with PBS-3%
BSA. Ten ig/ml of monoclonal antibodies against ICAM-1, VCAM-1, E-Selectin, and
control igGi were then added to the ceils for 2 hours at 37°C. After washing, endothelial
celis were incubated for 90 minutes with horseradish conjugated anti-mouse igG
(1/1000) (Bio-Rad). The peroxidase substrate, o-phenylnediamine dihydrochioride, was
then added to the cells. The reaction was stopped by addition of 50111 cf H2S04 (0.5M)
and the optical density was read at 490 nm.
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Uptake of DiI-0xLDL
Native LDL (density, 1.019 to 1.063) was isolated from plasma obtained from
healthy donots by sequential ultracentrifugation using potassium bromide for density
adjustment.27 Native LDL was extensively dialyzed for 24 hours at 4°C against 5 mmol/L
TrisI5O nmol/L NaCI to remove EDTA. Oxidation of LDL was performed by incubating
native LDL (2mg proUmi) at 37°C for 20 hours in serum-free RPMI 1640 containing 7.5
jig/ml CuSO4. Oxidation of LDL was monitored by measuring the amount of
thiobarbituric acid-reactive substances (approximatively 10 nmol malondialdehyde
equivalenUmg protein ) and by electrophoretic mobility on agarose gel (data not shown).
Labeling of oxLDL with Dil was performed as described previously.28 b examine
cellular uptake cf oxLDL, HAECs were seated in 8-well cultureslides (FALCON©) and
incubated for 3 hours in medium containing 5% of lipoprotein-deficient serum with Dii
labeled 0xLDL (80 ig/ml) in the presence or absence of a 500-fold excess of uniabeled
oxLDL. At the end cf the incubation period, ceils were washed, mounted on coverslips
with mounting medium and examined by fluorescence microscopy. To measure
amounts cf Dil-oxLDL accumulated in ceNs, HAECs were seated in 12-well plates
receiving the same treatment as mentioned above. At the end of the incubation period,
Dii was extracted by isopropanol and the fluorescence was determined at 520/564 nm.
Results were normalized to total cell protein concentrations.29
Statistical Analysis
AIl values were expressed as the mean ± SEM. Data were analyzed by one-way
analysis of variance (ANOVA) followed by the Tukey test. A P value less than 0.05 was
considered statistically significant.
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RESU LIS
Effect of CRP on endotheHal LOX-f mRNA expression.
Incubation of HAECs for 6 hours with 25 tgIml CRP enhanced LOX-1 mRNA
levels. This effect was sustained up to 24 hours (Fig. lA-a). LOX-1 mRNA levels,
normalized to the levels of GAPDH mRNA (Fig. lA-b) are presented in Fig. lA-c. The
stimulatory effect of CRP on LOX-1 was already present at a concentration of 5 jig/mI
and was maximal with CRP concentrations ranging between 10 and 25 jig/ml. (Fig. 1 B
a). LOX-l mRNA levels, normalized to the levels of GAPDH mRNA (Fig. lB-b) are
presented in Fig. lB-c. Preincubation of the cells with actinomycin D (5tgIml)
prevented this effect (LOX-1 gene expression (% of control values): controls:100±13;
CRP(25.Ig/ml):21 5±45; actinomycin D+CRP:95±1 3). Interestingly, an increase in LOX-l
mRNA expression was also observed when cells were treated for 7 days with 51g/ml
CRP (LOX-1 gene expression (% of control values): CRP (5ig/ml):143+8, P<0.05 vs
controls).
Effect cf CRP on endothelial LOX-J protein expression.
Treatment of HAECs for 15 hours with 25 jig/ml CRP significantly increased
LOX-1 protein levels. This effect was sustained up to 48 hours (Fig. 2A-a). LOX-1
protein levels normalized to the levels of 13-actin (Fig.2A-b) are illustrated in Fig. 2A-c.
CRP-induced LOX-1 protein expression was dose-dependent with maximal effect being
observed between 10 and 25 ig/ml CRP. (Fig. 2B-a). LOX-1 protein levels normalized
to the levels of J3-actin (Fig.2B-b) are illustrated in Fig. 2B-c. To determine whether the
. CRP effect on LOX-1 is receptor-mediated, HAECs were pre-incubated in the presence
of antibodies to CD32 and/or CD64 prior treatment with CRP. CRP effect on LOX-1 was
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teduced in part by anti-CD32 and anti-CD64 antibodies and coincubation cf the ECs
with both antibodïes totally abrogated this effect (Fig. 2C).
Effect of glucose and IL-6 on CRP-induced endothelial LOX-1 protein expression.
Because diabetes is associated with inflammatory processes wïth an increase inthe levels of CRP3031 and pro-inflammatory cytokines323, we studied the effect of CRP
on LOX-1 expression in high glucose and IL-6-treated HAECs. As reported earlier34,incubation of HAECs in a high glucose environment led to increased endothelial LOX-1protein expression. Addition of CRP did not increase additionally LOX-1 expression
under hyperglycemic conditions (controls: 100±1 CRP: 173±8; glucose: 209÷13;CRP+glucose: 161±5). Treatment cf HAECs with IL-6 (0-200ng/mi) resulted in a dosedependent increase in LOX-1 protein expression with maximal effect at 100 ng/mlf Fig.3) CRP did not potentiate this effect (LOX-1 protein expression f% cf control
values): controls: 100±1; CRP: 173+8; IL-6: 168±15; CRP+lL-6: 169÷12). CRP-induced
LOX-1 expression was reduced by ET-1 and IL-6 inhibition. Coincubation of endothelial
cells with anti-ET-1 and IL- 6 antibodies totally suppressed this effect (LOX-1 protein
expression (¾ of control values): controls:100±1; CRP:178±8; CRP+anti-IL-6:120+19;
CRP+anti-ET-1 :142±22; CRP+anti-IL-6÷anti-ET-1 :88± 6).
CRP enhances monocyte binding to HAECs. Role of LOX-1
Treatment of HAECs with CRP (25 j.ig/ml) or lipopolysaccharide (lOng/ml), used
in these experiments as positive control (data not shown), increased monocyte
adhesion te these celis (Fig.4). Anti-LOX-1 antibody suppressed this effect, while anti
IgGl antibody was ineffective (Fig.4). Under our experimental conditions, CRP did net
enhance celI associated ICAM-1, VCAM-1 or E-Selectin fadhesion molecule protein
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expression (% over control values): ICAM-1: 115±7; VCAM-1: 97±5; E-Selectin: 90±9)
and incubation of HAECs with antibodies to ICAM-1 VCAM-1, and E-Selectin failed to
affect CRP-induced monocyte adhesion (Fig.4).
CRP stimulates oxLDL uptake in endothelial ceils via LOX-1.
To evaluate whether induction cf LOX-1 by CRP results in enhanced uptake cf
0xLDL by endothelial ceils, HAECs were treated for 14 hours with CRP (25 ig/mI), then
incubation was pursued foc 1 hour in the presence of saturating amounts (20 igIml) of
antibodies to LOX-1 or IgGi. At the end cf the incubation pericd, ceils were exposed for
3 hours to Dil-oxLDL (80 )lg/ml) in the presence or absence cf excess unlabeled oxLDL.
Incubation of HAEC5 with CRP Ied to enhanced uptake of OxLDL by these celis as
assessed by fluorescence microscopy (Fig 5A) and measurement cf extracted Dii
oxLDL (Fig 5B). This effect was abrcgated by incubating HAECs with anti-LOX-1
antibody or with excess unlabeled 0xLDL. In contrast, exposure of these ceils te anti
IgGi did net affect CRP-induced oxLDL uptake by endothelial ceils (Fig 5A and B).
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DISCUSSION
Accumulating evidences indicate that chronic 10w-grade inflammation is a majorpathogenic component cf endothelia! dysfunction.’ Consistent with this concept,e$evated serum CRP levels have been found to be associated with bluntedendothelium-dependent vasodilation in vivo.35 and a direct proinflammatory effect ofCRP on endothelial ceH has been documented in vitro.913 Ihe present study whichdemonstrates that CRP enhances the expression of LOX-1, a limiting factor for oxLDLuptake by endothelial ceils, further stresses the potential key role of CRP in endothelialdysfunction. Induction of LOX-1 by CRP is receptor-mediated and appears to beexerted at the transcriptional level, as reflected by the parae! increase in LOX-1 gene
and protein expression and the inhibitory effect of actinomycin D on CRP-induced LOXI gene expression. Transcriptional activation of the LOX-I gene by CRP maytheoretically involve NE-KB. Supporting this possibility, a NF-icB responsive element hasbeen located in the promoter cf the LOX-1 gene36 and increased transcriptional activity
of this factor has been documented in CRP-treated endothelial cells.37 CRP predictsincident type 2 diabetes38’39 and is increased in subjects with diabetes.4° Thus,hyperglycemia, in states of high CRP, may exaggerate the deleterious effects of CRP
on endothelial ceN activation. In contrast to previous observations showing that highglucose potentiates the proatherogenic effects of CRP in endothelial cells’341, we foundthat induction of LOX-I by CRP remained unchanged by hyperglycemia, suggestingthat CRP and glucose may operate through common molecular mechanisms to induceLOX-1. Because glucose induces endothelial LOX-I through NF-KB activation34 and
—
-
because CRP activates this transcription factor in endotheliai cells37, it is tempting to
205
Çspeculate that NF-KB may represent a common signal mediator of CRP and glucose
effect on LOX-1.
CRP and glucose are weIl known activators of ET-1 release by endothelial
cells1142 and this peptide mediates the proinflammatory effects of CRP11. lnterestingly,
ET-1 is also a LOX-1 stimulatory factor
, and thus may mediate CRP effect on LOX-1.
In support for this possibility, our data demonstrate that inhibition of ET-1 attenuates
CRP effect on LOX-1. ET-1 is one of the upstream activators of IL-6 secretion’ and
recent data suggest that CRP may stimulate the release of this cytokine by endothelial
cells.11 Our results which demonstrate that IL-6 induces endothelial LOX-1 and that
inhibition cf IL-6 reduces CRP-induced LOX-1 expression clearly identify IL-6 as one
mediator of CRP effect on LOX-1. Our finding that attenuation of CRP-induœd LOX-1
expression was greater during coïncubation with anti-ET-1 and IL-6 antibodies support
the concept that CRP induces LOX-1 via stimulating the production of ET-1 and IL-6
concurrently.
One major pathophysiological event associated with endothelial dysfunction is
increased monocyte adhesion to endothelial cells. Recent studies have demonstrated
that CRP increases monocyte-endothelium interaction7” by inducing endothelial and
monocyte adhesion molecules.79 Our findings that CRP increases the expression of
, a well identified cell-adhesion molecule’, and that blockade cf LOX-1 abolished
CRP-induced monocyte adhesion demonstrate a new role for LOX-1, that of mediating
the stimulatory effect of CRP on monocyte adhesion. In contrast to one previous study
showing that CRP increases the expression of E- selectin, ICAM-1 and VCAM-1 in
endothelial cells8, we did not observe an upregulation of these antigens in CRP-treated
CHAECs. Severai differences in the experimenta) conditions used in the two studies,
including the time points at which adhesion molecule expresssion was determined and
the concentrations of human serum present in the incubation medium are Iikely to
provide a good expanation for this discrepancy.
In contrast to other vascular ceils that do express multiple oxLDL receptors, LOX
1 is definïtively the limiting factor for 0xLDL uptake by endothelial ceNs and uptake of
0xLDL by this receptor induces endotheal dysfunction. Our resuits showing that CRP
enhances, through LOX-1, the uptake of 0xLDL by endothelial ceils suggest that CRP
may trigger the toxic effect 0f 0xLDL on vascular endothelium.In conclusion, the present study demonstrates that CRP, at concentrations
applicable to both acute and 10w-grade chronic inflammation, increases endothelial
LOX-1 expression. Whether this potentially proatherogenic effect of CRP has clinical
relevance remains to be evaluated.
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Fig.J. lime- and dose-dependent effect of CRP on LOX-1 mRNA levets in
HAECs. HAECs were incubated for 3 to 24 hours with 25 p.g/mI CRP (A) or for
6 hours with 1 to 25 jiglml CRP (B). At the end of the incubation period, celis
were !ysed and LOX-1 mRNA was analyzed by RT-PCR. LOX-1 mRNA leves
fa) were normalized to the levels of GAPDH mRNA (b). Data illustrated on the
graph bar (c) represent the mean ± SEM of 6 different experiments. * p<O.05
vs control.
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protein expression. HAECs were cuftured for 6 to 48 hours with 25 jig/mI
CRP (A) or for 15 hours with 1-25 ig/mI CRP (B). In some experiments,
HAECs were preincubated with anti-CD32 andlor anti-CD64 antibodies
prior exposure for 15 hours with 25 j.tglml CRP (C). At the end of the
incubation period, celis were Iysed and LOX-1 membrane protein
expression was determined by Western blot analysis (a). LOX-1 protein
levels were normalized to the levels of f3—actin protein (b). Data
illustrated on the gtaph bar reptesent the mean ± SEM of 5 (A) and 6 (B-
C) different experiments (C). * p<O.05, , p<O.O1, , P<O.001 vs
control.
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Fig.5. Effect of CRP on oxLDL uptake by HAECs. HAECs were
treated for 14 hours with CRP (25 jig/mI), then incubation was
pursued for an additional 1 hour period in the presence of saturating
amounts (20 igIml) of antibodies to LOX-1 or lgG1. At the end of the
incubation period, celis were exposed for 3 hours to Dit-oxLDL (80
p.g/mt) in the ptesence or absence of excess uniabeied 0xLDL. After
washing, fluorescence of Dii was detected in cytoplasm of HAECs by
fluorescence microscopy (A) or measured at 5201564nm (B). Data
iliustrated on the graph bar represent the mean ± SEM of 6
independent experiments. p<O.01 vs contrai.
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III. DISCUSSION
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Diabetes mellitus is one of the most costly and burdensome chronic
diseases. The number of diabetic patients is increasing worldwide and the WHO
predicts that between 1997 and 2025, the number of diabetics wiII double from
150 to about 300 million. The incidence of type 2 diabetes in the US has
increased by about 33% over the past decade and is expected to increase
further. The most important factors contributing to the development of type 2
diabetes are obesity and physical inactivity. During the past decade, the
percentage of Americans defined as obese has increased by about 33%. It is not
a coincidence that these figures mirror the dramatic tise in diabetes ovet the
same 10-year period.
Type 2 diabetes, accounts for 80-90% of diabetes mellitus worldwide
[Simpson et al. 2003]. lt is a major risk factor for CVD [McGill et al. 1998,
Khamaisi et al. 2003] and is associated with a two- to eight-fold increase in the
risk of CVD morbidity and mortality [Harris et al. 1998]. The pathogenesis of CVD
in type 2 diabetes is multifactorial. Although conventional CVD risk factors such
as dyslipidemia and hypertension, are operative in type 2 diabetes, these risk
factors only partly account for the excessive risk of developing CVD in the
diabetic population. Recognition of this fact has recently led to the identification
of novel risk factors specific to individuals with diabetes. These factors include
insulin resistance, post-prandial hyperglycemia, inflammation, AGE formation,
endothelial dysfunction and oxidative stress. Today evidence exists that much of
the increased risk of developing CVD in diabetes is related to insulin resistance.
Insulin resistance is a hallmark of type 2 diabetes that precedes and ptedicts the
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disease for several years. It is related to both traditional and nontraditional CV
risk factors, including hyperglycemia, dyslipidemia, hypertension and obesity,
linking ail these abnormalities to the development of CV disease. For such
reasons, insulin resistance might be regarded as an accomplice in the
pathogenesis of CV disease in type 2 diabetes. It has been recently proposed
that insulin resistance might also contribute to CV disease in a direct and
independent pathway, i.e. independentiy of classic risk factors [Bonora et al.
2002]. Insulin resistance is associated with endothelial dysfunction and
inflammation, thus supporting the concept that the atherosclerotic process may
actually begin earlier in the spectrum of insulin resistance. These data suggest
that detection of insulin resistance relatively early in life may offer the opportunity
to identify those persons Iikely to develop dyslipidemia, hypertension and
ultimately, diabetes and CVD. Improvement of insulin resistance might have
beneficial effects not only on glucose control but also on CV disease in patients
with type 2 diabetes.
Type 2 diabetes is pteceded by a long period of asymptomatic
hyperglycemia. While glucose is the driving force in microvascular complications
of diabetes, yet the extent to which hyperglycemia contributes to diabetic
macrovascular complications is still controversiai. Although some epidemiological
and intervention studies have reported a correlation among glucose,
atherosclerotic plaque burden, CV events and increased morbidity and mortality
[Laakso et al. 1996, Tominaga et aI, 1999, Ledru et al. 2001] as weIl as a
reduction of CV risk by glycemic control [Laakso et al. 1999, Gerstein et al. 1996,
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Fuller et al. 1983, Fuller et al. 1980, Singer et al. 1992], other studies have
demonstrated that hyperglycemia ïs not a particularly strong determinant for
developing CVD in type 2 diabetic patients. For example the UKPDS has shown
that intensive blood-glucose control by either suiphonylureas or insulin does not
statisticafly reduce the risk of developing macrovascular disease in patients with
type 2 diabetes, although treatment sufficient to Iower median HbA1 to 7% over
10 years reduced the risk of myocardial infarction by 16% in these subjects
[UKPDS Group 1998]. There are two possible explanations for the weak
association between glycemia and CVD. The first possible explanation is that
postprandial glycemia may be more importantly related to CVD than fasting
glycemia. Supporting this possibility, epidemiological data have demonstrated
that postprandial plasma glucose is an independent risk factor for CVD in
diabetic subjects [Ihe DECODE Study Group 1999, Bonora et al 2000, 2001,
Haffner et al. 2003] Another possible explanation for the weak influence 0f
glycemia on CVD in diabetes is the existence of an atherogenic prediabetic state.
Numerous studies have shown that subjects before diabetes have an adverse
pattern of dyslipidemia and hypertension, with increased levels of inflammatory
markers and PAl-1 [Medalie et al. 1975, McPhillips et al. 1990, Mykkanen et al.
1993, Haffner et al. 1990, Fagot-Campagna et al. 1997]. This provides possible
mechanisms for the common basis of type 2 diabetes and CVD as initially
suggested by Stem in the “common soil” hypothesis [Stem 1995],.
As mentioned above, patients with type 2 diabetes present elevated
( serum levels of inflammatory markers and cytokines, such as CRP, fibrinogen,
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TNFŒ and IL-6, thus suggesting a 10w-grade inflammatory condition in type 2
diabetes. Because atherosclerosis is an inflammatory-mediated disease [Ross
1999], it has been proposed that diabetes and atherosclerosic CV disease might
share a common inflammatory basis. Epidemiological evidence showing that
inflammatory markers predict incident diabetes mellitus, metabolic syndrome in
addition to CV events supports this hypothesis.
Iwo viewpoints exist on the factors that initiate the acute phase response
in insulin-resistant and diabetic patients. The first hold that the acute phase
response is activated by ongoing intraarterial inflammation in which arterial wall
resident inflammatory ceils secrete cytokines in response to multiple stimuli.
According to the second view, extravascular stimuli, including obesity, aging,
infections, smoking, and stress induce a chronic, low-Ievel activation of the acute
phase response. In this regard, it is now well accepted that obesity constitutes a
low-grade inflammatory state and that adipose tissue is the source of many
biologically active proinflammatory sectetoty molecules such as INFŒ , IL-6
PAl-1 and CRP The final result of both views would be the triggering 0f the
inflammatory cascade leading to atherosclerosis.
As discussed before, much of the increased risk of developing CVD in
diabetes is related to insulin resistance. Evidence that insulin resistance is
closely associated with chronic subclinical inflammation [Pradhan et al. 2001,
Barzilay et al. 2001, Hanley et al. 2002, Pradhan et al. 2003] and in particular
with increased plasma CRP levels [Yudkin et al. 1999, Hak et al. 1999, Lemieux
et al. 2001], supports the notion that prointlammatory processes may conttibute
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to atherogenesis by inducing insulin resistance [Nesto 20041. For example,
expression cf TNFŒ and IL-6 at high levels in the adipose tissue may function
locally and systematically to decrease insulin release and action. Although there
is good evidence that these mediators may contribute to insulin resistance in
animal models, the exact molecular mechanisms that lead to the proinflammatory
changes resulting in insulin resistance in humans are however unclear.
Conversely, defects in insulin action on the main insulin-sensitive tissues, i.e.
adipose tissue, muscle and liver, may also lead to a worsening of the chronic,
low-grade inflammatory state. For exampe, in the liver, insulin seems to be one
cf the main inhibitors 0f the cytokine-associated acute-phase response. Thus, the
lack cf significant insulin action, as found in type 2 diabetes, would net be able te
block TNFŒ, IL-1 and IL-6 actions. From this, it s tempting te conclude that the
relationship is bidirectional: any process linked te chronic inflammation will
decrease insulin action and insulin resistance will lead te worsening of
inflammation in a vïcious cycle.
There is little doubt that one important link between insulin resistance and
diabetic vasculopathy is endothelial dysfunction. Indeed, endothelial dysfuncticn
is a key early event in atherogenesis, predicts CV events and evidence exists
that endothelial dysfunction and insulin resistance closely coexist throughout the
natural history cf type 2 diabetes [Steinberg et al. 1996, Balletshofer et aI. 2000].
lndeed, endothelial dysfunction is detected in obese patients, in relatives without
diabetes as well as in the spectrum of insulin tesistance, before the detection cf
any distinct carbohydrate intolerance. Jnsulin resistance may contribute te
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endothelial dysfunctïon through systemic defect cf the P13 kinase pathway and
decreased insuIinmediated endothelial NO production. In the same way insulin
resistance may contribute to endothelial dysfunction, evidence aise exists that
defects in NO-mediated vasodilation may contribute to insulin resistance. Multiple
interrelated mechanisms likely contribute 10 endothelial dysfunction in insulin
resistance. Virtuaily ail components of the metabolic syndrome, such as
hypertension, dyslipidemia and hyperglycemia have been shown to induce
endothelial dysfunction. Hyperglycemia may induce endothelial dysfunction
thtough multiple mechanisms including protein glycation, oxidative stress,
activation of the PKC and polyol pathways as well as activation of the
coagulation cascade.
Two potentiai mechanisms that may iink insulin resistance with endothelial
dysfunction are oxidative stress and inflammation. Supporting this possibility, it
has been shown that insulin resistance is associated with increased oxidative
stress and inflammation and that agents with antioxidant and antiinfiammatory
properties improve endothelium-dependent vasodilation and insulin sensitivity in
diabetic patients. While the causal role of inflammation on endothelial dysfunction
is well demonstrated, the possibility that the mechanistic basis for the powerful
predictive value cf CRP may reside at the level of the endothelium has only been
recently investigated. In 2000, Fichtlcherer et al have reported that elevated CRP
serum levels are associated with blunted systemic endothelial vasodilation,
suggesting that identification of elevated CRP levels as an independent risk
factor for endothelial dysfunction might provide an important due to link a
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systemic marker of inflammation to atherosclerotic disease development. More
recently, in vitro studies have suggested a direct causal role for CRP in
endothelial dysfunction. These studies have demonstrated that CRP increase
s
the expression of ET-l, MCP-1 and adhesion molecules, activates NF-icB and
decreases NO release [Verma et al. 2002, Szmitko et aI 2003]. From these data
it appears that CRP is not merely an inflammatory marker but may be dire
ctly
involved in atherogenesis. These findings may have important implications
for
future cardiovascular reseatch.
LOX-1 is a newly identified endothelial receptor for 0xLDL, which is also
expressed by other vascular ceil types, including macrophages and SMC
s
[Sawamura et aI. 1997]. Numerous studies support s role of LOX-1 as a potential
mediator of endothelial dysfunction. lndeed, evidence exists that oxLDL
binding
to LOX-1 in endothelial celis generates superoxide anions, decreas
es NO,
activates NF-KB pathway [Cominacini et al. 2000, Cominacini et al. 2001], and
induces endothelial apoptosis [Li et al. 2000]. LOX-1 also acts as an adhesion
molecule favoring monocyte adhesion to endothelium [Honjo et al. 2003, Li et al.
20021. 0f most importance, we and others have reported that
metabolic factors
potentially involved in endothelial dysfunction associated with
diabetes
upregulate endothelial LOX-1. For example, Chen et al [2001] have
demonstrated that diabetic rat serum and AGEs induce endothelial
LOX-1
expression, and we have recently generated preliminary data showing that
FFAs
increase endothelial LOX-1 expression both at gene and protein level
s. In the
present study, we obtained evidence that high glucose concentrations
enhance
229
endothelial LOX-1 expression. Recause increased serum concentrations of AGEs
in patients with type 2 diabetes is associated with endothelial dysfunction [Tan et
al. 20021 and because AGEs induce endothelial LOX-1 expression in vitro, this
effect of glucose may theoretically be related to AGE formation in endothelial
ceNs. Studies by Brownlee et al have characterised the time course for
intracellular glycoxidation in vascular ceNs cultured in a high glucose
environment. These investigators have shown that the levels of cytosol AGE
proteins increase in a time-dependent manner upon exposure of endothelial ceils
to high glucose, being signiflcantly increased by 2- to 12-fold after 5 and 7 day -
exposure to 3Ommol/L glucose, respectively [Giardino et al. 1994, Du et al.
2003]. Since one week was not sufficient to reach a steady state even of early
protein glycation products with glucose, these authors suggested that the
unexpected magnitude of the increase 0f AGE proteins in high glucose-treated
endothelial celis most likely results from glycosylation by more highly reactive
intracellular sugars and glucosones. The correctness cf this hypothesis was later
demonstrated by studies showing the critical role for intracellular accumulation cf
3-deoxyglucosone synthesized via the Maillard reaction and the polyol pathway
in intracellular AGE formation [Niwa T et al. 2001]. From these data, it appears
that length cf incubation time s critical for AGE formation in cultured vascular
ceNs and that this process occurs over a period cf week. Considering the short
incubation period cf endothelial celis with high glucose in our study, it seems
unlikely that, under our experimental conditions, AGE formation may be
C
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responsible for the stimulatory effect of high glucose on endothel
ial LOX-1
expression.
As discussed above, high glucose per se is believed to play a key
role in
endothelial dysfunction associated with diabetes. In accord
ance with this
possibility, acute hyperglycemia has been shown to induce
endothelial
dysfunction in both healthy subjects [Titie et al. 2000] and patients with type 2
diabetes [Lee et al. 20021. On the basis of these results and on the potential k
ey
role of LOX-1 in endothelial dysfunction, our data dem
onstrating that
hyperglycemia enhances endothelial LOX-1 expression sugge
st a role for this
receptor as mediator cf the in vivo effect cf hyperglycem
ia on endothelial
dysfunction.
Although the signaling events underlying hyperglycemi
a-induced
endothelial dysfunction are not well known, recent studies ha
ve strongly pointed
to a decisive role of the diacylglycerol (DAG)-PKC pathway in this alteratio
n [lshii
et al. 1998]. PKC and its activating cofactor DAG are elevated in norma
l tissues
exposed to high glucose [Koya et al. 1998) as well as in several org
ans in
diabetes [Shiba et al. 1993, Craven et al. 1989]. In particular, the PKC
isoform f3
is more selectively activated in the heart and the aorta of dia
betic rats [Inoguchi
et aI. 1992]. lmportantly, inhibition cf PKC attenuates vascular dysfu
nction in
diabetes and glucose-induced endothelial dysfunction [Tesfamariarn et
al. 1991].
Recent studies investigating the role of PKC in glucose-ind
uced endothelial
dysfunction have proposed that PKC reduces the activity cf
NOS III protein by
inducing the phosphorylation cf this enzyme [Hirata et al. 1995] and a
ctivates
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vascular NADPH oxidase, thereby leading to increased superoxide pro
duction
and NOS III uncoupling in diabetic vesseis [Hink et ai. 2001]. Conversely,
inhibition of PKC activity increases the avaiiabihty of endotheiium-der
ived NO
and attenuates leukocyte-endothelium interaction in microvesseis of
diabetic
animais [Nonaka et ai. 2000], probabiy through the anti-infiammatory and
inhibitory effects 0f NO on endotheliai ceil adhesion moiecuies [Aitman 2003].
Giucose-induced activation of PKC and more particuiariy ot the PKCI3
and
isoforms aise ieads to enhanced ETI production [Park et ai. 2000]. Furthermore
,
PKC activation increases the production cf growth factors by the e
ndotheiium,
such as VEGF, EGR, and TGF3 [Xia et ai. 1996].
Previous studies have demonstrated that activation cf LOX-1 decrea
ses
NO reieased from endotheiiai celis and induces the expression of E
T-1 and ceil
adhesion moiecuies. it has been postuiated that activation cf LOX-1
decreases
the release cf NO not oniy by enhancing the catabolism cf NO
through the
generation of ROS but aise by attenuating eNOS activity [Mehta et al. 200
2,
2003]. Our in vitro study which demonstrates that high glucose upreguiat
es
endotheiiai LOX-1 expression suggests that this effect may iead t
e enhanced
binding of oxLDL and/or AGEs te LOX-1 thus resuiting in furth
er functionai
changes in endotheiiai ceiis in response te these factors. Futur
e experiments
shouid evaluate whether incubation cf endothelial ceiis in a hyper
giycemic milieu
potentiates the deleterous effect cf LOX-1 ligands on severai biolo
gicai events
associated with endothelial dysfunction such as inactivation cf NO,
increase in
ET-1 and chemokine expression and NF-K5 activation.
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Diabetes is associated with changes in endothelial function that augur the
development of atherosclerosis. Endothelial dysfunction mainly results
from an
imbalance in the local production and/or activity of potent vasoactiv
e agents
including NO and ET-1 in the vessel wall [Clement et al. 1990, Haynes et al.
1994, Martin et al. 1996]. Endothelium-derived NO is the most potent
endogenous vasodilator, which inhibits leukocyte and platelet adhere
nce to the
vessel wall [Kubes et al. 1991, Tsao et al. 1994]. ET-1, produced directly by
vascular endothelial cells, is the most important locally produced va
soconstrictor,
acting principally through type A receptors on vascular smooth
muscle cells
[Levin et al. 1995]. NO and ET-1 not only function as mutual antagonists in th
e
determination of vascular tone, but also act in net as antiatheros
clerotic (NO) or
proatherosclerotic (ET-1) factors through modulation of platelet activity, lipid
oxidation, leukocyte chemotaxis, and local production of thromb
otic factors as
well as growth and proliferation 0f vascular smooth muscle cells
and flbroblasts
[Levin et al. 1995, Moncada et al. 1993, De Meyer et al. 1997]. Experimenta
l
evidence supports the notion that hyperglycemia can direc
tly decrease
endothelium-derived NO [Tesfamariam et al. 1991] and alter ET-1 system [K
ing
et al. 1996]. Besides PKC activation [Tesfamariam et al. 1991, Nishio et al. 1
996,
lshii et al. 1996], potential mechanisms through which hyperglycemia
may
decrease NO include CRP and LOX-1. lndeed, elevated plas
ma levels of CRP
have been shown to be associated with hyperglycemia and in
vitro studies have
provided evidence that CRP decreases NO release [Verma et aI. 2002, Szmi
tko
et al. 2003]. Furthermore,decreased NO production by endothelial cells has
been
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closely related to increased LOX-1 expression through NFKB activation
[Cominacini et la. 2000, 2001, Morawietz et al. 2001, 2002]. Endothelial LOX-1
expression is upregulated by its ligands, 0xLDL and AGE [Chen et al. 2001],
whom increased formation in diabetes results at least partly from oxidative stress
[Creager et al. 2003]. Because high glucose induces oxidative stress, one may
postulate that this metabolic factor by favoring oxLDL and AGEs formation may
increase LOX-1 activation, thereby decreasing NO. Alternatively, hyperglycemia
may directly, by generating oxidative stress and NF-icB activation in endothelial
ceils, enhance LOX-1 expression. Induction of LOX-1 by high glucose may
provide a new mechanism by which hyperglycemia reduces NO and induces
endothelial dysfunction in type 2 diabetes.
As mentioned above, endothelial cells respond to high glucose by
increasing PKC activation and, activation of this signaling pathway plays a critical
role in hyperglycemia-induced endotheliaf dysfunction. In accordance with these
observations, we found that glucose-induced upregulation of endothelial LOX-1,
a key mediator cf oxLDL-induced endotheliat dysfunction, requires PKC
activation, as reflected by the complete inhibition cf LOX-1 induction by glucose
in endothelial cells pretreated with the pan specific PKC inhibitor, caiphostin C as
welt as by the specific PKCf32 inhibitor, LY379196. Because activation of LOX-1
induces the generation of superoxide anion that activates NE-KB and inactivates
NO and enhances the expression of vasoconstrictive molecules such as ET-1,
adhesion molecules and MCP-1, upregulation cf LOX-1 through PKC activation
may represent a new mechanism by which PKC induces endothelial dysfunction.
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While there are no other reports in the literature showing a role for PKC as
signal transduction molecule involved in the regulation of endothelial LOX-J
expression, previous studies have demonstrated that LOX-1 is upregulated by
oxidative stress as well as by molecules that induce oxidative stress [Halvorsen
et al. 2001]. Oxidative stress is increased in patients with diabetes [Wolff et al.
1991, Oberley 1988, Mullarkey et al. 1990, Bayes 1991, Williamson et al. 1993,
Sano et al. 1998]. and may represent a key mechanism underlying endothelial
dysfunction in diabetes mellitus. Although there is no evidence that antioxidants
improve endothelium dysfunction in chronic studies, this possibility is supported
by short-term studies demonstrating the acute beneficial effect cf ascorbic acid
on vascular function in type 2 diabetic patients [Ting et al. 1996]. It is well
accepted that high glucose Ieads ta intracellular changes in the redox state
resulting in depletion cf the cellular NADPH pool [Williamson et al. 1993] and
generates superoxide production [Ohara et al. 1993J. Consistent with these
findings and acccrdingly ta the redox sensitive regulation cf LOX-1, we
demonstrated that antioxidants such as NAC, vitamin E, vitamin C, and DMSO,
significantly decrease glucose-induced endothelial LOX-1 expression. Based on
the link established between oxidative stress and PKC activation [Pricci et al.
2003], it is tempting to speculate that ROS generated by glucose metabolism
may induce the activation cf PKC thereby leading ta the induction cf LOX-1.
Because glucose activates different members cf the MAPK family in endcthelial
ceils [Liu et al. 2000] and that cc-activation cf PKC and MAPK occurs in vascular
C celis maintained in high glucose [Haneda et al. 1995], cur cbservation that MAPK
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inhibitor completely attenuates glucose-induced endotheliai LOX-1 gene
expression is flot surprising. On the basis of the growing literature showing that
PKC can activate MAPK and that PKC inhibitors can prevent their activation by a
range of stimuli, one may postulate that under our experimentai conditions,
MAPK are activated downstream of a cascade initiated by PKC activation. This
may explain our finding that inhibitors of PKC totaliy abrogate giucose-induced
LOX-1 expression.
The MAPK pathway consists of a group of interconnecting protein kinase
cascades that link signais at the plasma membrane to nuciear events. Four
different families of MAPKs that are linked to different signais and have different
substrate specificities have been described, inciuding ERK-1 and -2, c-jun NH2-
terminal kinases (]NKs), p38 kinases and big MAPK1 or ERK 5 [Tomiinson
1999]. ]NKs respond to severai forms of ceiiuiar stress and ERKs are primariy
regarded as growth factor signaling kinases. Activation of the sorbitol pathway,
increased oxidative stress and AGE formation, and other biochemical anomalies
arising from hypergiycemia in diabetes, share the capacity to activate MAPK,
thus indicating that these enzymes function as glucose transducers. [Tomiinson
1999]. By phosphoryiating transcription factots such as NFKB and AP-1, these
kinases alter the balance of gene expression, leading to a spectrum 0f changes
from celiular proliferation, aitered production of extraceiiular materials or an
aitered phenotype [Tomhnson 1999, Haneda et ai. 1997, Igarashi et aI. 1999].
Many studies have indeed demonstrated that proinflammatory cytokines,
C mitogens, ROS, and shear stress trigger signai moiecuies to initiate the activation
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of multiple intracellular pathways, which often converge at M
APK activation and
endothelial dysfunction [Bogatcheva et al. 2003]. Importantly, several s
tudies
have documented that MAPK activation plays a role in endo
thelial dysfunction
associated with diabetes. For example, studies have shown th
at glucose inhibits
endothelial growth and induces endothelial apoptosis through a
ctivation of MAPK
pathway [Liu et al. 2000, Nakagami et al. 2001]. In addition, a recent study
has
reported that hyperglycemia accelerates MCP-1 produ
ction by vascular
endothelial ceils through MAPK activation [Takaishi et al. 2003].
Despite
evidence supporting a role of MAKP in several biological ev
ents associated with
LOX-1 activation [Li et al. 2000, Iwai-kanai et al. 2001, Li et al. 2003],
a role for
MAPK in the regulation cf endothelial LOX-1 expression h
as not been reported.
Our study which demonstrates that glucose-induc
ed endothelial LOX-1
expression occurs through the activation of the MAPK pat
hway further stress the
critical importance of MAPK in endothelial dysfunction assoc
iated with diabetes
[Li et al. 2003].
Previcus studies have shown that the signaling pathway
s involved in
oxLDL-induced endothelial dysfunction include the activati
on cf the transcription
factor NFKB [Li et aI. 2000, Cominacini et al. 2000]. Glucose is a w
ell known
activator 0f this transcription factor and a number cf trans
cription-factor-binding
sites including a NFKB element have been found in the p
romoter cf the LOX-1
gene [Aoyama et al. 1999]. NFiB is a well known oxidative stress
-sensitive
transcription factor [Ho et al. 1999] that s activated by
glucose and
proinflammatory cytokines [Lavroysky et al. 2000]. Five NF-KB subunits
that form
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dimers have been identified in mammalian celis, including Rel A (p65), p50,
ReIB, c-Rel, and p52. The most common and best-characterized form of NF-iB
15 the p65-p50 heterodimer [Delfino et al. 1999]. In the present study, we found
that glucose induces LOX-J gene expression and that antibodies to P65 and P50
significantly attenuate glucose-enhanced nuclear proteins binding to the NFicB
regulatory element present in the promoter of endotheliai LOX-1 gene [Li et al.
2003]. This effect was abrogated by antioxidants, and inhibitors of PKC and
MAPK. Taken together, these results suggest that glucose induces LOX-1
expression at the transcriptional level and that induction of LOX-1 gen
e
expression in glucose-treated endothelial ceils involves oxidative stress an
d
activation of PKC/MAPK and NFKB.
The transcription factor NE-KB has been proposed as a critical bridge
between oxidant stress and gene expression [Barnes et al. 1997]. Translocation
of activated NE-KB into the nucleus results in gene expression of NF-KB
controlled target genes such as adhesion molecules, cytokines eNOS, MCP
-1
endothelin-1 and IF. Ihus, this signal transduction system appears capa
ble of
transforming the appearance and disappearance of short-lived oxygen spe
cies
into more sustained signais for cellular activation. Whiie poor glycemic con
trol
has been shown to induce activation of NF-KB in ex vivo isolated perip
heral
blood mononuclear ceils of patients with type 1 diabetes [Levin 1998], a long
lasting sustained activation of NE-KB has recently been documen
ted in
mononuclear celis from patients with diabetes [Bierhaus et al. 2001]. While ROS
produced by the mitochondrial respiratory chain have been described as
one
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major mediator of hypergiycemia-dependent NE-KB activation [Giugliano et ai.
1996], monocytes do not contain mitochondria and thus additionai routes 0f ROS
production seem to be involved. In this regard, a recent study ha
s demonstrated
that upon AGE engagement of RAGE, NADPH oxidase is on
e major source cf
ROS in endothelial ceils [Wautier et ai. 2001], thus suggesting that m
ultiple
sources cf oxidative stress may contribute to NE-KB activation in dia
betes.
That NE-KB activation can occur by a variety of signais, inciudin
g oxidative
stress, raises the possibility that the diverse risk factors ass
ociated with the
initiation of atheroscierosis, may be linked by a final common pa
thway of induced
endotheliai gene expression. The agents associated
with activated or
dysfunctional endothelium may act through second mess
enger systems te
activate specific members of the NE-KB family. Transcript
ional activation of
specific sets of endothelial genes wiil result in the genera
tion cf numerous
endotheliai products, inciuding adhesion proteins, cytokines, gr
owth factors and
chemokines contributing to endothelial dysfunction and ac
tivation, In diabetes,
hyperglycemia, AGE, oxidative stress and 0xLDL can lead
to the activation of
NF-KB and products of the NF-KB controlled target gen
es are believed to be
directly involved in the pathogenesis of diabetic vasculopathies
. Dur study, which
demonstrates that high glucose enhances LOX-1 expression
through a NE-KB
dependent pathway, identifies a new NE-KB target gene po
tentially involved in
endotheliai dysfunction in diabetes. Whether induction of en
dothelial LOX-1 by
other metabolic or inflammatory factors is mediated by NE
-KB remains to be
evaiuated.
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Besides metabolic factors, inflammatory mediators may contribute to
endothelial dysfunction in diabetes. Indeed, diabetes constitutes a 10w grade
inflammatory state and is associated with overproduction cf various
proinflammatory cytokines and AAPs, including CRP, TNFŒ and IL-6 [Pradhan et
al. 2001]. It has been shown that proinflammatory cytokines such as TNFa and
IL-6 induce endothelial activation/dysfunction. For example, TNFŒ increases
procoagulant activity cf endothelial ceNs, enhances endothelial celI adhesion
molecule expression and stimulates the release cf MCP-1 and IL-6 by endothelial
cells, suggesting that this cytokine may, alone or in concert with other cytokines,
alter endothelial function. Despite these in vitro observations, it is not yet known
to what extent chronic, moderate elevations cf this cytokine levels induce
endothelial dysfunction in diabetes [Bilsborough et al. 2002]. In a similar manner,
elevated levels of IL-6 may also contribute te endothelial dysfunction in diabetes.
Supporting this possibility, it has been recently shown that IL-6 causes
endothelial barrier dysfunction via the PKC pathway [Desai et al. 2002] and
induces endothelial dysfunction by increasing the expression of Ail [Wassmann
et al. 2004J. Alternatively, this cytokine may alter endothelial ceil function
thorugh its stimulatory effect on CRP release from the liver.
CRP concentrations correlate with indirect markers cf endothelial function
and recent data suggest that this acute phase protein per se may affect
endothelial function. Indeed, it has been shown that CRP exerts direct pro
inflammatory effects on human endothelial cells by increasing the expression cf
( adhesion molecules and MCP-l and decreasing the production cf NO. Several
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rnechanisms have been proposed by which CRP may contribute t
o endothelial
dysfunction, including increased expression of , NF-KB act
ivation, and
decreased NO release [Verma et aI. 2002, Szrnitko et al 2003].
Our study which demonstrates that CRP enhances the expression
of LOX
1 in endothelial celis supports a new mechanisrn by which CR
P may promote
endothelial dysfunction. As discussed before, LOX-1 is a key me
diator of 0xLDL-
induced endothelial injury, activation and dysfunction [Chen et al. 2002, Mehta et
al. 2002]. Since endothelial dysfunction is one of the earliest eve
nts in
atherogenesis, induction of LOX-1 in response to CRP may pla
y an essential tale
in the initiation of the atherosclerotic process. Further suppo
rt for this hypothesis
cornes frorn our observation that CRP-induced LOX-1 expres
sion is associated
with increased monocyte adhesion ta endothelium. LOX-1 ha
s been recently
identified as an adhesion molecule [Honjo et al. 2003] and blocking LOX-1
mRNA using an antisense has been shown to inhibit oxLDL-m
ediated monocyte
adhesion to endothelial cells [Li et al 2000]. While previous stu
dies have
documented a stimulatory effect of CRP on monocyte-endo
thelium interaction
through the induction of endothelial ceil adhesion molecules,
including VCAM-1,
ICAM-1, and E-selectin [Pasceri et al. 2000], we found that CR
P induces
monocyte adhesion through LOX-1 and that this effect w
as independent of
VCAM-1, ICAM-1, and E-selectin. Pasceri et al reported t
hat CRP’s effect on E
selectin was evident at 6 but not 24 hours, whereas induc
tion of ICAM-1 and
VCAM-1 was observed at 24 hours. lmportantly, these inve
stigators noted that
CRP effect was dependent on presence of human serum,
being achieved only in
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the presence of 15% human serum. Undet our experimental conditions,
endothelial celis were exposed to CRP for 15 hours and incubation was
performed in the presence cf 2% FBS. Such differences in the experimental
conditions used in the two studies are Iikely to provide a good explanation for
these discrepancies.
Recause endotheliai LOX-1 is the major receptor for oxLDL and that
infiltration cf this lipoprotein in the intimai space is a key event in the
pathogenesis of atherosclerosis, increased expression of LOX-1 in the
endothelium may fayot lipoprotein accumulation in the vessel wall. Is it well
known that LDL particles either pass between the endothelial cells or cross the
endothelium in transcytotic vesicles [Vasile et al. 1983, Kac et al. 1994, Kao et al.
1995J and evidence exists that CRP binds to aggregated lipoproteins and favors
macrophage-derived foam cell formation. Our finding that CRP enhances oxLDL
uptake by HAECs through LOX-1 receptor supports a raie for this protein in
arteriai Iipid infiltration. These resuits and the recent observations that endothelial
LOX-1 expression is increased in diabetic animais and that lipoprotein flux into
the arterial wall is increased in patients with type 2 diabetes [Kornerup et al.
20021 further stress a role for LOX-1 in transvascular LDL transport in diabetes.
Further in vivo studies using CRP and LOX-1 transgenic animais are required ta
address this important issue.
Among the proinflammatory cytokines that predict and are increased in
type 2 diabetes, IL-6 is a centrai mediator cf the acute-phase response and the
primary determinant of CRP production [Heinrich et al. 1990]. IL-6 circulates in
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plasma cf diabetic subjects at high concentration and one third of circulating IL-6
concentrations seem to originate from the adipose tissue. lncreased IL-6 le
vels
have been shown to predict cardiovascular mortality and future myoca
rdial
infarction [Miyao et al. 1993, Libby et al. 1999, Ridker et al. 2000, Bennet et al.
2003]. IL-6 may promote coronary disease through a number cf metabolic,
endothelial and procoagulant mechanisms [Yudkin et al. 2000, Woods et al.
2000]. For example, high secretion rate cf this cytokine is associated with
decteased insulin release and action and in vitro studies demonstrate th
at IL-6 is
correlated with resistance cf insulin action of glucose uptake in ad
ipose tissue
[Bastard et al. 2002, Sopasakis et al. 2004]. Exposure cf endothelial cells to IL-6
induces expression cf adhesion molecules and enhances binding cf
lymphocytes
[Watson et al. 1996]. In addition, binding cf IL-6 te its receptor stimulates
leukocyte recruitment and promotes endothelial celI inflammatory
responses
[Modur et al. 1997, Romano et al. 1997]. Our finding that IL-6 enhances
endothelial LOX-1 expression further supports the notion that this cy
tokine may
contribute to endcthelial dysfunction associated with diabetes.
The mechanisms through which IL-6 upregulates endothelial LOX-
1 are
unknown. On the basis cf our and previcus data showing that PKC
is involved in
endothelial LOX-1 regulation by glucose and mediates IL-6-induced
endothelial
barrier dysfunction [Desai et al. 2002], one may postulate a role of PKC in IL-6-
induced LOX-1 expression. Because activation of PKC in respons
e to many
stimuli enhances NFiB activity [Ghcsh et al. 1990, Li et al. 2000], a critical
transcription factcr in the regulation of endothelial LOX-1 gene exp
ression [Li et
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C al. 2002], a rote for this factor as downstream target of PKC may further be
proposed. tnterestingly, we found that IL—6 and CRP did flot synergize for LOX-1
induction, suggesting that these factors may act through common signaling
events to induce endothelial LOX-1 expression. Importantly, it has recentty been
documented that CRP stimulates the release cf IL-6 by endothelial cells [Verma
et al. 2002] and we found that inhibition cf IL-6 reduces CRP-induced LOX-1
expression. Taken together, these results strongty support a rote for IL-6 as
mediator cf CRP effect on LOX-1.
The monocytes/macrophages ptay a critical role in the initiation and
progression of atherogenesis. The macrophage functions both as a scavenger
and an immune mediator cett and as a source cf chemotactic molecules,
proinflammatory cytokines such as TNFŒ, IL-6, and IL-1 [Linton et al. 2003], and
APPs such as CRP [Yasojima et al. 20011. Macrophages ccntribute to the local
inflammatory responses through production cf cytokines, free cxygen radicals,
proteases, and ccmplement factors. By serving as antigen-presenting ceils,
macrophages participate in the immune response by activating T-cells. The
uptake cf mcdified lipcproteins by macrophages leads to the accumulation cf
cholestercl esters and formation cf macrophage-derived foam cells, the hallmark
of the fatty streak in atherosclerosis. This process cf lipcprotein internalization by
macrophages involves scavenger receptors expressed on the surface cf these
cells. In contrast te endothelial cetls which do net express or express in very
small amounts the classic scavenger receptors [Bickel et al.1992], macrophages
do express multiple cxLDL receptors, including SR-A, SR-B1, CD36, CD68, and
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LOX-l [Yamada et al. 19981. In these cells, over 50% of the uptake of oxLDL
seems to occur via CD36, whereas SRA has to share the rest with the other
scavenger receptors, including LOX-1. It has recently been proposed that
accelerated foam celi formation may occur in the diabetic state [Dobrian et al.
2000]. Inflammatory and metabolic factors dysregulated in diabetes, including
CRP, hyperglycemia and AGEs, may contribute to this alteration. Indeed, t has
been shown that CRP is expressed on the surface of foam cells [Torzewski et al.
1998], and mediates LDL uptake by macrophages in vitro [Bharadwaj et al.
1999, Zwaka et al. 2001]. Furthermore, it has been documented that high
glucose and AGEs upregulate in vitro macrophage scavenger receptors [Griffin
et al. 2001, Iwashima et al. 2000] and that monocytes of patients with type 2
diabetes show increased CD36 expression. lncreased monocyte CD36
expression after monocyte entry into the subendothelial space, or increased
expression of CD36 in the earliest stages of macrophage transformation could be
highly atherogenic.
b further substantiate the role of high glucose on macrophage scavenger
receptors, we evaluated LOX-1 expression in macrophages cultured in a high
glucose environment. We demonstrated that high glucose concentrations
significantly increase macrophage LOX-1 expression both at the gene and
protein levels. As observed in endothelial celis, induction of macrophage LOX-1
gene expression by glucose was totally inhibited by pre-incubating the cells with
PKC and MAPK inhibitors and appeared to involve NFKB activation. However, in
contrast to our observations in endothelial ceils, we found that glucose also
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enhanced the binding of nuclear proteins binding to the AP-1 regulatory element
present in the promoter of the LOX-1 gene, suggesting that regulation of LOX-1
gene expression in vascular celis may involve different transcription factors.
While many data have been generated showing that uptake of modifled
lipoproteins by macrophages is in large part mediated by CD36 and SR-A, no
studies have examined the contribution of LOX-1 in foam cell formation. Recause
we assumed that the contribution cf LOX-1 in this process may be weak, we
assessed the relative role 0f LOX-1 vs other scavenger receptors in oxLDL
induced foam celi formation by preincubating the cells with anti-CD36, anti-SRA
and anti-LOX-1 antibodies. Using this approach we successfully demonstrated
that glucose-induced LOX-1 expression was associated with foam celi formation.
Ihese results togethet with the observation that high glucose increases CD36
further stress the role for hyperglycemia in foam cell formation. Although the
contribution of LOX-1 in lipoprotein uptake by macrophages may be weak,
evidence that LOX-1 is highly expressed in macrophages present in human
atherosclerotic lesions [Kataoka et al. 1999] supports a role for this receptor in
macrophage foam cefl formation in vivo. To address this possibility and evaluate
the relevance of our work to the diabetic human setting, we measured the levels
of LOX-1 expression in monocyte-derived macrophages isolated from control and
type 2 diabetic patients. Our results showing increased expression of
macrophage LOX-1 in human diabetes further stress the potential role of
macrophage LOX-1 expression in atherogenesis.
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IV.1. Conclusion
Despite advances in out understanding of the pathogenesis of
atherosclerosis, the mechanisms underlying the increased risk cf CVD in type 2
diabetes remain incompletely delineated. Endothelial dysfunction and foam ceil
formation are early and key pctentially reversible events in atherogenesis and
better understanding cf the relationship between these features and risk factors
in diabetes is required. Diabetes, like atherosclerosis is an infiammatory disease.
Importantly, chronic subclinical inflammation preceeds overt diabetes and may
represent, in the prediabetic state, a triggering factor for endothelial dysfunction
and atherosclerosis. Because endothelial dysfunction predicts CV events,
precedes the detection cf any distinct carbohydrate intolerance and links insulin
tesistance syndrome with atherosclerosis, determination of markers cf
endothelial dysfunction may be part cf the strategies aimed at preventing the
development cf atherosclerosis associated with diabetes. Based on the
stimulatory effect cf CRP on endothelial LOX-1 and on the identification cf
soluble forms cf LOX-1, determination cf the plasma levels cf this receptor in
subjects at risk cf developing diabetes may represent a novel diagnostic and
therapeutic tool for vascular diseases associated with human diabetes.
In overt diabetes, three major mechanisms have emerged that encompass
mcst cf the diabetic vasculopathies. These mechanisms include oxidative stress,
PKC activation, and AGE formation. Evidence has been prcvided that high
glucose operates through these mechanisms to induce endothelial dysfunction.
In accordance with this notion, we found that glucose-induced LOX-1 expression
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involves oxidative stress and PKC activation. Although we were unable to
document the formation of AGE in the cytosolic extracts of high glucose-treated
human macrophages, a rote for these factors in the induction of LOX-1 cannot be
ruled out.
In conclusion, our resuits demonstrate that metabolic and inflammatory
factors dysregulated in diabetes upregulate vascular LOX-1 expression. These
data and our observation that macrophages of patients with type 2 diabetes
overexpress LOX-1 support a contributive rote for this receptor in the accelerated
atherosclerosis associated with diabetes. Detailed understanding of the role of
hyperglycemia and inflammation in the regulation of vascular LOX-1 expression
could provide new strategies in the prevention and treatment of diabetic
atherosclerosis.
IV.2. Perspectives
Although we have demonstrated that CRP and hyperglycemia upregulate
vascular LOX-1 expression in vitro, the functional relevance cf these
observations in diabetic patients remains unclear. To address this question, we
have generated some preliminary data showing that macrophages isolated from
several patients with diabetes show increased LOX-1 gene expression. Future ex
vivo studies are needed to a) confirm these data in a larger study population, b)
determine macrophage LOX-1 protein levels in human diabetes and c) study the
impact of LOX-1 inhibitory agents such as statins and PPAR gamma ligands on
macrophage foam celi formation in human diabetes.
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In a similar manner, future experiments wiIl need to evaluate the functional
relevance cf the upregulation cf endotheHal LOX-1 by CRP. The question cf
whether the relationship between CRP and LOX-1 holds in vivo is of critical
importance and will be examined by determining endothelial LOX-1 expression in
CRP transgenic mice and by measuring in these animal models monocyte
endothelium interaction and several parameters cf endothelial function.
Finally, experiments aimed at determining the molecular mechanisms
involved in the induction cf endothelial LOX-1 gene expression by CRP wiII also
be conducted.
Chronic inflammation is a promising candidate mechanism underlying the
common sou hypothesis linking type 2 diabetes and atherosclerotic CVD. While
impressive evidence has accumulated over the past years that chronic
subclinical inflammation is a risk factor for both diabetes and CVD, little is known
about the potentially unique features of the inflammatory process associated with
CVD in diabetes. Is the inflammatory process in diabetic patients different from
those in nondiabetic individuals? Ihe release of inflammatory markers may be
greater in diabetes because some cf the processes known te activate
macrophages and therefore the release cf cytokines, such as oxidation and
glycoxydation of proteins and lipids and increased formation cf immune
complexes, are enhanced in diabetes. Further elucidation of whether there is an
unique role for inflammation in CVD in diabetes and states of insulin resistance is
required and if so the cellular and molecular mechanisms should be determined.
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Also, flot much is known about plaque differences in subjects with versus
those without diabetes. Pathologic and angiographic studies have shown that
diabetes favors diffuse and accelerated progression of atherosclerosis. Diabetic
plaques are also commonly complicated and at greater risk of subsequent
complications. Moreover diabetics who die suddenly show an increased number
of fissured atherosclerotic plaques as compared with nondiabetics. In fact,
diabetic patients with unstable angine have a higher incidence of plaque
ulceration and intracoronary thrombus formation than nondiabetic patients and
diabetic plaques usually have a greatet lipid cote burden, an increased content of
macrophages and are more commonly complicated by overlying thrombosis.
Furthermore, cell-rich and necrotic areas with large lipid core seem to be features
of coronary atherosclerosis in persons with diabetes. The relationship between
plaque content and risk factors in type 2 diabetes requires more insight.
o
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